2014-2015 IACC AUTISM SPECTRUM DISORDER RESEARCH

PORTFOLIO ANALYSIS REPORT

Prepared by the Office of Autism Research Coordination (OARC), on behalf of the Interagency Autism Coordinating Committee (IACC)





INTERAGENCY AUTISM COORDINATING COMMITTEE

2014-2015 IACC AUTISM SPECTRUM DISORDER RESEARCH

PORTFOLIO ANALYSIS REPORT

Prepared by the Office of Autism Research Coordination (OARC), on behalf of the Interagency Autism Coordinating Committee (IACC)



Cover Design

Medical Arts Branch, Office of Research Services, National Institutes of Health

Copyright Information

All material appearing in this report is in the public domain and may be reproduced or copied. A suggested citation follows.

Suggested Citation

Office of Autism Research Coordination, National Institute of Mental Health, on behalf of the Interagency Autism Coordinating Committee (IACC). 2014-2015 IACC Autism Spectrum Disorder Research Portfolio Analysis Report. October 2017. Retrieved from the U.S. Department of Health and Human Services Interagency Autism Coordinating Committee website: https://iacc.hhs.gov/portfolio-analysis/2015/index.shtml

TABLE OF CONTENTS

About the IACC	V
Introduction and Analysis Framework	v i
The IACC Strategic Plan Questions and Corresponding Research Areas	2
Subcategory Classification	3
ASD Research Funders and Funding in 2014 and 2015	4
Who funded ASD research in 2014 and 2015?	5
How much ASD research was funded in 2014 and 2015?	6
What funding trends were observed?	8
Where is research being funded in the U.S.?	9
How much ASD research funding did each funder provide in 2014?	11
How much ASD research funding did each funder provide in 2015?	14
Summary of ASD Research Funding in 2014 and 2015	17
ASD Research Areas and Progress in 2014 and 2015	18
What areas of ASD research were funded in 2014 and 2015?	19
How many new research projects were added in 2014 and 2015 compared to ongoing research?	24
What types of research are funded by the different agencies and organizations?	25
How did the research projects funded in 2014 and 2015 align with the objectives in the IACC Strategic Plan?	28
Summary of Progress toward IACC Strategic Plan Objectives	32
Analysis of Progress toward IACC Strategic Plan Objectives by Research Area	35
Question 1: Screening and Diagnosis	36
Question 2: Biology	45
Question 3: Risk Factors	55
Question 4: Treatments and Interventions	65
Question 5: Services	76
Question 6: Lifespan Issues	85
Question 7: Infrastructure and Surveillance	93
Summary and Conclusion	106

Appendices	108
Appendix A: Federal Agency and Private Organization Mission Statements	109
Appendix B: ASD-Related Research Projects not included in the IACC Portfolio Analysis	113
Appendix C: ASD Research Progress on IACC Strategic Plan Objectives: Summary of Years 2008-2015	122
Appendix D: Subcategory Definitions	124
Interagency Autism Coordinating Committee Member Roster	130
Office of Autism Research Coordination Staff Roster	133

ABOUT THE IACC

The Interagency Autism Coordinating Committee (IACC) is a Federal advisory committee charged with coordinating federal activities concerning autism spectrum disorder (ASD) and providing advice to the Secretary of Health and Human Services on issues related to autism. The Committee was established by Congress under the Children's Health Act of 2000, reconstituted under the Combating Autism Act (CAA) of 2006, and renewed most recently under the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2014.

Membership of the Committee includes a wide array of Federal agencies involved in ASD research and services, as well as public stakeholders, including self-advocates, family members of children and adults with ASD, advocates, service providers, and researchers, who represent a variety of perspectives from within the autism community. The IACC membership is composed to ensure that the Committee is equipped to address the wide range of issues and challenges faced by individuals and families affected by autism.

Under the CAA and subsequent authorizations, the IACC is required to (1) develop and annually update a strategic plan for ASD research, (2) develop and annually update a summary of advances in ASD research, and (3) monitor Federal activities related to ASD.

Through these and other activities, the IACC provides guidance to HHS and partners with other federal departments, federal agencies, research and advocacy organizations, and the broader autism community to accelerate research and enhance services with the goal of profoundly improving the lives of people with ASD and their families.

For more information about the IACC, see www.iacc.hhs.gov.



In 2009, the Interagency Autism Coordinating Committee (IACC) launched its *Strategic Plan for Autism Spectrum Disorder Research*, providing a framework to guide the efforts of Federal and private funders of autism research. The *IACC Strategic Plan*, developed with extensive input from a broad array of Federal and public stakeholders, organizes research priorities around seven general topic areas represented as community-focused "questions." The questions are divided further into research objectives that address key research needs, gaps, and opportunities identified by the Committee. Each objective includes a recommended budget that serves as an estimate of how much the Committee projects it might cost to conduct the research-related activities described. The *IACC Strategic Plan* was updated in 2010 and 2011, leading to a total of 78 objectives on autism research.

Following the development of the *IACC Strategic Plan*, the Office of Autism Research Coordination (OARC) – the office within the National Institutes of Health (NIH) that manages the activities of the IACC—began issuing a series of *IACC Autism Spectrum Disorder (ASD)* Research Portfolio Analysis Reports to provide the IACC with comprehensive information about the status of autism research funding among Federal agencies and private research organizations in the U.S. The reports align data on individual research-related projects with objectives in the *IACC Strategic Plan*, providing an accounting of how much funding has gone toward support of projects related to *Strategic Plan* objectives and highlighting trends. This information has been used to help the IACC in their efforts to monitor ASD research efforts and track progress made each year toward achievement of objectives in the *IACC Strategic Plan for ASD Research*. The 2014-2015 *IACC ASD Research Portfolio Analysis Report*, in addition to information on progress made toward each of the 78 objectives in the *IACC Strategic Plan* in 2014 and 2015, also provides an analysis of progress that was made over the eight-year period from 2008-2015. The 2014-2015 *Portfolio Analysis Report* is the last portfolio analysis measuring these objectives, with a new *IACC Strategic Plan* and objects forthcoming.

To accompany the *IACC 2014-2015 ASD Research Portfolio Analysis Report*, detailed Federal and private organization project data are available in the Autism Research Database (ARD), a database accessible via the IACC website (https://iacc.hhs.gov/funding/data/). This database provides stakeholders with a centralized place from which to gather valuable information about ASD research that can support their efforts to serve the autism community.

IACC Strategic Plan Questions and Corresponding Research Areas

The Office of Autism Research Coordination (OARC) requested 2014 and 2015 autism-related research project and funding information from several Federal agencies and private organizations, including the annual

budget for each project and its relevance to the seven critical questions/chapters of the 2011 IACC Strategic Plan for ASD Research, illustrated below (**Figure 1**).

IACC STRATEGIC PLAN QUESTIONS AND CORRESPONDING RESEARCH AREAS



Question 1: When should I be concerned? SCREENING & DIAGNOSIS



Question 2: How can I understand what is happening? BIOLOGY



Question 3: What caused this to happen and can it be prevented? RISK FACTORS



Question 4: Which treatments and interventions will help? TREATMENTS & INTERVENTIONS



Question 5: Where can I turn for services? SERVICES



Question 6: What does the future hold, particularly for adults? LIFESPAN ISSUES



Question 7: What other infrastructure and surveillance needs must be met? INFRASTRUCTURE & SURVEILLANCE

Figure 1. The research areas corresponding to the seven questions of the 2011 IACC Strategic Plan for ASD Research are represented by the icons to the left of each question.

Subcategory Classification

In 2010, OARC introduced the subcategory classification system (**Figure 2**) to the *IACC Portfolio Analysis Report* to help the Committee and other readers of this report better understand the types of research encompassed by the projects in the research portfolio — especially those projects that are categorized as outside the objectives of the *Strategic Plan* but within a question's research area. For the subcategory analysis, each project in the *2014-2015 Portfolio Analysis Report* was assigned to

a subcategory based on the research area it addressed. The application of subcategory coding to projects in the portfolio helped to break the portfolio into easy-to-understand topical areas. For example, within Question 1 (Screening and Diagnosis), the projects were divided into four subcategories: Diagnostic and screening tools, Early signs and biomarkers, Intermediate phenotypes/Subgroups, and Symptomology.

IACC Strategic Plan Questions and Corresponding Research Areas
IACC STRATEGIC PLAN QUESTIONS AND CORRESPONDING RESEARCH AREAS BY SUBCATEGORY

IACC Strategic Plan for ASD Research

Question 1. When should I be concerned?	Question 2. How can I understand what is happening?	Question 3. What caused this to happen and can it be prevented?	Question 4. Which treatments and interventions will help?	Question 5. Where can I turn for services?	Question 6. What does the future hold, particularly for adults?	Question 7. What other infrastructure and surveillance needs must be met?
Screening & Diagnosis	Biology	Risk Factors	Treatments & Interventions	Services	Lifespan Issues	Infrastructure & Surveillance
Subcategories * Early signs and biomarkers * Diagnostic and screening tools * Intermediate phenotype/ subgroups * Symptomology	Subcategories * Cognitive studies * Computational science * Co-occuring conditions * Developmental trajectory * Immune/metabolic pathways * Molecular pathways * Neural systems * Neuropathology * Sensory and motor function * Subgroups/ biosignatures	Subcategories * Genetic risk factors * Environmental risk factors * Epigenetics * Geneenvironment	* Technology-based intervention and supports * Behavioral * Complementary, dietary, and alternative * Educational * Medical/pharmacologic * Model systems/therapeutic targets * Occupational, physical, and sensory-based	Subcategories * Services utilization and access * Community inclusion programs * Efficacious and cost-effective service delivery * Family well-being and safety * Practitioner training	* No subcategories created due to small number of projects. Subcat- egories may be established in the future.	Subcategories * Biobanks * Data tools * Research infrastructure * Surveillance and prevalence studies * Research workforce development * Research recruitment and clinical care

Figure 2. A subcategory classification system was created to allow an understanding of the autism research portfolio based on simple research topics that are relevant to each of the *IACC Strategic Plan* questions. Appendix D provides detailed definitions of the subcategory research areas.

ASD RESEARCH FUNDERS AND FUNDING IN 2014 AND 2015

Who funded ASD research in 2014 and 2015?

Nine Federal agencies and nine private funders provided their autism funding data for this analysis. These 18 agencies and organizations are listed in **Table 1**. The New England Center for Children (NECC) submitted ASD research funding data to the *IACC Portfolio Analysis* for the first time this year. Brief summaries of the mission areas and portfolios of NECC and other funding

agencies and organizations that contributed to the 2014-2015 Portfolio Analysis can be found in **Appendix A** of this report. Some funders included in previous years' Portfolio Analysis Reports either did not have projects to report in 2014 and 2015 or did not choose to participate in the 2014-2015 analysis.

AGENCIES AND ORGANIZATIONS INCLUDED IN THE 2014-2015 IACC PORTFOLIO ANALYSIS

FEDERAL AGENCIES

- Administration for Community Living (ACL)
- Agency for Healthcare Research and Quality (AHRQ)
- Centers for Disease Control and Prevention (CDC)
- · Department of Defense (DoD)*
 - Army-Autism Research Program (Army)
 - Air Force (AF)
- Department of Education (ED)
- Environmental Protection Agency (EPA)
- Health Resources and Services Administration (HRSA)
- National Institutes of Health (NIH)
- National Science Foundation (NSF)

PRIVATE ORGANIZATIONS

- Autism Research Institute (ARI)
- Autism Science Foundation (ASF)
- Autism Speaks (AS)
- Brain & Behavior Research Foundation (BBRF)
- · Center for Autism and Related Disorders (CARD)
- New England Center for Children (NECC)
- · Organization for Autism Research (OAR)
- Patient-Centered Outcomes Research Institute (PCORI)
- Simons Foundation (SF)

Table 1. Projects from nine Federal agencies and nine private organizations were included in the 2014-2015 IACC Autism Spectrum Disorder Research Portfolio Analysis Report.

^{*} The DoD Autism Research Program and Air Force reported as two separate entities for the purpose of this Portfolio Analysis.

How much ASD research was funded in 2014-2015?

Combined, the estimated Federal and private investment in ASD research in 2014 was \$309,873,907. The overall funding for autism research was relatively unchanged from 2013 to 2014. However, the relative contributions of Federal and private funders reported during this period were significantly different from the previous year, with

the proportion of overall funding provided by the federal government increasing from 76% in 2013 to 81% in 2014. In 2014, the Federal government provided \$250 million in ASD research funding, and private organizations provided \$59.4 million (19%) of the total funding for ASD research (**Figure 3**).




Figure 3. In 2014, 81% of ASD research was provided by Federal sources, while 19% of funding was provided by private organizations.

In 2015, the estimated Federal and private investment in ASD research was \$342,636,029. The overall funding for autism research increased by \$34.2 million from 2014 to 2015, and the proportion of Federal and private funding

remained constant over this period. In 2015, the Federal government provided 81% (\$277.6 million) and private organizations provided 19% (\$65 million) of the total funding for ASD research (**Figure 4**).




Figure 4. In 2015, 81% of ASD research was provided by Federal sources, while 19% of funding was provided by private organizations.

What funding trends were observed?

- ASD research funding progressively increased from 2013-2015. In 2013, combined Federal and private investment in ASD research was \$305.6 million. In 2014, the total reported funding was \$309.9 million. In 2015, the total funding was \$342.6 million, an increase of 12%. (Figure 5).
- Private investment in ASD research was higher in 2015 (\$65 million) than in 2014 (\$59.4 million) but considerably lower than in 2013 (\$72.9 million).
- The amount of Federal investment in autism research reported in 2015 (\$277.6 million) was significantly higher than the 2014 (\$250 million) and 2013 levels (\$235.9 million).
- As stated in previous IACC Portfolio Analysis Reports, the American Recovery and Reinvestment Act
 (ARRA), which provided an additional \$63.9 million in 2009 and \$59.9 million in 2010 to support autism research projects, created a temporary increase in total autism research funding levels during those years, resulting in a high of \$408.6 million in 2010. In 2011, levels significantly decreased in comparison to 2010, but have been slowly rising since then.
 Nevertheless, current funding in 2015 was still far below the 2010 high.
- While one new private funder (New England Center for Children) was added to the 2014-2015 Portfolio Analysis, the new funder contributed a small proportion of ASD research funding, so the impact on the total funding was relatively small.




Figure 5. This figure illustrates levels of autism research funding from combined Federal and private sources during 2008-2015 based on data collected for the *IACC Portfolio Analysis* of those years.

Where is research being funded in the U.S.?

Figure 6 shows the distribution of autism research projects across the U.S. funded by both Federal agencies and private organizations in 2015. The map shows that research is concentrated along the east and west coasts of the U.S. and in major metropolitan areas or areas

with large universities in the middle portion of the country. **Table 2** provides some additional information about the institutions and states that had a large number of projects in 2014 and 2015.




Figure 6. A map of the U.S. and Canada displaying the distribution of autism-related research projects in 2015 funded by Federal agencies and private organizations.

Which U.S. institutions had the highest levels of funding in 2014 and 2015?					
2014			2015		
Institution	Funding	Project Count	Institution	Funding	Project Count
National Institutes of Health - Intramural Research Program	\$ 23,654,941	20	National Institutes of Health - Intramural Research Program	\$ 23,571,416	17
University of California, Los Angeles	\$ 19,131,129	51	University of California, Davis	\$ 17,581,758	55
University of California, Davis	\$ 15,992,131	57	Yale University	\$ 15,386,762	47
University of North Carolina, Chapel Hill	\$12,950,335	41	University of California, Los Angeles	\$ 14,969,102	49
Yale University	\$ 9,802,235	37	University of North Carolina, Chapel Hill	\$ 14,265,467	38
Vanderbilt University	\$ 7,353,330	41	University of California, San Diego	\$ 8,359,906	25
Emory University	\$ 7,284,749	26	Stanford University	\$ 7,828,949	34
Boston Children's Hospital	\$ 6,959,687	19	Vanderbilt University	\$ 7,136,490	35
Massachusetts Institute of Technology	\$ 6,913,905	16	Boston Children's Hospital	\$ 6,958,946	11
Stanford University	\$ 6,690,041	36	Massachusetts Institute of Technology	\$ 6,912,012	14

Which states had the highest levels of funding in 2014 and 2015?					
2014			2015		
State	Funding	Project Count	State	Funding	Project Count
California	\$ 64,958,473	289	California	\$ 71,224,493	287
Maryland	\$ 39,311,594	69	New York	\$ 46,770,187	158
Massachusetts	\$ 36,215,168	207	Maryland	\$ 40,977,880	62
New York	\$ 30,546,027	143	Massachusetts	\$ 33,767,096	190
North Carolina	\$ 15,644,937	63	North Carolina	\$ 17,907,155	59
Pennsylvania	\$ 14,599,464	87	Connecticut	\$ 17,774,925	55
Connecticut	\$ 14,247,234	50	Pennsylvania	\$ 14,168,386	77
Georgia	\$ 13,406,969	42	Georgia	\$ 11,954,686	43
Texas	\$ 8,617,018	51	Texas	\$ 9,060,685	37
Washington	\$ 7,359,330	45	Washington	\$ 7,731,124	28

Table 2. Institutions and states with the most ASD-related research funding from Federal and private sources in 2014 and 2015.

How much ASD research funding did each funder provide in 2014?

The 18 stakeholders, agencies, and organizations that participated in the *2014 Portfolio Analysis* supported 1,441 ASD research projects totaling \$309,873,907 (**Table 3**).

The National Institutes of Health (NIH) was the leading Federal (and overall) contributor of funding for ASD research in 2014 with a total of \$197.1 million, funding 457 projects. NIH funding for autism research increased by \$21.2 million from 2013 to 2014. The next largest Federal funder was the Department of Education,

with \$17.3 million, followed by the Centers for Disease Control and Prevention (CDC), with \$15.2 million. The Department of Education experienced a \$5.4 million decrease in funding, and CDC had a \$4.1 million decrease from 2013 to 2014. As in previous years, the Simons Foundation and Autism Speaks were the largest private funders of ASD research in 2014, with investments of \$44.0 million and \$12.6 million, respectively. The percentage of overall ASD research funding provided by each agency is depicted in **Figure 7**.

2014 ASD RESEARCH FUNDING BY AGENCY/ORGANIZATION

Funding Agency/Organization	2014 Funding	Project Count
National Institutes of Health (NIH)	\$197,079,206	457*
Simons Foundation (SF)	\$44,017,469	271
Department of Education (ED)	\$17,323,061	106
Centers for Disease Control & Prevention (CDC)	\$15,157,020	25
Autism Speaks (AS)	\$12,588,143	192
Health Resources and Services Administration (HRSA)	\$9,137,969**	45
Department of Defense - Army (DoD-Army)	\$5,533,865	59
National Science Foundation (NSF)	\$2,881,721	42
Administration for Community Living (ACL)	\$1,656,454	5
Brain & Behavior Research Foundation (BBRF)	\$1,005,098	60
Department of Defense - Air Force (DoD-AF)	\$966,000	1
Centers for Autism and Related Disorders (CARD)	\$769,850	20
Environmental Protection Agency (EPA)	\$639,214	1
Autism Science Foundation (ASF)	\$405,000	41
New England Center for Children (NECC)	\$204,683	69
Autism Research Institute (ARI)	\$186,566	17
Organization for Autism Research (OAR)	\$179,984	23
Agency for Healthcare Research & Quality (AHRQ)	\$142,604**	6
Patient-Centered Outcomes Research Institute (PCORI)	\$0	1
Grand Total	\$309,873,907	1,441

^{*}The NIH project number shown reflects unique NIH projects. Projects funded by more than one NIH institute ("co-funds") were combined and only counted as a single project. This approach differs from that used in the NIH RePORT database, where each co-fund is counted as a separate project.

Table 3. The table lists the total funding and number of projects provided by the 18 Federal agencies and private organizations included in the *Portfolio Analysis* for 2014. Together, the agencies and organizations funded 1,441 projects, representing an overall investment of \$309,873,907.

^{**}The annual funding amount for some projects reported by AHRQ and HRSA are prorated estimates for the autism-related portion of a larger project.




Figure 7. The figure illustrates the percentage of total ASD research funding contributed by the 18 Federal agencies and private organizations included in 2014. NIH provided the largest proportion of funding (63.3%), while Simons Foundation was the largest private funder (14.3%).

How much ASD research funding did each funder provide in 2015?

In 2015, the 18 stakeholders, agencies, and organizations that participated in the Portfolio Analysis had 1,410 ASD research projects totaling \$342,636,029 (**Table 4**).

As in previous years, the NIH was the leading Federal (and overall) funder of ASD research in 2015 with a total of \$216.7 million, funding 500 projects. NIH funding for autism research increased by \$40.8 million from 2014 to 2015. The next largest Federal funder was the Department of Education, with \$26.4 million, followed

by the Centers for Disease Control and Prevention (CDC), with \$15.8 million. The Department of Education experienced a \$3.7 million increase in funding from 2014 to 2015, however CDC had a \$3.5 million decrease in autism research funding. For private funders, the Simons Foundation and Autism Speaks continued to be the largest funders of ASD research in 2015, with investments of \$48.4 million and \$12.3 million, respectively. The percentage of overall ASD research funding provided by each agency is depicted in **Figure 8**.

2015 ASD RESEARCH FUNDING BY AGENCY/ORGANIZATION

Funding Agency/Organization	2015 Funding	Project Count
National Institutes of Health (NIH)	\$ 216,657,540	500*
Simons Foundation (SF)	\$ 48,443,781	293
Department of Education (ED)	\$ 26,362,194	93
Centers for Disease Control & Prevention (CDC)	\$ 15,789,418	25
Autism Speaks (AS)	\$ 12,324,957	136
Health Resources and Services Administration (HRSA)	\$ 9,618,017**	40
Department of Defense - Army (DoD-Army)	\$ 5,440,886	64
Patient-Centered Outcomes Research Institute (PCORI)	\$ 1,695,006	3
Administration for Community Living (ACL)	\$ 1,528,535	6
National Science Foundation (NSF)	\$ 1,291,726	39
Brain & Behavior Research Foundation (BBRF)	\$ 1,290,484	52
Agency for Healthcare Research & Quality (AHRQ)	\$ 576,949**	6
Environmental Protection Agency (EPA)	\$ 343,850	1
Center for Autism & Related Disorders (CARD)	\$ 314,060	9
Autism Science Foundation (ASF)	\$ 330,000	43
Organization for Autism Research (OAR)	\$ 229,755	20
New England Center for Children (NECC)	\$ 219,416	63
Autism Research Institute (ARI)	\$ 179,456	17
Grand Total	\$342,636,029	1,410

^{*}The NIH project number shown reflects unique NIH projects. Projects funded by more than one NIH institute ("co-funds") were combined and only counted as a single project. This approach differs from that used in the NIH RePORT database, where each co-fund is counted as a separate project.

Table 4. The table lists the total funding and number of projects provided by the 18 Federal agencies and private organizations included in the *2015 Portfolio Analysis*. Together, the agencies and organizations funded 1,410 projects, representing an overall investment of \$342,636,029.

^{**}The annual funding amount for some projects reported by AHRQ and HRSA are prorated estimates for the autism-related portion of a larger project.




Figure 8. The figure illustrates the percentage of total ASD research funding contributed by the 18 Federal agencies and private organizations included in 2015. NIH provided the largest proportion of funding (63.2%), while Simons Foundation was the largest private funder (14.1%).

Summary of ASD Research Funding in 2014 and 2015

As outlined in this section, numerous Federal and private funders invested in ASD research conducted across the U.S. in 2014 and 2015. Since the last *Portfolio Analysis Report* in 2013, funding for autism research increased from \$305.6 million to \$342.6 million in 2015, representing a 12% increase in funding. Funding for the overall autism research portfolio increased 10.6% from 2014 to 2015, with Federal funding growing 10.8% and private funding increasing 9.6%. Over the eight-year span from 2008-2015, funding increased by 54.2%, which suggests a continued overall growth in support

of ASD research. However, over the period from 2008 to 2015, ASD funding has gone through some periods of significant change and other periods of incremental change. Autism research reached a peak in funding (including ARRA) in 2010 and then experienced a decrease, which eventually plateaued through 2015. The new 2016-2017 IACC Strategic Plan calls for a doubling of the ASD research budget to \$685 million by 2020. In future years, funding trends will continue to be monitored to determine whether this ambitious new IACC budget recommendation is met.

ASD RESEARCH AREAS AND PROGRESS IN 2014 AND 2015

What areas of ASD research were funded in 2014 and 2015?

TTo better understand what areas of research were funded in 2014 and 2015, projects were aligned with the corresponding questions in the 2011 IACC Strategic Plan.

Figure 9 and Figure 10 illustrate the breakdown of the research funding per each of the Strategic Plan's seven questions, which are related to Screening and Diagnosis (Q1), Biology (Q2), Risk Factors (Q3), Treatments and Interventions (Q4), Services (Q5), Lifespan Issues (Q6),

and **Infrastructure and Surveillance (Q7)**. Identifying how current research investments correspond to the *Strategic Plan* provides an understanding of how funders have directed investments across each of the priority areas identified by the IACC, as well as an indication of which areas are well-supported versus those that may need additional attention or development.




Figure 9. Topic areas are defined by each question in the *IACC Strategic Plan*. The seven questions of the *Strategic Plan* are represented in the clockwise direction, beginning with Screening and Diagnosis (**Question 1**) and ending with Infrastructure and Surveillance (**Question 7**).




Figure 10. The seven questions of the *Strategic Plan* are represented in the clockwise direction, beginning with Screening and Diagnosis (**Question 1**) and ending with Infrastructure and Surveillance (**Question 7**).

ASD research funding in 2014 and 2015 supported projects relevant to all seven of the critical questions in the IACC Strategic Plan for ASD Research. As in previous years, the largest portion of funding addressed the underlying biology (Question 2) of ASD (32% in 2014 and 2015). In 2014, this was followed by research into treatments and interventions (Question 4) for ASD (20%), including behavioral therapies, pharmacological treatments, and technology-based interventions. Question 3, research aimed at identifying potential causes and risk factors for the disorder, followed closely with 16% of total funding in 2014. However, in 2015, Question 4 and Question 3 exchanged rankings; there was a greater investment in research related to Question 3 (18%), which became the second largest portion of funding, while Question 4 was the third largest portion of funding with 17% of funding. The proportion of investment in research infrastructure and surveillance (Question 7) stayed relatively the same as in previous years (14% in 2014; 16% in 2015). Research to improve screening and diagnosis (Question 1) of ASD stayed relatively the same with 10% of research funding in 2014 and 9% in 2015. Research focused on services (Question 5) and lifespan issues (Question 6) remained

the smallest areas of funding. Question 5 was 6% of ASD research funding in 2014 and 2015 and Question 6 was 2% of funding for both years. In both 2014 and 2015, the percentages of funding for each question were similar to those seen in 2013.

When the number of projects that align with each question, as opposed to the total funding for these projects is considered, the distribution is subtly different due to differences in the relative sizes of projects falling under each of the seven question categories. In 2014, the percentage of total projects aligned with each question were as follows: Question 1, 8%; Question 2, 35%; Question 3, 11%; Question 4, 25%; Question 5, 9%; Question 6, 2%; Question 7, 10% (Figure 11). In 2015, the percentage of total projects aligned with each question were as follows: Question 1, 10%; Question 2, 34%; Question 3, 14%; Question 4, 24%; Question 5, 7%; Question 6, 3%; Question 7, 9% (Figure 12). The proportion of projects stayed relatively constant throughout the two-year period. Figure 11 and Figure 12 show the distribution of active projects among the Strategic Plan questions.




Figure 11. 2014 projects aligned to Strategic Plan questions.




Figure 12. 2015 projects aligned to *Strategic Plan* questions.

How many new research projects were added in 2014 and 2015 compared to ongoing research?

Each project included in the Portfolio Analysis is classified as either "Ongoing" or "New." Ongoing projects were active in the previous year, and new projects became active and received funding for the first time in the current year of analysis. In 2014, approximately 74% of overall ASD research funding went to ongoing projects while 26% went to new projects. In 2015, ongoing projects made up 70% of all ASD research funding and 30% went towards new research projects. Since most research projects are funded for a duration of multiple years of work, a larger number of ongoing projects compared with new projects is expected. However, it is interesting to note that both 2014 and 2015 experienced

increases in funding towards new projects compared to new projects in 2013 (23%). Research related to screening and diagnosis (Question 1), treatments and interventions (Question 4), and lifespan issues (Question 6) had higher proportions of funding devoted to new projects compared with the overall average. In contrast, funding for infrastructure and surveillance (Question 7) and risk factors (Question 3) had a higher portion of funding going to ongoing projects, which would be expected due to the long-term infrastructure and large-scale studies these projects provide to the autism research community (**Figure 13**).




Figure 13. The percentages of ASD research funding going to ongoing versus new projects varies between *Strategic Plan* questions in 2014 and 2015.

What types of research are funded by the different agencies and organizations?

The Federal and private funders included in this *Portfolio Analysis Report* fund a wide range of autism-related research projects. As shown in **Figure 14**, Federal and private funders contributed to funding for each of the question areas in the *IACC Strategic Plan* for ASD Research in 2015. However, the proportions of Federal and private funding vary by question area, suggesting that some areas align more closely with Federal or private priorities and/or capabilities. For example, infrastructure and surveillance projects (Question 7) received nearly equal support from Federal and private sources, while research on screening and diagnosis (Question 1) and services (Question 5) is largely supported by funding from Federal sources.

In addition to the variation in Federal and private support of research in each question area, the type of research represented in the portfolios of individual funders varies based on the mission of each individual agency or organization. **Figure 15** shows the agencies and organizations that funded projects in 2015 in each of the seven question areas of the *IACC Strategic Plan*. **Figure 16** provides a graphic illustrating the breadth of the mission areas of the funding agencies and organizations included in the *IACC Portfolio Analysis Report*. While some agencies and organizations have broad portfolios that cover many different research areas described in the *IACC Strategic Plan*, others focus their efforts on a narrower range of research topics.





Figure 14. Federal and private funding was provided for each *Strategic Plan* question area in 2015, although the proportion of Federal vs. private funding varied between question areas.

2015Percentage of Funding by Each Funder According to Question



ORGANIZATION

- Administration for Community Living (ACL)
- Agency for Healthcare Research and Quality (AHRQ)
- Autism Research Institute (ARI)
- Autism Science Foundation (ASF)
- Autism Speaks (AS)
- Brain & Behavior Research Foundation (BBRF)
- Center for Autism and Related Disorders (CARD)

- Centers for Disease Control and Prevention (CDC)
- Department of Defense Army (DoD-Army)
- Department of Education (ED)
- Environmental Protection Agency (EPA)
- Health Resources and Services Administration (HRSA)
- National Institutes of Health (NIH)

- National Science Foundation (NSF)
- New England Center for Children (NECC)
- Organization for Autism Research (OAR)
- Patient-Centered Outcomes Research Institute (PCORI)
- Simons Foundation (SF)

Figure 15. The proportion of each Federal agency and private organization's funding in the *Portfolio Analysis* organized by *IACC Strategic Plan* question for 2015.




Figure 16. The portfolio of each federal agency and private organization's autism-related projects by *Strategic Plan* question for 2015. Please note that this figure is based on funding amount from 2015. Thus, while funders may support additional areas of research, that may not be reflected in this particular year.

How did the research projects funded in 2014 and 2015 align with the objectives in the *IACC Strategic Plan*?

The 78 Strategic Plan objectives were developed by the IACC to set priorities for investment, and they represent areas where the Committee perceived gaps in research that required increased efforts. All autism research-related projects in 2014 and 2015 were matched with the best fitting research objective in the Strategic Plan, though in some cases, projects could only be assigned to a Strategic Plan question, and for the objective category, were assigned to Core/ Other. The Core/Other category captures projects that may be related to crosscutting or "core" activities that help support the autism research field, projects in well-established areas of science that do not fit within the parameters of the specific research objectives outlined in the Strategic Plan, or that represent emerging areas of research. The Core/Other designation was developed by the IACC because the Committee felt it would help readers understand that even though activities in this category fall outside the specific

research objectives of the *Strategic Plan*, they represent projects that are contributing in important ways to the progress of ASD research.

Analysis of the 2014-2015 project portfolios determined the proportion of projects that fit within *Strategic Plan* objectives versus the proportion that did not fit within *Strategic Plan* objectives (**Figure 17**). In 2014, 27% of the funding went to projects that were not specific to a particular objective, whereas in 2015 only 25% of funding went to projects designated as Core/Other. In addition, **Figures 18 & 19** show that every question of the *Strategic Plan* included projects that were not specific to a particular objective (projects coded to Core/Other). Of all seven questions of the *Strategic Plan*, Question 2 contained the largest proportion of funding that did not align with any specific objective (2014, 48%; 2015, 49%), encompassing projects that largely represent established areas of basic research.




Figure 17. In 2014, 27% of funding went to projects that were not specific to a particular *Strategic Plan* objective, and were designated Core/Other; in 2015, 25% of funding went to projects designated as Core/Other.




Figure 18. In 2014, the majority of funding for ASD projects was assigned to a specific objective within the IACC *Strategic Plan* questions. However, each question in the *Strategic Plan* contained projects that were not specific to a particular objective, designated Core/Other. Funding for projects that fall under specific objectives are indicated in blue, and Core/Other projects are indicated in yellow. Subcategory analysis provided within the summary for each question of the *Strategic Plan* provides a description of the research areas addressed by all projects, including those assigned to Core/Other.




Figure 19. In 2015, the majority of funding for ASD projects was assigned to a specific objective within the *IACC Strategic Plan* questions. However, each question in the *Strategic Plan* contained projects that were not specific to a particular objective, designated Core/Other. Funding for projects that fall under specific objectives are indicated in blue, and Core/Other projects are indicated in yellow. Subcategory analysis provided within the summary for each question of the *Strategic Plan* provides a description of the research areas addressed by all projects, including those assigned to Core/Other.

Summary of Progress toward IACC Strategic Plan Objectives

The 78 objectives in the Strategic Plan describe specific research priorities identified by the IACC, each with a goal date for initiation and a professional judgment estimate of the budget that may be required to accomplish the objective. Each ASD project that received funding in 2015 was evaluated with respect to the 78 objectives in the 2011 IACC Strategic Plan for ASD Research² in order to determine which Strategic Plan question and objective it fulfilled. Analysis of the full portfolio of government and privately funded projects aligned with the IACC Strategic Plan objectives yielded information about the progress that has been made toward completion of the objectives in the 2011 Strategic Plan. In 2015, this analysis indicated that of the 78 objectives in the IACC Strategic Plan, 97% (76 objectives) were underway or completed (green or yellow in the stoplight figure as explained below) (Figure 20). Further discussion of the progress toward achievement of individual Strategic Plan objectives is found in subsequent chapters of this report. The analysis also enabled assessment of areas of research where more work may be needed to achieve Strategic Plan objectives.

Upcoming chapters in this report give an overview of the progress on completing objectives in each question of the Strategic Plan in 2015. The overall progress for each question over the period from 2008-2015 is denoted by a stoplight figure at the end of each chapter. Within each stoplight figure, the number in the green light indicates the number of objectives that are considered completed, the number in the yellow light indicates the number of objectives partially completed, and the number of objectives in the red light indicates the number of objectives where no progress has been documented through the portfolio analysis. Each of the chapters describing the progress in the seven Strategic Plan question areas also contains a table that provides information about the progress made toward completion of the Strategic Plan objectives over an eight-year period from 2008 through 2015.

¹Professional judgment budget estimates for each of the *IACC Strategic Plan* objectives were formulated by scientific and program experts in the field and provide an estimate of what it may cost to conduct each of the projects described. The IACC provided these budget recommendations as guidance to Federal agencies and partner organizations on the potential cost of conducting the recommended research. The IACC's role in research is advisory, and the Committee does not have its own research budget to conduct or support research.

²The 2011 IACC Strategic Plan is the most recent update of the Strategic Plan where new objectives were added. The subsequent 2012 and 2013 Updates of the Strategic Plan did not include any edits to the objectives, therefore the objectives as described in the 2011 IACC Strategic Plan were used to code the 2014-2015 projects to specific objectives.




Figure 20. This figure provides the percentage of the total number of *IACC Strategic Plan* objectives that have been completed to date, based on an analysis of funded projects assigned to each of the *Strategic Plan*'s 78 objectives. As of 2015, 97% of objectives were either complete or partially complete (had all or some of the required funded projects), with 3% of objectives having no activity/assigned projects.

ANALYSIS OF PROGRESS TOWARD IACC STRATEGIC PLAN OBJECTIVES BY RESEARCH AREA



ASPIRATIONAL GOAL: CHILDREN AT RISK FOR ASD WILL BE IDENTIFIED THROUGH RELIABLE METHODS BEFORE ASD BEHAVIORAL CHARACTERISTICS FULLY MANIFEST.

RESEARCH FOCUS OF QUESTION 1

Question 1 of the IACC Strategic Plan ("When should I be concerned?") pertains to the issues surrounding screening for and diagnosis of ASD, with a focus on early identification of children showing signs of ASD so that they have the opportunity to receive interventions and supports that will lead to improved outcomes. The objectives within this chapter of the Strategic Plan include research to develop biomarkers, screening tools, and diagnostic instruments to aid in early identification. Question 1 also includes research to better understand and overcome barriers to early identification, including efforts to increase access to health services, and to develop or adapt screening and diagnostic tools for use in a wide variety of community settings, at low cost, and in diverse populations. In addition, the Committee prioritized the need for screening and diagnostic tools for use in adolescents and adults, and for improved measures that can be used to assess intervention and service needs. Projects addressing issues related to adult screening and diagnosis may be captured either within Question 1 or Question 6 of the Strategic Plan (Question 6 focuses on issues relevant to transitioning youth and adults on the autism spectrum).

In an effort to describe the research funded in Question 1 in 2014 and 2015, a word cloud was generated using the project titles listed under this question (**Figure 21**). The size of each word within the word cloud indicates the frequency of its use in project titles. The word cloud visually portrays the main research themes and topics that were funded in Question 1.



Figure 21. Word cloud representing themes in Question 1 project titles.

ANALYSIS OF 2014-2015 QUESTION 1 PORTFOLIO

When analyzing the distribution of research dollars across the seven question areas described in the *IACC Strategic Plan*, projects assigned to Question 1 comprised 10% (\$31.0 million) of the total ASD research in 2014 and 9% (32.1 million) in 2015. The number of projects assigned to Question 1 totaled 117 projects (8% of all projects) in 2014 and 134 projects (10% of total projects) in 2015. The largest funders of research pertaining to Question 1 in 2014 are the

National Institutes of Health, Simons Foundation, and Autism Speaks, whereas in 2015, the Health Resources and Services Administration became the third largest funder of research in Question 1. Progress made on Question 1 is measured through nine objectives.

Figures 22 & 23 provide a detailed overview of each objective's total funding in 2014 and 2015 as well as the number of projects assigned to each objective.




Figure 22. Question 1 objectives broken down by their funding and project count in 2014.

In 2014, six Question 1 objectives received funding, while two objectives did not have any funding or activity. As was the case in 2013, the Question 1 objective receiving the most funding in 2014 was 1.L.A, which focuses on identifying biomarkers for

ASD; it received 30% (\$9.1 million) of the Question 1 funding in 2014. This was followed by Objective 1.L.B, which supports the development of behavioral and biological measures for diagnosis and risk assessment, accounting for 19% (\$5.9 million) of Question 1 overall

funding. Objective 1.S.B. also received 19% (\$5.8 million) of Question 1 funding; this objective focuses on improving the sensitivity and specificity of new and existing screening and diagnostic tools. Objective 1. L.B received the largest number of projects (35 projects), followed by Objective 1.L.A which had 31 projects. All other objectives received less than 20% of Question 1 funding in 2014, and only 3% of Question 1 funding

went to projects categorized as Core/Other, which are projects not specific to Question 1 objectives. Studies to understand the impact of early diagnosis on choice of intervention and outcomes (1.S.D) received funding for the first time in 2014. Although Objective 1.S.F was also not funded in 2014, it was already considered completed due to workshops convened in previous years.



Figure 23. Question 1 objectives broken down by their funding and project count in 2015.

In 2015, seven Question 1 objectives had funding and two objectives had no funding or activity. The Question 1 objective receiving the most funding in 2015 was 1.L.B, which supports the development of behavioral and biological measures for diagnosis and risk assessment; it received 31% (\$10.0 million) of the Question 1 funding. This was followed by Objective 1.L.A, which focuses on identifying biomarkers for ASD,

accounting for 20% (\$6.3 million) of Question 1 overall funding. Only 2% of Question 1 funding went to projects categorized as Core/Other. Again, Objective 1.S.F did not receive any funding in 2015, however it was already considered completed due to workshops convened in previous years. **Table 5** lists all the objectives and their progress to date.

QUESTION 1 SUBCATEGORY ANALYSIS

With the development of the subcategory categorization scheme for the *IACC ASD Research Portfolio Analysis*, all projects can be categorized into broad research-related topic areas or themes, including projects that did not fit within the specific research objectives laid out in the *Strategic Plan*. This enables a more comprehensive understanding of the distribution of all projects across the general research areas aligning with Question 1. Overall, projects in Question 1 were divided into four subcategories: **Diagnostic and screening tools; Early signs and biomarkers;** Intermediate phenotypes/Subgroups; and Symptomology (Figures 24 & 25).

Of the four subcategories related to Question 1 (Screening and Diagnosis), in 2014 and 2015 the

largest proportion of funding was devoted to the development of **Diagnostic and screening tools** for ASD (45% in 2014; 41% in 2015). Identifying **Early signs and biomarkers** was the second largest research investment in Question 1 (32% in 2014; 31% in 2015). Included in this subcategory were biological indicators (including genetic, metabolic, and brain structure/connectivity) and behavioral biomarkers that can be used for screening/diagnosis or to measure progress or treatment response. This was followed by research characterizing **Symptomology** (14% in 2014; 15% in 2015). The subcategory receiving the lowest proportion of funding included research on identifying/characterizing **Intermediate phenotypes/Subgroups** of people with ASD (9% in 2014; 13% in 2015).




Figure 24. Question 1 funding by subcategory in 2014.




Figure 25. Question 1 funding by subcategory in 2015.

PROGRESS MADE ON QUESTION 1 FROM 2008-2015

Figure 26 shows the trend in Question 1 funding over time. When considering annual funding for Question 1 from 2008-2015, portfolio analysis data showed that funding levels stayed relatively flat since 2008, with the

exception of 2009 and 2010, during which federal funding for autism research was increased due to the American Recovery and Reinvestment Act.




Figure 26. Question 1 ASD research funding from 2008-2015. Funding for Question 1 was moderate and stayed relatively flat over the eight-year span.

PROGRESS MADE ON QUESTION 1 OBJECTIVES FROM 2008-2015

After eight years of funding, six of the nine Question 1 objectives were considered completed in terms of the recommended amount of total funding invested. Of the remaining Question 1 objectives, partial progress was made on three, and no objectives were considered inactive (**Figure 27**). Objective 1.S.D received funding for the first time in 2014, changing the status from inactive to partially completed. Since 2013, two objectives reached their recommended funding budget. **Table 5** provides an overview of progress made on all nine of the research objectives within Question 1 over the period from 2008-2015.





Figure 27. Overall status of progress for the nine Question 1 objectives.



1.S.F*

\$0

0 projects

1.S.F*

0 projects

1.S.F*

\$71,489

1 project

1.S.F*

\$0

O projects

1.S.F*

\$0

0 projects

Question 1: Multiyear Funding Table, see Appendix C for a color-coding key and further details.

1.S.F

\$0

0 projects

N/A

N/A

\$71,489

ear	2008	2009	2010	2011	2012	2013	2014	2015	Total
isk for dev nonitoring	veloping ASD, a g and screening	and evaluate whet	her these risk ma	in combination, ac rkers or profiles ca					
	1.3 \$2,885,940 14 projects	1.L.A \$16,465,034 43 projects	1.L.A \$13,270,045 45 projects	1.L.A \$12,416,466 43 projects	1.L.A \$12,894,621 40 projects	1.L.A \$9,357,851 37 projects	1.L.A \$9,147,180 31 projects	1.L.A \$6,308,892 33 projects	\$82,746,02
hat clearly	y relate to etiol	ogy and risk, treat t: \$71,100,000 over	ment response ar	l heterogeneity in nd/or outcome by	2015.		d variation in intell	ectual disability,	
	1.4	1.L.B	1.L.B	1.L.B	1.L.B	1.L.B	1.L.B	1.L.B	\$7F CC1 F7
1	\$5,773,203 18 projects	\$8,760,010 34 projects	\$15,228,060 52 projects	\$9,376,400 42 projects	\$12,813,396 39 projects	\$7,822,255 38 projects	\$5,889,944 35 projects	\$9,998,311 40 projects	\$75,661,57
lentify and estrictive leads	18 projects Ind develop mean behaviors) of Anarcoss the lifes	34 projects sures to assess at ASD symptoms and	52 projects Least three "contided severity that care		39 projects " (i.e., social recip	38 projects	35 projects	40 projects d repetitive/	\$75,661,57
dentify and estrictive l vith ASD a ACC Recom	18 projects Ind develop mean behaviors) of Anarcoss the lifes	34 projects assures to assess at ASD symptoms and pan by 2016.	52 projects Least three "contided severity that care	42 projects nuous dimensions	39 projects " (i.e., social recip	38 projects	35 projects	40 projects d repetitive/	
dentify and estrictive l with ASD a ACC Recom	d develop mea behaviors) of A across the lifes ₁ nmended Budge 1.5 \$912,159	34 projects sures to assess at ASD symptoms and pan by 2016. t: 18,500,000 over 1.L.C \$861,069 6 projects	52 projects Eleast three "contide severity that care th	42 projects nuous dimensions a be used by pract 1.L.C \$2,353,440	39 projects " (i.e., social recipitioners and/or fail	38 projects rocity, communication milies to assess research 1.L.C \$1,224,987	35 projects ation disorders, an sponse to interver	40 projects d repetitive/ ntion for people 1.L.C \$2,626,122	\$75,661,57 \$15,926,65
dentify and estrictive I with ASD a ACC Recom	d develop mea behaviors) of A across the lifesy mmended Budge 1.5 \$912,159 2 projects	34 projects sures to assess at ASD symptoms and pan by 2016. t: 18,500,000 over 1.L.C \$861,069 6 projects	52 projects Eleast three "contide severity that care th	42 projects nuous dimensions i be used by pract 1.L.C \$2,353,440	39 projects " (i.e., social recipitioners and/or fail	38 projects rocity, communication milies to assess research 1.L.C \$1,224,987	35 projects ation disorders, an sponse to interver	40 projects d repetitive/ ntion for people 1.L.C \$2,626,122	
dentify and estrictive lestrictive lestrictive lestrictive lestrictive lestrictive lestrictive lestrictive de la communicación	Is projects In develop mean behaviors) of Accross the lifesy numerided Budge 1.5 \$912,159 2 projects In Core/Other Activities \$18,229,985	34 projects assures to assess at ASD symptoms and pan by 2016. t: 18,500,000 over 1.L.C \$861,069 6 projects tive 1. Core/ Other Activities \$9,766,926 37 projects	52 projects I least three "contid severity that car 5 years 1.L.C \$3,893,622 22 projects 1. Core/ Other Activities \$3,643,562	1.L.C \$2,353,440 15 projects 1. Core/ Other Activities \$2,310,877	39 projects 5" (i.e., social recipitioners and/or fail 1.L.C \$2,600,028 15 projects 1. Core/ Other Activities \$2,175,749	38 projects rocity, communication in the second se	35 projects ation disorders, an sponse to intervel 1.L.C \$1,455,269 8 projects 1. Core/ Other Activities \$833,472	40 projects d repetitive/ ntion for people 1.L.C \$2,626,122 20 projects 1. Core/ Other Activities \$577,973	\$15,926,69

Table 5. Multiyear funding table for Question 1.



ASPIRATIONAL GOAL: DISCOVER HOW ASD AFFECTS DEVELOPMENT, WHICH WILL LEAD TO TARGETED AND PERSONALIZED INTERVENTIONS.

RESEARCH FOCUS OF QUESTION 2

Question 2 ("How can I understand what is happening?") addresses the underlying biology of ASD. Research in this field focuses on identifying the biological differences and mechanisms in early development and throughout life that contribute to ASD, as well as the characterization of the behavioral and cognitive aspects of ASD. Projects range from basic neuroscience using cellular and animal models to clinical studies. Taken together, the aim of the research represented by Question 2 is to understand the biological processes underlying ASD from the molecular level to sensory, motor, behavioral, and cognitive development and functioning.

A word cloud was created using the project titles listed under Question 2 to provide a visual representation of the research funded in 2014 and 2015 (**Figure 28**). The size of each word within the word cloud indicates the frequency of its use in project titles. The word cloud visually depicts the main research themes and topics that were funded in Question 1.




Figure 28. Word cloud representing themes in Question 2 project titles.

ANALYSIS OF 2014-2015 QUESTION 2 PORTFOLIO

Among the seven question areas described in the *IACC Strategic Plan*, Question 2 accounted for the largest portion of the ASD research portfolio in 2014 and 2015. Following similar trends as previous years, research in the biology of ASD (Question 2) comprised 32% of total funding in both years (\$100.0 million in 2014; \$107.7 million in 2015). Question 2 also had the largest portion of overall projects in 2014 (35%, 504 projects) and 2015 (34%, 481 projects). Among federal agencies and private organizations, the National Institutes of Health provided the largest investment, contributing 87% of Question 2 research funding in 2015. The Simons Foundation was the next

major funder for Question 2. Research funding under Question 2 is categorized under nine objectives.

Figures 29 & 30 provide a detailed overview of each objective's total funding in 2014 and 2015 as well as the number of projects assigned to each objective.

All nine objectives in Question 2 experienced at least some progress in 2014. The majority of projects that were categorized under this question did not fit into any of the specific Question 2 research objectives and were assigned as Question 2 Core/Other (\$47.9 million, 48%), similar to what was reported in previous years. Core/Other also accounted for nearly half of the project




Figure 29. Question 2 objectives broken down by their funding and project count in 2014.

count towards Question 2 research. As is described in the previous section of this report, projects designated as Core/Other correspond to research areas that were already established and/or well-funded at the time the *Strategic Plan* was developed, as well as areas of emerging science that may not have been captured in the Strategic Plan objectives. The next largest portion of funding went to Objective 2.S.D (\$20.4 million, 20%), which focuses on the underlying biology of genetic conditions related to ASD, such as Rett Syndrome and Fragile X Syndrome. Objective 2.S.G, which includes projects investigating a link between specific genotypes and functional or structural phenotypes, had the next greatest portion of funding (\$13.2 million, 13%). Across

portfolio analyses, Objectives 2.S.D and 2.S.G. have received the largest portion of Question 2 funding consistently since 2009.

Eight of the Question 2 objectives had active funding in 2015. Question 2 objectives followed similar funding patterns in 2015 as in prior years. The majority of Question 2 research funding was assigned to Core/Other (\$52.9 million, 49%) as well as majority of the project count (215 projects). The next largest portions of funding continued to be Objective 2.S.D (\$18.6 million, 17%), followed by Objective 2.S.G (\$13.6 million, 13%). **Table 6** lists all the objectives and their progress to date.




Figure 30. Question 2 objectives broken down by their funding and project count in 2015.

QUESTION 2 SUBCATEGORY ANALYSIS

Due to the large proportion of research in Question 2 that could not be assigned to a particular objective, the subcategory analysis was particularly useful in understanding the distribution of research on the underlying mechanisms of ASD. Research in this area covers a broad array of science, and therefore Question 2 was divided into several subcategories. These include: Cognitive studies; Computational science; Co-occurring conditions; Developmental trajectory; Immune/Metabolic pathways; Molecular pathways; Neural systems; Neuropathology; Sensory and motor function; and Subgroups/Biosignatures (Figures 31 & 32).

As in previous years, the Question 2 subcategory with the largest portion of funding was **Molecular pathways** (33% in 2014; 36% in 2015), which includes systems of genes, proteins, and other molecules that are involved in ASD and related disorders. Research exploring the **Neural systems** was the second largest investment

for both years (19% in 2014; 20% in 2015). The third largest subcategory focused on projects aiming to identify Subgroups/Biosignatures (14% in 2014; 10% in 2015). Research into the **Developmental trajectory** of ASD, including longitudinal studies that follow social, behavioral, and physical development over time accounted for 8% of Question 2 funding in 2014 and 7% of funding in 2015. Cognitive studies accounted for 8% of ASD funding in 2014, but had a slight drop to 4% of funding in 2015. Projects investigating Immune/ Metabolic pathways received 4% of research funding in 2014 and 5% of 2015 funding. Sensory and motor **function** accounted for 3% of funding in 2014 and 4% in 2015. Co-occurring conditions was 4% of Question 2 funding in 2014; this stayed relatively consistent at 5% of funding in 2015. Research in **Computational science** accounted for 3% of funding in 2014 and 2% of funding in 2015. Lastly, Neuropathology accounted for 4% of funding in 2014 and 7% of funding in 2015.




Figure 31. Question 2 funding by subcategory in 2014.




Figure 32. Question 2 funding by subcategory in 2015.

PROGRESS MADE ON QUESTION 2 FROM 2008-2015

Figure 33 shows the trend in Question 2 funding over time. Overall, funding for projects within Question 2 was higher than those of other question areas. When considering annual funding for Question 2 from 2008-2015, portfolio analysis data showed that funding levels for this question had only a moderate increase

in recent years, despite having undergone a significant increase since 2008. Question 2 is the only question area that has been on a strongly upward funding trend over the period from 2008-2015. All other areas remained relatively flat or decreasing.




Figure 33. Question 2 ASD research funding from 2008-2015. Funding for Question 2 rapidly increased, and then leveled off, over the eight-year span.

PROGRESS MADE ON QUESTION 2 OBJECTIVES FROM 2008-2015

As of 2015, seven of the nine Question 2 objectives were considered completed in terms of meeting their overall budget recommendations, while two objectives were considered partially completed (**Figure 34**). The funding received for Question 2 Objective 2.S.B and 2.L.B in 2014 and 2015 was enough to change each objective's overall status from partially completed as of 2013 to completed as of 2015. **Table 6** provides a snapshot of progress made on all nine of the research objectives within Question 2 over the period from 2008-2015.



Figure 34. Overall status of progress for the nine Question 2 objectives.



Question 2: How Can I Understand What Is Happening? IACC Strategic Plan Objectives

	2008	2009	2010	2011	2012	2013	2014	2015	Total
system	that may influen	search projects to i ce ASD during prei get: \$9,800,000 over	natal-postnatal life				ons with the centr	al nervous	
	2.2 \$3,377,568 18 projects	2.S.A \$3,584,634 30 projects	2.S.A \$4,972,407 37 projects	2.S.A \$2,013,417 25 projects	2.S.A \$3,049,827 26 projects	2.S.A \$2,801,876 29 projects	2.S.A \$3,770,160 32 projects	2.S.A \$4,759,792 33 projects	\$28,329,68
by 2011		at specifically focu		velopment of fema	lles with ASD, spai	nning basic to clini	cal research on se	ex differences	
	2.3 \$0 0 projects	2.S.B \$1,370,107 5 projects	2.S.B \$1,096,678 5 projects	2.S.B \$150,000 1 project	2.S.B \$3,239,998 5 projects	2.S.B \$2,859,333 7 projects	2.S.B \$4,595,343 15 projects	2.S.B \$4,489,112 10 projects	\$17,800,57
researc	h by 2011.	e awareness amon get: \$1,400,000 over		trum community c	of the potential val	lue of brain and tis	sue donation to fu	ırther basic	
	2.4 \$0 0 projects	2.S.C \$726,911 2 projects	2.S.C \$17,000 1 project	2.S.C \$22,000 1 project	2.S.C \$90,120 1 project	2.S.C \$674,525 5 projects	2.S.C \$805,331 4 projects	2.S.C \$887,893 4 projects	\$3,223,780
Fragile	X, Rett syndrome	nat target improve e, tuberous sclero get: \$9,000,000 ove	sis complex) and						
	N/A	2.S.D \$9,171,542	2.S.D \$13,162,905	2.S.D \$12,360,956	2.5.D \$18,452,242	2.S.D	2.S.D	2.S.D	
		48 projects	57 projects	64 projects	83 projects	\$18,627,373 94 projects	\$20,375,986 106 projects	\$18,582,014 101 projects	\$110,733,01
disorders	s, wandering/elop	48 projects t target the underly pement behavior, a t: \$9,000,000 over 5	ying biological me nd familial autoim	64 projects chanisms of co-oc	83 projects	94 projects	106 projects	101 projects	\$110,733,01
lisorders	s, wandering/elop	t target the underly pement behavior, a	ying biological me nd familial autoim	64 projects chanisms of co-oc	83 projects	94 projects	106 projects	101 projects	
disorders ACC Reco	s, wandering/elop ommended Budget N/A u two studies that	t target the underly pement behavior, a t: \$9,000,000 over 5 2.S.E \$3,893,300	ying biological me and familial autoim 5 years 2.S.E \$4,611,058 14 projects	chanisms of co-oc mune disorders, b 2.S.E \$4,807,760 23 projects	83 projects curring conditions y 2012. 2.S.E \$3,218,960 22 projects	94 projects s with autism, inclu 2.S.E \$4,848,555 23 projects	2.S.E \$3,102,820 23 projects	101 projects depsy, sleep 2.S.E \$4,646,472 28 projects	\$110,733,01 \$29,128,92

Question 2: Multiyear Funding Table, see Appendix C for a color-coding key and further details.



Question 2: How Can I Understand What Is Happening? IACC Strategic Plan Objectives

Year	2008	2009	2010	2011	2012	2013	2014	2015	Total
(e.g., no	nverbal individua	associate specificals with ASD and the	ose with cognitive		tural phenotypes, i v 2015.	including behavio	ral and medical ph	enotypes	
	N/A	2.S.G \$5,903,875 21 projects	2.S.G \$9,149,672 39 projects	2.S.G \$11,105,408 45 projects	2.S.G \$15,618,073 44 projects	2.S.G \$12,646,192 49 projects	2.S.G \$13,216,265 55 projects	2.S.G \$13,560,682 53 projects	\$81,200,167
develop develop	mental profiles o ing people by 20	f individuals, with	a special emphasi		lly and comprehen ths, and adults witl				
	2.5 \$8,523,806 49 projects	2.L.A \$2,721,384 6 projects	2.L.A \$2,283,875 6 projects	2.L.A \$972,559 5 projects	2.L.A \$6,160,017 9 projects	2.L.A \$5,201,378 7 projects	2.L.A \$5,030,774 7 projects	2.L.A \$6,707,672 10 projects	\$37,601,465
assessn	nent, or clinical ir	udies that evaluat ntervention by 201 et: 7,200,000 over	15.	of ASD phenotyp	oe and/or biologica	al signature findir	ngs for performing	diagnosis, risk	
	N/A	2.L.B \$1,532,262 16 projects	2.L.B \$450,271 2 projects	2.L.B \$324,241 4 projects	2.L.B \$1,321,632 8 projects	2.L.B \$3,096,581 13 projects	2.L.B \$1,111,662 15 projects	2.L.B \$1,107,147 15 projects	\$8,943,796
Not Spe	ecific to any object	ctive							
	2. Core/ Other Activities \$23,701,450 133 projects	2. Core/ Other Activities \$34,348,933 163 projects	2. Core/ Other Activities \$55,114,888 246 projects	2. Core/ Other Activities \$41,127,339 228 projects	2. Core/ Other Activities \$48,851,715 261 projects	2. Core/ Other Activities \$45,800,151 248 projects	2. Core/ Other Activities \$47,855,595 246 projects	2. Core/ Other Activities \$52,930,907 227 projects	\$349,730,977
Total	Funding for	Question 2 [†]							
	\$40,621,403 202 projects	\$63,252,948 302 projects	\$91,260,349 409 projects	\$73,223,388 399 projects	\$100,254,414 461 projects	\$96,872,439 476 projects	\$100,029,453 504 projects	\$107,671,690 481 projects	\$668,167,505*

Question 2: Multiyear Funding Table, see Appendix C for a color-coding key and further details.

Table 6. Multiyear funding table for Question 2.

^{*}This total reflects all funding for projects aligned to current objectives in the 2011 IACC Strategic Plan and incorporates funding for projects that may have been coded differently in previous versions of the Plan.

[†]The totals reflect the funding and projects coded to this Question of the Strategic Plan in the particular year indicated at the top of the column. When reading each column vertically, please note that the projects and funding associated with each objective for 2008 may not add up to the total at the bottom of the column; this is due to revisions of the Strategic Plan that caused some objectives to be shifted to other Questions under the Plan. The projects and funding associated with these reclassified objectives are now reflected under the Question in which they appear in the 2011 Strategic Plan.



ASPIRATIONAL GOAL: CAUSES OF ASD WILL BE DISCOVERED THAT INFORM PROGNOSIS AND TREATMENTS AND LEAD TO PREVENTION/PREEMPTION OF THE CHALLENGES AND DISABILITIES OF ASD.

RESEARCH FOCUS OF QUESTION 3

Question 3 ("What caused this to happen and can it be prevented?") focuses on the risk factors associated with the development of ASD. Research related to Question 3 looks at the role of genetics, epigenetics, and the environment in the development of ASD, as well as the interactions between risk factors. Question 3 objectives address topics such as the need to develop improved approaches to study environmental exposures and gene-environment interactions, and to explore the potential roles of the microbiome and epigenetics on etiology. Also included are studies of risk factors and protective factors (factors that may protect an individual from developing ASD, even in the presence of other risk factors).

To describe the research funded in Question 3 in 2014 and 2015, a word cloud was generated using the project titles listed under this question (**Figure 35**). The size of each word within the word cloud indicates the frequency of its use in project titles. The word cloud visually portrays the main research themes and topics that were funded in Question 3.



Figure 35. Word cloud representing themes in Question 3 project titles.

ANALYSIS OF 2014-2015 QUESTION 3 PORTFOLIO

In 2014, research on risk factors associated with ASD (Question 3) accounted for \$48.5 million (16%) of total ASD research funding. In 2015, Question 3 funding increased to \$62.6 million and accounted for 18% of overall ASD funding. The number of projects assigned to Question 3 totaled 157 projects (11% of all projects) in 2014 and 197 projects (14% of total projects) in 2015.

The largest funders of Question 3 are the National Institutes of Health, Simons Foundation, and Centers for Disease Control and Prevention. Question 3 consists of 15 objectives. **Figures 36 & 37** provide a detailed overview of each objective's total funding in 2014 and 2015 as well as the number of projects assigned to each objective.




Figure 36. Question 3 objectives broken down by their funding and project count.

In 2014, thirteen of the fifteen objectives experienced at least some level of activity (one of the inactive objectives was completed in a previous year). Objective 3.L.B received the largest proportion of funding, which identifies genetic risk factors for ASD (\$11.4 million; 24% of Question 3 funding). This was followed by Objective 3.L.D, which supports multiple sites within a large-scale study that collects data on environmental factors before and during pregnancy to assess any

potential risk factors (\$10.8 million, 22%). Objective 3.L.B had the largest number of projects (49 projects), followed by 3.S.J with 24 projects. All other objectives in Question 3 received a smaller portion of funding and number of projects. Though objective 3.S.G did not receive any new funding in 2014, it was completed by a workshop convened by the National Institute of Environmental Health Sciences (NIEHS) in 2011; objective 3.L.A did not receive funding in 2014.




Figure 37. Question 3 objectives broken down by their funding and project count in 2015.

In 2015, the majority of the objectives maintained funding activity. Only two objectives did not experience any funding or projects – one objective continuing to be the objective (3.S.G), which was completed in a previous year. Funding for objectives followed similar patterns to 2014; Objective 3.L.B received the largest portion of funding with \$22.5 million and 36% of Question 3 funding. This was followed by Objective 3.L.D with \$10.2 million and 16% of funding. When comparing project counts, 3.L.B continued to have the largest number of projects (60 projects). This was followed by Objective 3.S.H with 25 projects. **Table 7** lists all the objectives and their progress to date.

QUESTION 3 SUBCATEGORY ANALYSIS

Projects in Question 3 were divided into four subcategories to determine the funding distribution across the research areas relating to understanding and identifying risk factors for ASD. These subcategories include: Environmental risk factors; Epigenetics; Gene-Environment studies; and Genetic risk factors (Figures 38 & 39).

In 2014 and 2015, studies focused on **Genetic risk factors** accounted for the highest percentage of Question 3 funding (38% in 2014; 50% in 2015). This is




Figure 38. Question 3 funding by subcategory in 2014.

a change from 2013, when gene-environment research led Question 3 funding. Instead, investigating the role of environmental risk factors, genetic susceptibility, and/or the context of human physiology (**Gene-Environment**) was the second largest research investment in 2014 and 2015 (35% in 2014; 29% in 2015). Projects considering

only **Environmental risk factors** received 16% of Question 3 funding in 2014 and 13% in 2015. Projects on **Epigenetics** received 11% of funding in 2014 and 8% in 2015, which included studies investigating DNA modifications and exploring altered gene expression due to environmental influences.




Figure 39. Question 3 funding by subcategory in 2015.

PROGRESS MADE ON QUESTION 3 FROM 2008-2015

Figure 40 shows the trend in Question 3 funding over time. While research on risk factors remained supported at high levels over the eight-year period compared to some of the other question areas, the

overall trend showed an initial increase followed by a rapid decrease and then a general leveling off of the annual funding level from 2011-2015.




Figure 40. Question 3 ASD research funding from 2008-2015. Funding for Question 3 initially showed an increase followed by a steady decrease, and then leveled off, over the eight-year span.

PROGRESS MADE ON QUESTION 3 OBJECTIVES FROM 2008-2015

As of 2015, eleven of Question 3's objectives were considered completed, while the remaining four were partially complete based on the total recommended budget levels (Figure 41). Of the eleven completed objectives, two changed from an overall partially completed status as of 2013 to a completed status as of 2015. The objectives that have been newly completed as of 2015 include: 3.S.K, which supports research on model systems that explore environment interactions with genetic susceptibilities; and 3.S.A, which coordinates the inclusion of subjects for genome-wide association studies as well as the study of candidate genes through sequencing studies. **Table 7** provides a snapshot of progress made on all 15 of the research objectives within Question 3 over the period from 2008-2015.



Figure 41. Overall status of progress for the 15 Question 3 objectives.



Question 3: What Caused This To Happen And Can It Be Prevented? IACC Strategic Plan Objectives

	2008	2009	2010	2011	2012	2013	2014	2015	Total
		ent the inclusion of kamine more than							
		hare an identified (
ICC Re	commended Budge	et: \$43,700,000 ov	er 4 years						
	3.2	3.S.A	3.S.A	3.S.A	3.S.A	3.S.A	3.S.A	3.S.A	
	\$4,065,392 14 projects	\$13,926,663 11 projects	\$16,688,932 14 projects	\$2,207,214 7 projects	\$1,699,432 6 projects	\$4,965,929 11 projects	\$3,972,844 12 projects	\$5,015,006 18 projects	\$52,541,4
		ty categories of ex in biospecimens b		identify and stand	ardize at least thr	ee measures for ic	dentifying markers	s of	
	•	et: \$3,500,000 over	-						
	3.3	3.S.B	3.S.B	3.S.B	3.S.B	3.S.B	3.S.B	3.S.B	
	\$713,227	\$0	\$0	\$0	\$100,000	\$0	\$231,692	\$468,290	\$1,513,20
	4 projects	0 projects	0 projects	0 projects	1 project	1 project	1 project	2 projects	
itiate	efforts to expand	l existing large cas	e-control and oth	er studies to enha	nce capabilities fo	or targeted gene-e	environment resea	rch by 2011.	
CC Re	commended Budge	et: \$27,800,000 ove	er 5 years						
	3.4	3.S.C	3.S.C	3.S.C	3.S.C	3.S.C	3.S.C	3.S.C	
	\$4,703,867	\$8,033,454	\$4,824,779	\$5,714,408	\$3,626,803	\$4,680,036	\$5,154,023	\$5,099,102	\$41,836,
	4 projects	9 projects	8 projects	10 projects	9 projects	6 projects	8 projects	11 projects	
nhanc	e existing case-c	ontrol studies to e	nroll racially and e	thnically diverse r	nonulations affects	ed by ASD by 2011			
		et: \$3,300,000 over		ameany arrerse p	opulations arrect	24 0) 7.32 0) 2011	•		
	2 E	3 C D	2 C D	2 C D	2 C D	2 C D	2 C D	2 C D	
	3.5 \$84,628	3.S.D \$103,827	3.S.D \$0	3.S.D \$0	3.S.D \$0	3.S.D \$3,168,451	3.S.D \$2,728,166	3.S.D \$2,715,972	\$8,801,0
									\$8,801,0
innor	\$84,628 2 projects	\$103,827 3 projects	\$0 O projects	\$0 O projects	\$0 O projects	\$3,168,451 2 projects	\$2,728,166 1 project	\$2,715,972 1 project	\$8,801,0
	\$84,628 2 projects t at least two study	\$103,827	\$0 0 projects if there are subpop	\$0 0 projects pulations that are	\$0 0 projects more susceptible	\$3,168,451 2 projects	\$2,728,166 1 project	\$2,715,972 1 project	\$8,801,0
nallen	\$84,628 2 projects t at least two studges related to infe	\$103,827 3 projects dies to determine i	\$0 0 projects if there are subpop ns, or underlying a	\$0 0 projects pulations that are	\$0 0 projects more susceptible	\$3,168,451 2 projects	\$2,728,166 1 project	\$2,715,972 1 project	\$8,801,0
nallen	\$84,628 2 projects t at least two studges related to infe	\$103,827 3 projects dies to determine i ections, vaccinatio	\$0 0 projects if there are subpop ns, or underlying a	\$0 0 projects pulations that are	\$0 0 projects more susceptible	\$3,168,451 2 projects	\$2,728,166 1 project	\$2,715,972 1 project	\$8,801,0
allen	\$84,628 2 projects t at least two studges related to infectormmended Budge	\$103,827 3 projects dies to determine ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200	\$0 0 projects if there are subpopers, or underlying a r 2 years 3.S.E \$1,162,679	\$0 0 projects pulations that are autoimmune probl 3.S.E \$419,215	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218	\$3,168,451 2 projects to environmental 3.S.E \$282,300	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859	\$2,715,972 1 project nmune 3.S.E \$1,129,886	
allen	\$84,628 2 projects t at least two studges related to infectormmended Budge	\$103,827 3 projects dies to determine ections, vaccinationet: \$8,000,000 over	\$0 0 projects if there are subpop ns, or underlying a r 2 years 3.S.E	\$0 0 projects pulations that are autoimmune probl	\$0 0 projects more susceptible ems) by 2012.	\$3,168,451 2 projects to environmental	\$2,728,166 1 project exposures (e.g., in	\$2,715,972 1 project mmune 3.S.E	
nalleng CC Re	\$84,628 2 projects t at least two studies related to infectommended Budge N/A studies on at lease	\$103,827 3 projects dies to determine in ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmenta	\$0 0 projects if there are subpolens, or underlying a r 2 years 3.S.E \$1,162,679 10 projects al factors identified	\$0 0 projects pulations that are autoimmune proble 3.S.E \$419,215 5 projects d in the recommen	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects	
nalleng CC Re itiate nallen	\$84,628 2 projects t at least two studies related to infectormmended Budge N/A studies on at least ges and Opportu	\$103,827 3 projects dies to determine in ections, vaccination et: \$8,000,000 over 3.5.E \$1,739,200 13 projects st 10 environmental nities for Research	\$0 0 projects If there are subpolens, or underlying are 2 years 3.S.E \$1,162,679 10 projects al factors identified " as potential caus	\$0 0 projects pulations that are autoimmune proble 3.S.E \$419,215 5 projects d in the recommen	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects	
nalleng CC Re	\$84,628 2 projects t at least two studies related to infectormmended Budge N/A studies on at least ges and Opportu	\$103,827 3 projects dies to determine in ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmenta	\$0 0 projects If there are subpolens, or underlying are 2 years 3.S.E \$1,162,679 10 projects al factors identified " as potential caus	\$0 0 projects pulations that are autoimmune proble 3.S.E \$419,215 5 projects d in the recommen	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects	
nalleng CC Re	\$84,628 2 projects t at least two studies related to infectommended Budge N/A studies on at least ges and Opportunctommended Budge 3.1	\$103,827 3 projects dies to determine in ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmental nities for Research et: \$56,000,000 over 3.S.F	\$0 0 projects If there are subpolens, or underlying are 2 years 3.S.E \$1,162,679 10 projects al factors identified " as potential causer 2 years 3.S.F	\$0 0 projects pulations that are autoimmune problem 3.S.E \$419,215 5 projects d in the recommenses of ASD by 201 3.S.F	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects adations from the 2.	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects 2007 IOM report	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects 'Autism and the En	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects nvironment:	\$5,086,3
nalleng CC Re	\$84,628 2 projects t at least two studies related to infectommended Budge N/A studies on at least ges and Opportunctommended Budge 3.1 \$7,600,673	\$103,827 3 projects dies to determine in ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmenta nities for Research et: \$56,000,000 over 3.S.F \$2,952,960	\$0 0 projects If there are subpoles, or underlying a received 2 years 3.S.E \$1,162,679 10 projects In factors identified and as potential causer 2 years 3.S.F \$166,362	\$0 0 projects pulations that are autoimmune problem 3.S.E \$419,215 5 projects d in the recommenses of ASD by 201 3.S.F \$0	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects adations from the 2. 3.S.F \$75,000	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects 2007 IOM report	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects 'Autism and the En 3.S.F \$264,597	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects nvironment: 3.S.F \$535,763	\$5,086,3
nalleng CC Re	\$84,628 2 projects t at least two studies related to infectommended Budge N/A studies on at least ges and Opportunctommended Budge 3.1	\$103,827 3 projects dies to determine in ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmental nities for Research et: \$56,000,000 over 3.S.F	\$0 0 projects If there are subpolens, or underlying are 2 years 3.S.E \$1,162,679 10 projects al factors identified " as potential causer 2 years 3.S.F	\$0 0 projects pulations that are autoimmune problem 3.S.E \$419,215 5 projects d in the recommenses of ASD by 201 3.S.F	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects adations from the 2.	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects 2007 IOM report	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects 'Autism and the En	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects nvironment:	\$5,086,3
alleng CC Re iitiate nallen CC Re	\$84,628 2 projects t at least two studies related to infector mended Budge N/A studies on at least ges and Opportuctor mended Budge 3.1 \$7,600,673 19 projects a workshop that	\$103,827 3 projects dies to determine in ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmenta inities for Research et: \$56,000,000 over 3.S.F \$2,952,960 14 projects explores the useful	\$0 0 projects If there are subpounds, or underlying a region 2 years 3.S.E \$1,162,679 10 projects If factors identified and a special causer 2 years 3.S.F \$166,362 5 projects Ulness of bioinform	\$0 0 projects pulations that are autoimmune problem 3.S.E \$419,215 5 projects d in the recommenses of ASD by 201 3.S.F \$0 3 projects	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects adations from the 2. 3.S.F \$75,000 1 project	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects 2007 IOM report 3.S.F \$0 1 project	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects "Autism and the En 3.S.F \$264,597 3 projects	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects nvironment: 3.S.F \$535,763	\$5,086,3
alleng CC Re iitiate hallen CC Re	\$84,628 2 projects t at least two studies related to infector mended Budge N/A studies on at least ges and Opportucton mended Budge 3.1 \$7,600,673 19 projects a workshop that commended Budget	\$103,827 3 projects dies to determine is ections, vaccinatio et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmenta nities for Research et: \$56,000,000 over 3.S.F \$2,952,960 14 projects explores the useful: \$35,000 over 1 years	\$0 0 projects If there are subpounds, or underlying a region 2 years 3.S.E \$1,162,679 10 projects If factors identified and a special causer 2 years 3.S.F \$166,362 5 projects Ulness of bioinform	\$0 0 projects pulations that are autoimmune problem 3.S.E \$419,215 5 projects d in the recommenses of ASD by 201 3.S.F \$0 3 projects	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects adations from the 2. 3.S.F \$75,000 1 project	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects 2007 IOM report 3.S.F \$0 1 project	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects "Autism and the En 3.S.F \$264,597 3 projects	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects nvironment: 3.S.F \$535,763	\$5,086,3
nalleng CC Re iitiate hallen CC Re nvene	\$84,628 2 projects t at least two studies related to infector mended Budget N/A studies on at least ges and Opportucton mended Budget 3.1 \$7,600,673 19 projects a workshop that commended Budget ective was complete	\$103,827 3 projects dies to determine is ections, vaccination et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmenta inities for Research et: \$56,000,000 over 3.S.F \$2,952,960 14 projects explores the useful in 2011	\$0 0 projects If there are subpoples, or underlying a region 2 years 3.S.E \$1,162,679 10 projects If factors identified a region 2 years 3.S.F \$166,362 5 projects Ulness of bioinformar	\$0 0 projects pulations that are autoimmune problem 3.S.E \$419,215 5 projects d in the recomments of ASD by 201 3.S.F \$0 3 projects matic approaches of	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects adations from the 2. 3.S.F \$75,000 1 project to identify environ	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects 2007 IOM report 3.S.F \$0 1 project mental risks for A	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects "Autism and the En 3.S.F \$264,597 3 projects SD by 2011.	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects nvironment: 3.S.F \$535,763 3 projects	\$5,086,3
nalleng CC Re iitiate hallen CC Re nvene	\$84,628 2 projects t at least two studies related to infector mended Budge N/A studies on at least ges and Opportucton mended Budge 3.1 \$7,600,673 19 projects a workshop that commended Budget	\$103,827 3 projects dies to determine is ections, vaccinatio et: \$8,000,000 over 3.S.E \$1,739,200 13 projects st 10 environmenta nities for Research et: \$56,000,000 over 3.S.F \$2,952,960 14 projects explores the useful: \$35,000 over 1 years	\$0 0 projects If there are subpounds, or underlying a region 2 years 3.S.E \$1,162,679 10 projects If factors identified and a special causer 2 years 3.S.F \$166,362 5 projects Ulness of bioinform	\$0 0 projects pulations that are autoimmune problem 3.S.E \$419,215 5 projects d in the recommenses of ASD by 201 3.S.F \$0 3 projects	\$0 0 projects more susceptible ems) by 2012. 3.S.E \$287,218 5 projects adations from the 2. 3.S.F \$75,000 1 project	\$3,168,451 2 projects to environmental 3.S.E \$282,300 7 projects 2007 IOM report 3.S.F \$0 1 project	\$2,728,166 1 project exposures (e.g., in 3.S.E \$65,859 5 projects "Autism and the En 3.S.F \$264,597 3 projects	\$2,715,972 1 project nmune 3.S.E \$1,129,886 3 projects nvironment: 3.S.F \$535,763	\$8,801,0 \$5,086,3 \$11,595,3

Question 3: Multivear Funding Table see Appendix C for a color-coding key and further detail



Question 3: What Caused This To Happen And Can It Be Prevented? IACC Strategic Plan Objectives

13 projects 16 projects 13 projects 12 projects 25 projects 25 projects 25 projects 25 projects 25 projects 25 projects 25 projects 25 projects 25 projects 25 projects 25 projects 25 projects 26 projects 18 projects 25 projects 27 projects 29 projects 28 projects 29 projects 29 projects 29 projects 29 projects 29 projects 29 projects 29 projects 29 projects 29 projects 20	ar	2008	2009	2010	2011	2012	2013	2014	2015	Total
pregnancy and the early postnatal period by 2012. Such studies could include: Comparisons of populations differing in geography, gender, ethnic background, exposure history (e.g., prematurity, maternal infection, nutritional deficiencies, toxins), and migration patterns; and Comparisons of phenotype (e.g., cytokine profiles), in children with and without a history of autistic regression, adverse events following immunization (such as fever and seizures), and mitochondrial impairment. These studies may also include comparisons of phenotype between children with regressive ASD and their siblings. Phylasis on environmental factors that influence prenatal and early postnatal development is particularly of high priority. Epidemiological studies ould pay special attention to include racially and ethnically diverse populations. 1C Recommended Budget: S12,000,000 over 5 years N/A N/A SS.H	pport	at least three stu	udies of special po	pulations or use e	existing databases	to inform our und	erstanding of env	ironmental risk fa	ctors for ASD	
deficiencies, toxins), and migration patterns; and Comparisons of phenotype (e.g., cytokine profiles), in children with and without a history of autistic regression, adverse events following immunization (such as fever and seizures), and mitochondrial impairment. These studies may also include comparisons of phenotype between children with regressive ASD and their siblings. Phylass on environmental factors that influence prenatal and early postnatal development is particularly of high priority. Epidemiological studies outly pay special attention to include racially and ethnically diverse populations. CR Recommended Budget: \$12,000,000 over 5 years N/A N/A 3.S.H 5.S.H	oregna	ancy and the ear	ly postnatal perio	d by 2012. Such st	udies could includ	le:				
Comparisons of phenotype (e.g., cytokine profiles), in children with and without a history of audistic regression, adverse events following mmmunization (such as fever and seizures), and mitochondrial impairment. These studies may also include comparisons of phenotype between children with regressive ASD and their siblings. Phasis on environmental factors that influence prenatal and early postnatal development is particularly of high priority. Epidemiological studies until day as pecial attention to include racially and ethnically diverse populations. C Recommended Budget: \$12,000,000 over 5 years N/A N/A S.S.H					r, ethnic backgrou	ınd, exposure histo	ory (e.g., prematu	rity, maternal infec	tion, nutritional	
immunization (such as fever and seizures), and mitochondrial impairment. These studies may also include comparisons of phenotype between children with regressive ASD and their siblings. phasis on environmental factors that influence prenatal and early postnatal development is particularly of high priority. Epidemiological studies build pay special attention to include racially and ethnically diverse populations. CRecommended Budget: \$12,000,000 over 5 years N/A N/A 3.S.H \$1,527,866 \$4,657,095 \$4,096,317 \$5,137,711 \$6,508,200 \$5,481,948 \$27,409,1000,000 over 2 years N/A N/A 3.S.H \$3.S.H \$3.S					dren with and with	nout a history of a	itistic regression	adverse events fo	llowing	
sphasis on environmental factors that influence prenatal and early postnatal development is particularly of high priority. Epidemiological studies ould pay special attention to include racially and ethnically diverse populations. IC Recommended Budget: \$12,000,000 over 5 years N/A N/A 3.S.H	immur	nization (such as	fever and seizure	es), and mitochono						
N/A N/A 3.5.H 3.5.	phasis	s on environmen	tal factors that in	fluence prenatal a			articularly of high	priority. Epidemiol	ogical studies	
N/A N/A 3.5.H S1,527,866 S4,657,095 S4,096,317 S5,137,711 S6,508,200 S5,481,948 S1,527,866 S4,657,095 S4,096,317 S5,137,711 S6,508,200 S5,481,948 S1,527,866 S4,657,095 S4,096,317 S5,137,711 S6,508,200 S5,481,948 S27,409,1 S1,300,000 over 2 years N/A N/A 3.5.I 3.5.I 3.5.I 3.5.I 3.5.I 3.5.I 3.5.I 3.5.I S53,960 S439,971 S2,553,332 S960,391 S1,127,918 S675,434 S90,000 S9 projects 4 projects 4 projects 6 projects 8 projects 9 projects 19 projects 24 projects 21 projects 10 projects					diverse population	ns.				
S1,527,866 S4,657,095 S4,096,317 S5,137,711 S6,508,200 S5,481,948 13 projects 16 projects 13 projects 12 projects 18 projects 25 projects pport at least two studies that examine potential differences in the microbiome of individuals with ASD versus comparison groups by 2012. CRecommended Budget: \$1,000,000 over 2 years N/A N/A 3.5.1 3.5.	.C Reco	ommended Budge	t: \$12,000,000 ov	er 5 years						
propert at least two studies that examine potential differences in the microbiome of individuals with ASD versus comparison groups by 2012. N/A N/A 3.S.I 3		N/A	N/A	3.S.H	3.S.H	3.S.H	3.S.H	3.S.H	3.S.H	
poport at least two studies that examine potential differences in the microbiome of individuals with ASD versus comparison groups by 2012. N/A N/A 3.S.I 3.				\$1,527,866	\$4,657,095	\$4,096,317	\$5,137,711	\$6,508,200	\$5,481,948	\$27,409,1
N/A N/A S.S.I S.S.				13 projects	16 projects	13 projects	12 projects	18 projects	25 projects	
N/A N/A S.S.I S.S.	nnort	at loast two stud	lies that evamine	notantial differen	os in the microbia	omo of individuals	with ACD vorces	omparison grave	- by 2012	
N/A N/A 3.S.I 3.S.				•	es in the microbio	ome or individuals	widi add versus c	ompanson groups	S UY 2012.	
S53,960 S439,971 S255,332 S960,391 S1,127,918 S675,434 Projects 9 projects 10 projects	.C Necc	Jililienaea Daage	t. 31,000,000 over	2 yeurs						
3 projects 4 projects 6 projects 8 projects 9 projects 9 projects poport at least three studies that focus on the role of epigenetics in the etiology of ASD, including studies that include assays to measure DNA thylations and histone modifications and those exploring how exposures may act on maternal or paternal genomes via epigenetic mechanisms alter gene expression, by 2012. IC Recommended Budget: \$20,000,000 over 5 years N/A N/A 3.S.J		N/A	N/A	3.S.I	3.S.I	3.S.I	3.S.I	3.S.I	3.S.I	
poport at least three studies that focus on the role of epigenetics in the etiology of ASD, including studies that include assays to measure DNA thylations and histone modifications and those exploring how exposures may act on maternal or paternal genomes via epigenetic mechanisms alter gene expression, by 2012. **C Recommended Budget: \$20,000,000 over 5 years** N/A N/A 3.5.1 3.5				\$53,960	\$439,971	\$255,332	\$960,391	\$1,127,918	\$675,434	\$3,513,00
thylations and histone modifications and those exploring how exposures may act on maternal or paternal genomes via epigenetic mechanisms alter gene expression, by 2012. C Recommended Budget: \$20,000,000 over 5 years N/A N/A N/A S.S.J S.S.O.72,389 S5,341,237 S6,122,724 S4,972,257 S5,503,732 S5,463,324 15 projects 19 projects 22 projects 19 projects 24 projects 21 projects 27 projects 28 projects N/A N/A N/A S.S.K S.S										
\$32,475,6 \$5,072,389	thylat	ions and histone	modifications an	n the role of epige	netics in the etiolo	ogy of ASD, includi	ng studies that in	clude assays to m	easure DNA	
\$32,475,6 \$5,072,389	thylat alter g	ions and histone ene expression,	modifications an by 2012.	n the role of epige d those exploring	netics in the etiolo	ogy of ASD, includi	ng studies that in	clude assays to m	easure DNA	
pport two studies and a workshop that facilitate the development of vertebrate and invertebrate model systems for the exploration of vironmental risks and their interaction with gender and genetic susceptibilities for ASD by 2012. CC Recommended Budget: \$1,535,000 over 3 years N/A N/A N/A S.S.K \$3.S.K \$3.S.K \$3.S.K \$733,922 \$463,841 \$90,000 \$0 \$145,373 \$1,747,078 \$1,747,078 \$5 projects \$3 projects \$3 projects \$3 projects \$4 projects \$10 projects \$	thylat alter g	ions and histone ene expression, ommended Budge	modifications an by 2012. t: \$20,000,000 ov	n the role of epige d those exploring er 5 years	netics in the etiok how exposures m	ogy of ASD, includi ay act on maternal	ng studies that in I or paternal geno	clude assays to m mes via epigeneti	easure DNA c mechanisms	
A subsequent pregnancies of 1,000 women with a child with ASD to assess the impact of environmental factors in a riod most relevant to the progression of ASD by 2014. 3.7 3.8.1.0 3.9.1.0 3	thylat alter g	ions and histone ene expression, ommended Budge	modifications an by 2012. t: \$20,000,000 ov	n the role of epige d those exploring er 5 years 3.5. J	netics in the etiolo how exposures man	ogy of ASD, includi ay act on maternal 3.S.J	ing studies that in l or paternal geno	clude assays to m mes via epigenetion	easure DNA mechanisms	\$32,475,6
N/A N/A 3.S.K 5733,922 \$463,841 \$90,000 \$0 \$145,373 \$1,747,078 \$53,180,2 \$100 most relevant to the progression of ASD by 2014. C.C. Recommended Budget: \$11,100,000 over 5 years 3.7 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 52,742,999 \$3,740,812 \$2,971,093 \$2,864,377 \$2,875,202 \$411,571 \$0 \$637,260 \$16,243,32 \$1,2	thylat alter g	ions and histone ene expression, ommended Budge	modifications an by 2012. t: \$20,000,000 ov	n the role of epige d those exploring er 5 years 3.S.J \$5,072,389	netics in the etiolo how exposures many 3.S.J \$5,341,237	ogy of ASD, includi ay act on maternal 3.S.J \$6,122,724	ing studies that in l or paternal geno 3.S.J \$4,972,257	clude assays to m mes via epigenetion 3.S.J \$5,503,732	easure DNA mechanisms 3.S.J \$5,463,324	\$32,475,6
N/A N/A 3.S.K 5733,922 \$463,841 \$90,000 \$0 \$145,373 \$1,747,078 \$53,180,2 \$5 projects 3 projects 3 projects 3 projects 4 projects 10 projects 10 projects 10 most relevant to the progression of ASD by 2014. C.C. Recommended Budget: \$11,100,000 over 5 years 3.7 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A \$3.L.A \$3.L.	ethylat alter g	ions and histone ene expression, ommended Budge N/A	modifications an by 2012. t: \$20,000,000 ov N/A	n the role of epige d those exploring er 5 years 3.S.J \$5,072,389 15 projects	netics in the etiolohow exposures management of the second	ogy of ASD, including act on maternal act on maternal act on maternal act of some series and some series act of the some series act of th	ing studies that in l or paternal geno 3.S.J \$4,972,257 19 projects	a.S.J S5,503,732 24 projects	easure DNA c mechanisms 3.S.J \$5,463,324 21 projects	\$32,475,6
N/A N/A N/A N/A N/A N/A N/A N/A	ethylat alter g C Reco	ions and histone ene expression, ommended Budge N/A two studies and	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that	n the role of epiged those exploring er 5 years 3.S.J \$5,072,389 15 projects Facilitate the devel	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of verteboors.	agy of ASD, including act on maternal 3.S.J \$6,122,724 22 projects	ing studies that in l or paternal geno 3.S.J \$4,972,257 19 projects ate model systems	a.S.J S5,503,732 24 projects	easure DNA c mechanisms 3.S.J \$5,463,324 21 projects	\$32,475,6
\$733,922 \$463,841 \$90,000 \$0 \$145,373 \$1,747,078 \$5,747,078 \$5 projects 3 projects 3 projects 3 projects 4 projects 10 projects Induct a multi-site study of the subsequent pregnancies of 1,000 women with a child with ASD to assess the impact of environmental factors in a riod most relevant to the progression of ASD by 2014. IC Recommended Budget: \$11,100,000 over 5 years 3.7 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A \$3.L.A	ethylat alter g CC Reco	ions and histone ene expression, ommended Budge N/A two studies and nental risks and t	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that their interaction w	n the role of epiged those exploring of those exploring of the series of	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of verteboors.	agy of ASD, including act on maternal 3.S.J \$6,122,724 22 projects	ing studies that in l or paternal geno 3.S.J \$4,972,257 19 projects ate model systems	a.S.J S5,503,732 24 projects	easure DNA c mechanisms 3.S.J \$5,463,324 21 projects	\$32,475,6
5 projects 3 projects 3 projects 3 projects 4 projects 10 projects Induct a multi-site study of the subsequent pregnancies of 1,000 women with a child with ASD to assess the impact of environmental factors in a riod most relevant to the progression of ASD by 2014. IC Recommended Budget: \$11,100,000 over 5 years 3.7 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 52,742,999 \$3,740,812 \$2,971,093 \$2,864,377 \$2,875,202 \$411,571 \$0 \$637,260 \$16,243,35 \$1	ethylat alter g CC Reco	ions and histone ene expression, ommended Budge N/A two studies and nental risks and t	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that their interaction w	n the role of epiged those exploring of those exploring of the series of	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of verteboors.	agy of ASD, including act on maternal 3.S.J \$6,122,724 22 projects	ing studies that in l or paternal geno 3.S.J \$4,972,257 19 projects ate model systems	a.S.J S5,503,732 24 projects	easure DNA c mechanisms 3.S.J \$5,463,324 21 projects	\$32,475,6
nduct a multi-site study of the subsequent pregnancies of 1,000 women with a child with ASD to assess the impact of environmental factors in a riod most relevant to the progression of ASD by 2014. CC Recommended Budget: \$11,100,000 over 5 years 3.7 3.L.A 3.L.A 3.L.A 3.L.A 52,742,999 \$3,740,812 \$2,971,093 \$2,864,377 \$2,875,202 \$411,571 \$0 \$637,260	ethylat alter g CC Reco	ions and histone ene expression, ommended Budge N/A two studies and nental risks and to	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that their interaction wit: \$1,535,000 over	n the role of epiged those exploring of those exploring of the series and series are series as a series are series are series as a series are series are series as a series are seri	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of vertebranetic susceptibilities.	ay act on maternal 3.S.J \$6,122,724 22 projects Fate and invertebrates for ASD by 2013	3.S.J \$4,972,257 19 projects	3.S.J \$5,503,732 24 projects	assure DNA mechanisms 3.S.J. \$5,463,324 21 projects on of	\$32,475,6
riod most relevant to the progression of ASD by 2014. CC Recommended Budget: \$11,100,000 over 5 years 3.7 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A 3.L.A \$2,742,999 \$3,740,812 \$2,971,093 \$2,864,377 \$2,875,202 \$411,571 \$0 \$637,260 \$16,243,3	ethylat alter g CC Reco	ions and histone ene expression, ommended Budge N/A two studies and nental risks and to	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that their interaction wit: \$1,535,000 over	n the role of epiged those exploring of those exploring of the series of	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of vertebinetic susceptibilities.	ay act on maternal 3.S.J \$6,122,724 22 projects Fate and invertebrates for ASD by 2013	3.S.J \$4,972,257 19 projects ate model system: 2.	3.S.J \$5,503,732 24 projects	easure DNA c mechanisms 3.S.J \$5,463,324 21 projects on of	
iod most relevant to the progression of ASD by 2014. C Recommended Budget: \$11,100,000 over 5 years 3.7 B.L.A B.L.A B.L.A B.L.A B.L.A B.L.A B.L.A B.L.A B.L.A S2,742,999 \$3,740,812 \$2,971,093 \$2,864,377 \$2,875,202 \$411,571 \$0 \$637,260 \$16,243,37	thylat alter g C Reco	ions and histone ene expression, ommended Budge N/A two studies and nental risks and to	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that their interaction wit: \$1,535,000 over	n the role of epiged those exploring of those exploring of the series of	netics in the etiolohow exposures management of series opment of vertebinetic susceptibilities. 3.S.K. \$463,841	ay act on maternal 3.S.J \$6,122,724 22 projects Fate and invertebrates for ASD by 201: 3.S.K \$90,000	3.S.J \$4,972,257 19 projects ate model system: 2.	3.S.J \$5,503,732 24 projects 5 for the exploration 3.S.K \$145,373	easure DNA mechanisms 3.S.J \$5,463,324 21 projects on of 3.S.K \$1,747,078	
C Recommended Budget: \$11,100,000 over 5 years 3.7	thylat alter g C Reco	ions and histone ene expression, ommended Budge N/A two studies and nental risks and to	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that their interaction wit: \$1,535,000 over	n the role of epiged those exploring of those exploring of the series of	netics in the etiolohow exposures management of series opment of vertebinetic susceptibilities. 3.S.K. \$463,841	ay act on maternal 3.S.J \$6,122,724 22 projects Fate and invertebrates for ASD by 201: 3.S.K \$90,000	3.S.J \$4,972,257 19 projects ate model system: 2.	3.S.J \$5,503,732 24 projects 5 for the exploration 3.S.K \$145,373	easure DNA mechanisms 3.S.J \$5,463,324 21 projects on of 3.S.K \$1,747,078	
3.7 S2,742,999 S3,740,812 S2,971,093 S2,864,377 S2,875,202 S411,571 S0 S637,260 \$16,243,33	thylater g can be a care to the care to th	ions and histone ene expression, ommended Budge N/A two studies and nental risks and t ommended Budge N/A a multi-site stud	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that it their interaction whit: \$1,535,000 over N/A	n the role of epiged those exploring of those exploring of those exploring of the second of the seco	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of vertebranetic susceptibilities 3.S.K. \$463,841 3 projects	3.S.J \$6,122,724 22 projects Tate and invertebrates for ASD by 2013 3.S.K \$90,000 3 projects	3.S.J \$4,972,257 19 projects ate model systems 2. 3.S.K \$0 3 projects	3.S.J \$5,503,732 24 projects s for the exploration 3.S.K \$145,373 4 projects	assure DNA c mechanisms 3.S.J. \$5,463,324 21 projects on of 3.S.K. \$1,747,078 10 projects	
\$2,742,999 \$3,740,812 \$2,971,093 \$2,864,377 \$2,875,202 \$411,571 \$0 \$637,260 \$16,243, 3	pport: reconstruction of the control of the contro	ions and histone ene expression, ommended Budge N/A two studies and tental risks and t ommended Budge N/A a multi-site stud ost relevant to tl	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that it their interaction wit: \$1,535,000 over N/A ly of the subsequence progression of	n the role of epiged those exploring of those exploring of those exploring of the second of the seco	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of vertebranetic susceptibilities 3.S.K. \$463,841 3 projects	3.S.J \$6,122,724 22 projects Tate and invertebrates for ASD by 2013 3.S.K \$90,000 3 projects	3.S.J \$4,972,257 19 projects ate model systems 2. 3.S.K \$0 3 projects	3.S.J \$5,503,732 24 projects s for the exploration 3.S.K \$145,373 4 projects	assure DNA c mechanisms 3.S.J. \$5,463,324 21 projects on of 3.S.K. \$1,747,078 10 projects	
\$2,742,999 \$3,740,812 \$2,971,093 \$2,864,377 \$2,875,202 \$411,571 \$0 \$637,260 \$16,243,3	thylat thylater g C Reco	ions and histone ene expression, ommended Budge N/A two studies and tental risks and t ommended Budge N/A a multi-site stud ost relevant to tl	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that it their interaction wit: \$1,535,000 over N/A ly of the subsequence progression of	n the role of epiged those exploring of those exploring of those exploring of the second of the seco	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of vertebranetic susceptibilities 3.S.K. \$463,841 3 projects	3.S.J \$6,122,724 22 projects Tate and invertebrates for ASD by 2013 3.S.K \$90,000 3 projects	3.S.J \$4,972,257 19 projects ate model systems 2. 3.S.K \$0 3 projects	3.S.J \$5,503,732 24 projects s for the exploration 3.S.K \$145,373 4 projects	assure DNA c mechanisms 3.S.J. \$5,463,324 21 projects on of 3.S.K. \$1,747,078 10 projects	
	thylater g C Reco pport C Reco nduct	ions and histone ene expression, ommended Budge N/A two studies and hental risks and t ommended Budge N/A a multi-site stud ost relevant to tl ommended Budge	modifications an by 2012. t: \$20,000,000 ov N/A a workshop that itheir interaction wit: \$1,535,000 over N/A ly of the subsequence progression of the S11,100,000 over	n the role of epiged those exploring of those exploring of those exploring of the second of the seco	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of vertebranetic susceptibilities 3.S.K. \$463,841 3 projects	ay act on maternal 3.S.J \$6,122,724 22 projects Fate and invertebrates for ASD by 2013 3.S.K \$90,000 3 projects th a child with ASD	3.S.J \$4,972,257 19 projects ate model system: 2. 3.S.K \$0 3 projects	3.S.J \$5,503,732 24 projects s for the exploration 3.S.K \$145,373 4 projects pact of environments	assure DNA c mechanisms 3.S.J \$5,463,324 21 projects on of 3.S.K \$1,747,078 10 projects ntal factors in a	
	thylater g C Reco pport C Reco nduct	ions and histone ene expression, ommended Budge N/A two studies and the ion and the ion and ion	modifications an by 2012. tt: \$20,000,000 ov N/A a workshop that it their interaction wit: \$1,535,000 over N/A ly of the subsequence progression of tt: \$11,100,000 over 3.L.A	n the role of epiged those exploring of those exploring of those exploring of the second of the seco	netics in the etiolohow exposures management. 3.S.J. \$5,341,237 19 projects opment of vertebratic susceptibilities 3.S.K. \$463,841 3 projects	ay act on maternal 3.S.J \$6,122,724 22 projects Fate and invertebrates for ASD by 201: 3.S.K \$90,000 3 projects th a child with ASD	3.S.J \$4,972,257 19 projects ate model system: 2. 3.S.K \$0 3 projects to assess the imp	3.S.J \$5,503,732 24 projects s for the exploration 3.S.K \$145,373 4 projects pact of environme	assure DNA c mechanisms 3.S.J. \$5,463,324 21 projects on of 3.S.K. \$1,747,078 10 projects ntal factors in a	\$32,475,6 \$3,180,21

⁄ear	2008	2009	2010	2011	2012	2013	2014	2015	Total
	_	ors in at least 50% ore: \$33,900,000 ove		SD by 2014.					
	3.8 \$37,043,410 83 projects	3.L.B \$49,905,587 79 projects	3.L.B \$34,432,884 60 projects	3.L.B \$25,383,346 59 projects	3.L.B \$23,041,231 74 projects	3.L.B \$12,260,187 51 projects	3.L.B \$11,391,232 49 projects	3.L.B \$22,476,837 61 projects	\$215,934,7
y 2015.		at least five enviror		n the risk for subty	ypes of ASD in the	eprenatal and earl	y postnatal period	of development	
	3.6	3.L.C	3.L.C	3.L.C	3.L.C \$353,000	3.L.C \$490,000	3.L.C \$150,000	3.L.C	*
	\$1,803,628 13 projects	\$1,992,228 10 projects	\$820,320 10 projects	\$379,913 5 projects	5 projects	4 projects	3 projects	\$0 3 projects	\$5,989,08
collect	13 projects ancillary studies t data on enviror pooled (as need		10 projects e large-scale, popring preconceptions gets for potential	5 projects oulation-based sur on, and during prei	5 projects veillance and epid natal and early po	4 projects emiological studie stnatal developme	3 projects s, including U.S. p	3 projects opulations,	\$5,989,08
o collect ould be	13 projects ancillary studies t data on enviror pooled (as need	10 projects within one or mornmental factors dudled) to analyze targ	10 projects e large-scale, popring preconceptions gets for potential	5 projects oulation-based sur on, and during prei	5 projects veillance and epid natal and early po	4 projects emiological studie stnatal developme	3 projects s, including U.S. p	3 projects opulations,	\$5,989,08
o collect ould be ACC Reco	ancillary studies t data on enviror pooled (as need ommended Budge 3.9 \$17,297,788	within one or mornmental factors duded) to analyze target: \$44,400,000 ov 3.L.D \$9,135,505 12 projects	10 projects e large-scale, popring preconceptic gets for potential er 5 years 3.L.D \$11,464,011	5 projects oulation-based sur on, and during prei gene/environmen 3.L.D \$11,567,250	5 projects veillance and epid natal and early post t interactions by 2 3.L.D \$13,549,160	4 projects emiological studie stnatal developme 015. 3.L.D \$17,799,693	3 projects s, including U.S. p nt, as well as gene 3.L.D \$10,805,676	3 projects opulations, etic data, that 3.L.D \$10,187,969	
o collect ould be ACC Reco	13 projects ancillary studies t data on enviror pooled (as need commended Budge 3.9 \$17,297,788 29 projects	within one or mornmental factors duded) to analyze target: \$44,400,000 ov 3.L.D \$9,135,505 12 projects	10 projects e large-scale, popring preconceptic gets for potential er 5 years 3.L.D \$11,464,011	5 projects oulation-based sur on, and during prei gene/environmen 3.L.D \$11,567,250	5 projects veillance and epid natal and early post t interactions by 2 3.L.D \$13,549,160	4 projects emiological studie stnatal developme 015. 3.L.D \$17,799,693	3 projects s, including U.S. p nt, as well as gene 3.L.D \$10,805,676	3 projects opulations, etic data, that 3.L.D \$10,187,969	\$101,807,0
o collect ould be ACC Reco	ancillary studies t data on enviror pooled (as need ommended Budge \$3.9 \$17,297,788 \$29 projects \$3. Core/Other Activities \$6,791,008	within one or mornmental factors duded) to analyze target: \$44,400,000 ov 3.L.D. \$9,135,505 12 projects tive 3. Core/ Other Activities \$8,512,980 39 projects	10 projects e large-scale, popring preconceptic gets for potential er 5 years 3.L.D \$11,464,011 10 projects 3. Core/Other Activities \$1,312,450	5 projects pulation-based sur on, and during prei gene/environmen 3.L.D \$11,567,250 10 projects 3. Core/ Other Activities \$724,770	veillance and epid natal and early post t interactions by 2 3.L.D \$13,549,160 12 projects 3. Core/ Other Activities \$315,607	4 projects emiological studiestnatal development on the structure of the	3 projects s, including U.S. p nt, as well as gene 3.L.D \$10,805,676 14 projects 3. Core/ Other Activities \$405,039	3 projects opulations, etic data, that 3.L.D \$10,187,969 16 projects 3. Core/ Other Activities \$931,163	

Table 7. Multiyear funding table for Question 3.



ASPIRATIONAL GOAL: INTERVENTIONS WILL BE DEVELOPED THAT ARE EFFECTIVE FOR REDUCING BOTH CORE AND ASSOCIATED SYMPTOMS, FOR BUILDING ADAPTIVE SKILLS, AND FOR MAXIMIZING QUALITY OF LIFE AND HEALTH FOR PEOPLE WITH ASD.

RESEARCH FOCUS OF QUESTION 4

Question 4 asks "Which treatments and interventions will help?" and covers a range of intervention approaches currently being considered, including pharmacological, behavioral, educational, occupational, technology-based, and alternative/complementary/integrative medicine approaches. Research in this field encompasses the development of new treatments using model systems and small-scale experiments as well as full-scale clinical trials. Question 4 also includes studies to assess the safety and effectiveness of treatments already in use in the community.

A word cloud was created to describe the research funded in Question 4 using the project titles listed under the question (**Figure 42**). The size of each word within the word cloud indicates the frequency of its use in project titles. The word cloud visually portrays the main research themes and topics that were funded in Ouestion 4.



Figure 42. Word cloud representing themes in Question 4 project titles.

ANALYSIS OF 2014-2015 QUESTION 4 PORTFOLIO

Research focused on interventions and treatments (Question 4) received \$63.8 million (20%) of total ASD funding in 2014 and 59.6 million (17%) of funding in 2015. The number of projects assigned to Question 4 totaled 355 projects in 2014, which was 25% of all projects included in the portfolio. In 2015, there were 332 projects assigned to Question 4, which accounted for 24% of all ASD projects. A large number of agencies and organizations invest in treatments and interventions; however, the three largest funders are the National Institutes of Health, Department of Education,

and Simons Foundation. Question 4 has a total of 12 objectives focused on treatments and interventions.

Figures 43 & 44 provide a detailed overview of each objective's total funding in 2014 and 2015 as well as the number of projects assigned to each objective.

There was funding or projects associated with all twelve Question 4 objectives in 2014. As in previous years, the Question 4 objective receiving the most funding focuses on the development of model systems targeting areas for new interventions (4.S.B; \$17.0 million, 27%),




Figure 43. Question 4 objectives broken down by their funding and project count.

this objective also had the largest number of projects (102 projects). The second largest funded objective was Objective 4.S.D with \$8.7 million (14%) and supports investments in randomized controlled trials for early intervention. Objective 4.L.D followed, which supports community-based studies assessing the effectiveness of interventions and services (\$8.3 million; 13%). All other objectives received less funding in 2014, while a substantial portion (18%; \$11.3 million) of Question 4 funding went to projects categorized as Core/Other (4.O).

Question 4 research funding in 2015 was similar to funding in 2014. Progress was made on all of the objectives except one (4.S.E). Objective 4.S.B continued to receive the largest investment of Question 4 funding (\$15.3 million, 26%) and greatest number of projects (96 projects). The second largest funded objective was 4.L.D with \$12.5 million in funding and making up 21% of the Question 4 portfolio. Objective 4.S.D followed with \$10.5 million and 18% of funding. **Table 8** lists all the objectives and their progress to date.




Figure 44. Question 4 objectives broken down by their funding and project count in 2015.

QUESTION 4 SUBCATEGORY ANALYSIS

Question 4 represents research on a wide array of different approaches to treatments and interventions for ASD, ranging from medications to alleviate core and co-occurring symptoms, to behavioral therapies and technologies to improve communication, socialization, life skills, and learning. Projects under Question 4 were broken down into these seven subcategories: Behavioral; Complementary, dietary, and alternative; Educational; Medical/Pharmacologic; Model systems/Therapeutic targets; Occupational, physical, and sensory-based; and Technology-based interventions and supports (Figures 45 & 46).

The subcategories for Question 4 (Treatments and Interventions) illustrate the many approaches to treatments and interventions supported by autism research funders. In 2014 and 2015, the largest amount of funding supported projects to develop **Behavioral**

interventions (31% for each year), including applied behavior analysis (ABA), cognitive therapy, and social skills training. Research on Model systems/ **Therapeutic targets** (28% in 2014; 25% in 2015) followed, focusing on early development of animal and cellular models that mimic characteristics of ASD to test experimental therapies. Medical/Pharmacologic interventions received 20% of funding in 2014 and 11% in 2015. Educational (classroom-based) interventions received 8% of funding in 2014; this subcategory doubled in 2015, making up 16% in funding. **Technology-based interventions** and supports received 6% of funding in 2014 and 9% of funding in 2015. The subcategories with the smallest amounts of funding included Occupational, physical, and sensory-based (3% in 2014; 5% in 2015) and **Complementary, dietary,** and alternative interventions (4% in 2014; 3% in 2015).




Figure 45. Question 4 funding by subcategory in 2014.



Figure 46. Question 4 funding by subcategory in 2015.

PROGRESS MADE ON QUESTION 4 FROM 2008-2015

The trend in annual Question 4 funding over time is shown in **Figure 47**. Overall, research funding focused on treatments and interventions maintained a consistently moderate level over the eight-year time

span. In the most recent years, Question 4 has had one of the largest proportions of funding compared to other Question areas.




Figure 47. Question 4 ASD research funding from 2008-2015. Funding for Question 4 remained primarily flat, but relatively robust, over the eight-year span.

PROGRESS MADE ON QUESTION 4 OBJECTIVES FROM 2008-2015

Based on the cumulative funding over eight years, six objectives were considered complete, while the remaining six objectives showed partial progress as of 2015 (**Figure 48**). Since 2013, two objectives moved from partial progress to meeting the objective's recommended budget. Objective 4.L.A, which focuses on randomized controlled trials on medications targeting core symptoms of ASD, and Objective 4.L.D, which supports community-based studies assessing effective interventions, achieved completion of their recommended budgets. **Table 8** provides a snapshot of progress made on all 12 of the research objectives within Question 4 over the period from 2008-2015.



Figure 48. Overall status of progress for the 12 Question 4 objectives.



Question 4: Which Treatments And Interventions Will Help?

ear 20	800	2009	2010	2011	2012	2013	2014	2015	Total
		domized controll : \$13,400,000 ove		ess co-occurring r	medical conditions	s associated with <i>i</i>	ASD by 2010.		
\$4,5	4.2 583,171 rojects	4.S.A \$4,733,841 6 projects	4.S.A \$3,787,700 4 projects	4.S.A \$1,826,542 4 projects	4.S.A \$2,174,124 3 projects	4.S.A \$1,687,680 6 projects	4.S.A \$2,683,438 12 projects	4.S.A \$4,011,538 12 projects	\$25,488,0
nolecular targe	gets or neura		ble to existing or r	ular and/or anima new interventions l		atures of ASD and	l will allow identific	ation of specific	
\$15,8	4.5 879,827 projects	4.S.B \$20,162,709 70 projects	4.5.B \$23,229,501 92 projects	4.5.B \$21,606,118 89 projects	4.5.B \$21,232,514 94 projects	4.S.B \$14,344,873 86 projects	4.S.B \$17,006,996 102 projects	4.5.B \$15,303,589 96 projects	\$148,766,
est safety and rocedures) th	nat have not		studied for use in		n, medications, ass	sisted technologie	s, sensory integra	tion, medical	
est safety and rocedures) th ACC Recommen 4 \$64	nat have not	been rigorously	studied for use in		4.5.C \$1,288,226 17 projects	4.S.C S1,863,225 22 projects	4.S.C \$3,356,022 59 projects	4.S.C S471,865 51 projects	\$14,638,¢
est safety and rocedures) the ACC Recomment \$4 \$64. 8 procedures \$64. Complete two community in \$64.	nat have not nded Budget 4.6 41,285 rojects o multi-site nvolvement	the been rigorously: \$27,800,000 ove 4.S.C \$3,252,941 29 projects randomized cont	studied for use in r 5 years 4.S.C \$1,509,745 18 projects crolled trials of cor	4.S.C \$2,254,724 18 projects	4.S.C \$1,288,226 17 projects	4.S.C \$1,863,225 22 projects	<mark>4.S.C</mark> \$3,356,022	4.S.C \$471,865 51 projects	\$14,638,0
est safety and rocedures) the ACC Recomment \$64.8 procedures \$64.8 procedures \$4.23	nat have not nded Budget 4.6 41,285 rojects o multi-site nvolvement	the seen rigorously: \$27,800,000 over the seen rigorously: \$27,800,000 over the seen rigorously: \$20,252,941 the seen rigorously: \$2	studied for use in r 5 years 4.S.C \$1,509,745 18 projects crolled trials of cor	4.S.C \$2,254,724 18 projects	4.S.C \$1,288,226 17 projects	4.S.C \$1,863,225 22 projects	4.S.C \$3,356,022 59 projects	4.S.C \$471,865 51 projects	
est safety and rocedures) the ACC Recomment of Section 1 of Section 1 of Section 2	nat have not nded Budget 4.6 41,285 rojects o multi-site envolvement nended Budget 4.7 36,869 rojects rkshop to ac studies) by 2	### description of the control of th	4.S.C \$1,509,745 18 projects crolled trials of conver 5 years 4.S.D \$10,306,148 18 projects	4.5.C \$2,254,724 18 projects nprehensive early 4.5.D \$11,156,647 20 projects	4.S.C \$1,288,226 17 projects intervention that a 4.S.D \$8,848,130 21 projects eatment personali	4.S.C \$1,863,225 22 projects address core sym 4.S.D \$10,426,942 21 projects	4.S.C \$3,356,022 59 projects ptoms, family func 4.S.D \$8,727,192	4.5.C \$471,865 51 projects tioning and 4.5.D \$10,479,299 19 projects	\$14,638,0 \$71,721,8



Question 4: Which Treatments And Interventions Will Help? IACC Strategic Plan Objectives

Year	2008	2009	2010	2011	2012	2013	2014	2015	Total
• Five tri • ACC Ri • Three adoles IACC Ri • Three	unctional outcomials in infants and ecommended Bud trials in school-accents by 2013. ecommended Bud trials in adults by	nes in each of the d toddlers by 2013 dget: \$30,000,000 ged children and/	following groups: 3. O over 5 years (revi or O over 5 years (revi	sed in 2010)	ures and other m	easures to predict	response, and mo	onitor quality of	
:	4.3 & 4.4 \$12,109,516 16 projects & 30 projects	4.S.F \$9,791,270 42 projects	4.S.F \$7,575,212 30 projects	4.S.F \$5,445,599 23 projects	4.S.F \$6,255,438 21 projects	4.S.F \$2,444,294 13 projects	4.S.F \$2,682,322 12 projects	4.S.F \$2,759,232 14 projects	\$47,724,379
• Studies effecti • Studies function	lassroom and ad unication, and be s of novel treatm ve AAC approacl s assessing acce anal outcomes an	lult service-provis ehavior; nent approaches t hes for specific su ess and use of AAG	ion settings, such that facilitate com abpopulations of p C for children and	as residential serv munication skills in eople with ASD; a	vice-provision and n individuals who nd	native communicat the impact of suc are nonverbal, incl r partially limited s	h access on qualit	y of life, nents of	
	N/A	N/A	4.S.G \$1,907,721 11 projects	4.S.G \$2,830,851 13 projects	4.S.G \$4,991,831 17 projects	4.S.G \$3,904,625 9 projects	4.S.G \$3,829,474 7 projects	4.S.G \$3,307,905 5 projects	\$20,772,407
Secondar	ry conditions of i		eight issues and o			ndary conditions ir hiatric and medica		by 2012.	
	N/A	N/A	4.S.H \$225,877 2 projects	4.S.H \$222,265 1 project	4.S.H \$956,827 4 projects	4.S.H \$724,478 3 projects	4.5.H \$665,198 15 projects	4.S.H \$750,180 19 projects	\$3,544,825
		andomized contro t: \$22,200,000 <i>ove</i>		ications targeting	core symptoms ir	people with ASD	of all ages by 2014	4.	
	4.8 \$1,380,376 12 projects	4.L.A \$1,168,146 10 projects	4.L.A \$1,924,932 11 projects	4.L.A \$1,527,858 12 projects	4.L.A \$3,713,783 14 projects	4.L.A \$4,189,239 12 projects	4.L.A \$4,139,740 10 projects	4.L.A \$4,795,444 12 projects	\$22,839,518
		siblings of people t: \$6,700,000 over		e goal of reducing	the risk of recurr	ence by at least 30	0% by 2014.		
	4.9 \$14,256 1 project	4.L.B \$132,263 2 projects	4.L.B \$307,349 3 projects	4.L.B \$14,256 2 projects	4.L.B \$362,987 2 projects	4.L.B \$349,595 2 projects	4.L.B \$937,162 2 projects	4.L.B \$930,526 3 projects	\$3,048,394
Question -	4: Multiyear Func	ding Table, see App	endix C for a color-	coding key and fur	ther details.				

'ear 2008	2009	2010	2011	2012	2013	2014	2015	Total
pecific behavioral iss	study to evaluate the ues in people with AS dget: \$10,000,000 ow	SD by 2015.	iveness of medica	tions commonly us	sed in the treatme	nt of co-occurring	g conditions or	
N/A	4.L.C \$1,061,222 7 projects	4.L.C \$2,302,240 7 projects	4.L.C \$2,834,887 8 projects	4.L.C \$277,072 3 projects	4.L.C \$665,668 7 projects	4.L.C \$179,971 4 projects	4.L.C \$35,000 6 projects	\$7,356,0
• Different and/or co	ude comparative effe Imbined medical, pha	ırmacological, nut	ritional, behaviora	l, service-provisior	, and parent- or c	_ ,	nted treatments;	
 Studies of widely u utcome measures s 	vention programs for sed community inter- nould include assessr dget: \$37,500,000 ove	vention models for ment of potential h	r which extensive	published data are	not available.			
 Studies of widely u utcome measures s 	sed community internould include assessing	vention models for ment of potential h	r which extensive	published data are	not available.		4.L.D \$12,546,811 54 projects	\$57,803,
• Studies of widely u utcome measures s ICC Recommended Bu N/A	sed community internould include assessing dget: \$37,500,000 ove	vention models for ment of potential had been to the second second second the second second second the second second second the second second second second the second second second second the second second second second second the second second second second second second second the second secon	r which extensive narm as a result of 4.L.D \$6,296,024	published data are autism treatment 4.L.D \$10,186,313	e not available. s, as well as positi 4.L.D \$11,745,499	ve outcomes. 4.L.D \$8,272,411	\$12,546,811	\$57,803,
• Studies of widely u Jutcome measures s ACC Recommended Bu N/A	sed community inter- nould include assessing the distribution of the control of t	vention models for ment of potential had been to the second second second the second second second the second second second the second second second second the second second second second the second second second second second the second second second second second second second the second secon	r which extensive narm as a result of 4.L.D \$6,296,024	published data are autism treatment 4.L.D \$10,186,313	e not available. s, as well as positi 4.L.D \$11,745,499	ve outcomes. 4.L.D \$8,272,411	\$12,546,811	
• Studies of widely under the Dutcome measures is ACC Recommended But N/A Not Specific to any obtained the Core/Other Activities \$14,075,905	sed community inter- nould include assessi dget: \$37,500,000 ove N/A sjective 4. Core/ Other Activities 5. \$15,560,011 59 projects	vention models forment of potential har 5 years 4.L.D \$8,756,832 32 projects 4. Core/ Other Activities \$6,290,634	4.L.D \$6,296,024 32 projects 4. Core/ Other Activities \$4,777,350	4.L.D \$10,186,313 45 projects 4. Core/ Other Activities \$3,862,655	4.L.D \$11,745,499 50 projects 4. Core/ Other Activities \$5,714,722	4.L.D \$8,272,411 59 projects 4. Core/ Other Activities \$11,301,592	4. Core/ Other Activities \$4,227,930	\$57,803, ⁴ \$65,810,

Question 4: Multiyear Funding Table, see Appendix C for a color-coding key and further details.

Table 8. Multiyear funding table for Question 4.

^{*}This total reflects all funding for projects aligned to current objectives in the 2011 IACC Strategic Plan and incorporates funding for projects that may have been coded differently in previous versions of the Plan.

[†]The totals reflect the funding and projects coded to this Question of the Strategic Plan in the particular year indicated at the top of the column. When reading each column vertically, please note that the projects and funding associated with each objective for 2008 may not add up to the total at the bottom of the column; this is due to revisions of the Strategic Plan that caused some objectives to be shifted to other Questions under the Plan. The projects and funding associated with these reclassified objectives are now reflected under the Question in which they appear in the 2011 Strategic Plan.



ASPIRATIONAL GOAL: COMMUNITIES WILL ACCESS AND IMPLEMENT NECESSARY HIGH-QUALITY, EVIDENCE-BASED SERVICES AND SUPPORTS THAT MAXIMIZE QUALITY OF LIFE AND HEALTH ACROSS THE LIFESPAN FOR ALL PEOPLE WITH ASD.

RESEARCH FOCUS OF QUESTION 5

Question 5 ("Where can I turn for services?") focuses on services and supports for people with ASD. Objectives address issues including access to services for both individuals with ASD and their families, impact of self-directed care, coordination among State and local agencies' community-based supports, and the assessment of the health, safety, and mortality of people with ASD. Question 5 also includes research to develop and evaluate training of service providers (pediatricians, teachers, social workers, etc.), and improve the efficacy, cost-effectiveness, and dissemination of evidence-based practices.

In an effort to provide a visual representation of the research funded in Question 5 in 2014 and 2015, a word cloud was generated using the project titles listed under this question (**Figure 49**). The size of each word within the word cloud indicates the frequency of its use in project titles. The word cloud visually portrays the main research themes and topics that were funded in Question 5.



Figure 49. Word cloud representing themes in Question 5 project titles.

ANALYSIS OF 2014-2015 QUESTION 5 PORTFOLIO

Projects assigned to Question 5 comprised 6% of the total ASD research supported in 2014 (\$17.6 million) and 2015 (\$21.3 million). In 2014, Question 5 consisted of 127 projects, which was 9% of the total number of ASD projects. In 2015, Question 5 had 97 projects and accounted for 7% of the overall ASD project count. For both years, the largest funders of Question 5 are the Department of Education, National Institutes of Health, and Centers for Disease Control and Prevention. Question 5 contains nine objectives for tracking funding on ASD services research. **Figures 50 & 51** provide a detailed overview of each objective's total funding in 2014 and 2015 as well as the number of projects assigned to each objective.

Of the nine Question 5 objectives, seven Question 5 objectives had funding in 2014, and two objectives had

no active projects or funding. The majority of projects that were categorized under this question did not fit into any of the specific Question 5 objectives and were assigned as Core/Other (\$6.5 million, 37%). The next largest portion of funding went to 5.L.A, which supports projects improving dissemination, implementation, and sustainability of evidenced-based interventions (\$5.6 million, 32%). Objective 5.L.C, research focused on the evaluation of new and existing training of service providers, followed with \$2.9 million and 16% of Question 5 funding. Objectives 5.S.B and 5.S.D were not funded in 2014, but have received funding in previous years. Question 5 Core/Other had the largest number of projects (48 projects) while 5.L.C followed with 35 projects and 5.L.A had 24 projects. The rest of the objectives had significantly smaller project counts.




Figure 50. Question 5 objectives broken down by their funding and project count in 2014.

In 2015, the Question 5 objectives had comparable funding activities to previous years. Of the nine objectives in Question 5, seven objectives saw progress through funding or active projects. The largest portion of funding went to 5.L.A which accounted for \$6.9 million and 33% of Question 5 funding. Funding towards research not specific to Question 5 objectives (Core/Other) had the second greatest portion of funding (\$6 million; 28%). Objective 5.L.C followed

with \$5.4 million and 25% of Question 5 funding in 2015. Objective 5.S.A did not have any funding in 2015 but did have one active project. Objectives 5.S.B and 5.S.D were not funded in 2015, but have received funding in previous years. Objective 5.L.C had the largest number of projects (35 projects), followed by Question 5 Core/Other. **Table 9** lists all the objectives and their progress to date.




Figure 51. Question 5 objectives broken down by their funding and project count in 2015.

QUESTION 5 SUBCATEGORY ANALYSIS

Projects within Question 5 have been categorized into five subcategories which reflect the general scope of research on services and supports: **Community inclusion programs; Efficacious and cost-effective service delivery; Family well-being and safety;** development and evaluation of **Practitioner training;** and **Services utilization and access (Figures 52 & 53)**.

In 2014 and 2015, research falling under the development and evaluation of **Practitioner training** subcategory accounted for almost two-thirds (68% in 2014; 61% in 2015) of the funding for Question 5. Projects related to research on **Efficacious and**

cost-effective service delivery, which covers research projects that assess current service delivery models as well as developing new and efficient ways of providing services, followed with 13% of the Question 5 funding in 2014 and 30% in 2015. Research focused on disparities and potential barriers to access are covered in Services utilization and access and accounted for 9% of funding in 2014; however this subcategory experienced a significant drop to 1% in 2015. Family well-being and safety research projects received 5% of funding in 2014 and 4% of funding in 2015. Projects relating to Community inclusion programs received 5% of Question 5 funding in 2014 and 4% in 2015.




Figure 52. Question 5 funding by subcategory in 2014.




Figure 53. Question 5 funding by subcategory in 2015.

PROGRESS MADE ON QUESTION 5 FROM 2008-2015

Figure 54 shows the trend in Question 5 funding over time using the adjusted funding total from Table 9. The adjusted funding reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan that may have been coded differently under previous versions of the plan. Research related to Question 5 was funded at relatively low levels when compared to other question areas. Funding for projects within Question 5 appeared to decrease slightly after 2010. As mentioned in the prior Portfolio Analysis reports, adjustments in reporting were made to only report autism-specific and research-related portions of larger projects within Question 5. A dotted line representing Question 5 funding in 2010 using the criteria that were

applied in later years is included in the graph to enable a more accurate comparison among years. To calculate the estimated line for 2010, the same methodology for the prorated rates used in 2011 to 2015 was applied. (The projects that included practitioner training were prorated starting in 2011 to include only the portion of funding pertaining to development and evaluation of training, and not portions related to delivery of training). When these adjustments are made to the 2010 data set, the change from 2009 to 2010, and 2010 to 2011, appear to be less significant. Overall, when comparing 2008 funding for Question 5 with 2015 funding the general trend is upward.




Figure 54. Question 5 ASD research funding from 2008-2015. Compared to other *Strategic Plan* questions, funding for Question 5 remained relatively low over the eight-year span.

PROGRESS MADE ON QUESTION 5 OBJECTIVES FROM 2008-2015

An assessment of progress made on Question 5 objectives over the eight-year funding period shows that four objectives were considered completed as of 2015. All of the other five objectives have achieved partial progress toward their overall recommended budgeted goals since 2008 (**Figure 55**), despite the fact that two of these objectives did not see activity in 2015 specifically. Although many of the Question 5 objectives experienced growth in 2015, only one objective (5.L.E) moved from partial progress to being considered complete since 2013. **Table 9** provides a snapshot of progress made on all nine of the research objectives within Question 5 over the period from 2008-2015.




Figure 55. Overall status of progress for the nine Question 5 objectives.

	2009	2010	2011	2012	2013	2014	2015	Total
populations, by 2012.	that assess how varia udget: \$1,000,000 over		s to services affec	t family functionir	ig in diverse popul	ations, including u	ınderserved	
5.2 \$0 0 projects	5.S.A \$499,999 1 project	5.S.A \$2,061,834 9 projects	5.S.A \$1,351,793 8 projects	5.S.A \$1,364,087 6 projects	5.S.A \$1,090,183 6 projects	5.S.A \$1,011,266 8 projects	5.S.A \$0 2 projects	\$7,379,16
pectrum by 2014.	o examine how self-di		y-based services a	nd supports impa	ct children, youth,	and adults with A	SD across the	
N/A	5.S.B \$446,340 6 projects	5.S.B \$291,635 6 projects	5.S.B \$0 1 project	5.S.B \$0 0 projects	5.S.B \$0 0 projects	5.S.B \$0 0 projects	5.S.B \$0 0 projects	\$737,97
elf-sufficiency, and o lternative communion valuate a model of p	nunity-based support quality of life for peop cation [AAC] technolog policy and practice-lev udget: \$25,000,000 ov	le with ASD across gy), with at least o vel coordination ar	s the spectrum an one project aimed a	d their families, (v at the needs of tra	which may include ansitioning youth a	access to augmer and at least one st	ntative and udy to	
N/A	5.S.C \$0 0 projects	5.S.C \$4,225,315 15 projects	5.S.C \$600,000 3 projects	5.S.C \$600,000 2 projects	5.S.C \$340,000 2 projects	5.S.C \$40,000 2 projects	5.S.C \$40,000 1 project	\$5,845,3
upport two studies	\$0	\$4,225,315 15 projects fety, and mortality	\$600,000 3 projects	\$600,000 2 projects	\$340,000 2 projects	\$40,000	\$40,000	\$5,845,3
upport two studies	\$0 0 projects to examine health, sa	\$4,225,315 15 projects fety, and mortality	\$600,000 3 projects	\$600,000 2 projects	\$340,000 2 projects	\$40,000	\$40,000	\$5,845,3 \$164,13
upport two studies NCC Recommended N/A est four methods to ommunity settings b	\$0 0 projects to examine health, sa Budget: \$4,500,000 N/A improve disseminatio	\$4,225,315 15 projects fety, and mortality over 3 years 5.5.D \$159,135 3 projects on, implementation	\$600,000 3 projects issues for people 5.S.D \$0 1 project	\$600,000 2 projects with ASD by 2012 5.S.D \$5,000 1 project	\$340,000 2 projects	\$40,000 2 projects 5.S.D \$0 0 projects	\$40,000 1 project 5.S.D \$0 0 projects	
upport two studies CC Recommended N/A est four methods to ommunity settings b	\$0 0 projects to examine health, sa Budget: \$4,500,000 N/A improve dissemination by 2013. udget: \$7,000,000 over	\$4,225,315 15 projects fety, and mortality over 3 years 5.5.D \$159,135 3 projects on, implementation	\$600,000 3 projects issues for people 5.S.D \$0 1 project	\$600,000 2 projects with ASD by 2012 5.S.D \$5,000 1 project	\$340,000 2 projects	\$40,000 2 projects 5.S.D \$0 0 projects	\$40,000 1 project 5.S.D \$0 0 projects	\$164,13
Test four methods to ommunity settings by ACC Recommended Box 5.4 \$2,596,838 3 projects Test the efficacy and ges living in community	\$0 0 projects to examine health, sa Budget: \$4,500,000 N/A improve dissemination by 2013. udget: \$7,000,000 over	\$4,225,315 15 projects fety, and mortality over 3 years 5.5.D \$159,135 3 projects on, implementation 5 years 5.L.A \$7,747,912 22 projects f at least four evid	\$600,000 3 projects sissues for people 5.S.D \$0 1 project an, and sustainabilit 5.L.A \$5,840,814 24 projects	\$600,000 2 projects with ASD by 2012 5.S.D \$5,000 1 project y of evidence-bas 5.L.A \$7,210,677 32 projects	\$340,000 2 projects 5.S.D \$0 1 project sed interventions, s 5.L.A \$6,659,367 26 projects	\$40,000 2 projects 5.S.D \$0 0 projects services, and supp 5.L.A \$5,563,725 24 projects	\$40,000 1 project 5.S.D \$0 0 projects oorts in diverse 5.L.A \$6,938,201 16 projects	

Question 5: Multiyear Funding Table, see Appendix C for a color-coding key and further details.

			re Can I In Object	Turn Fo	r Servic	es?			
Year	2008	2009	2010	2011	2012	2013	2014	2015	Total
and legal guar practice by 20	dians, education 15.		service workers,			ders, including dir with ASD and to p			
	<mark>6.3</mark> \$30,000	5.L.C \$132,494	5.L.C \$36,433,257	5.L.C \$6,048,734	5.L.C \$3,724,262	5.L.C \$3,425,120	5.L.C \$2,886,724	5.L.C \$5,363,464	\$58,044,055
	1 project	6 projects	83 projects	30 projects	29 projects	29 projects	35 projects	35 projects	\$20,011,022
self-determina	ation and person nded Budget: \$2,0	al autonomy by 20 200,000 over 2 yec	015. ars			hat simultaneousl			
	N/A	N/A	5.L.D \$296,840 5 projects	5.L.D \$279,999 4 projects	5.L.D \$54,999 3 projects	5.L.D \$0 0 projects	5.L.D \$255,126 3 projects	5.L.D \$224,053 2 projects	\$1,111,017
 One study of services, de One study of One study of and promote 	on the cost-beneen enture coverage, focusing on the pervaluating pre-se te interdisciplinar	fit of providing co and sedation der provision of acces ervice and in-serv	omprehensive de ntistry to adults w sible, person-cen vice training progr	ith ASD as compa tered, equitable, e	uding routine, no ared to emergend effective, safe, ar	n-emergency med cy and/or no treat nd efficient dental ealth professional	ment. services to peop	ole with ASD.	
	N/A	N/A	5.L.E \$196,457 2 projects	5.L.E \$443,860 3 projects	5.L.E \$307,784 2 projects	5.L.E \$510,972 2 projects	5.L.E \$496,567 4 projects	5.L.E \$1,063,214 3 projects	\$3,018,854
Not Specific to	any objective								
	5. Core/ Other Activities \$1,247,714 5 projects	5. Core/ Other Activities \$2,004,687 8 projects	5. Core/ Other Activities \$13,436,737 66 projects	5. Core/ Other Activities \$11,553,704 63 projects	5. Core/ Other Activities \$9,060,297 62 projects	5. Core/ Other Activities \$7,250,109 57 projects	5. Core/ Other Activities \$6,488,878 48 projects	5. Core/ Other Activities \$6,028,680 34 projects	\$57,070,806
Total Fund	ling for Que	stion 5							
Reported Funding for Question 5*	\$1,685,222 13 projects	\$8,648,050 36 projects	\$64,849,122 211 projects	\$26,118,904 137 projects	\$22,827,101 138 projects	\$20,047,285 125 projects	\$17,616,239 127 projects	\$21,280,931 97 projects	\$183,052,313

Question 5: Multiyear Funding Table, see Appendix C for a color-coding key and further details.

\$64,849,122

\$8,648,051

\$20,047,285

\$17,616,239

\$26,118,904

\$185,241,644

\$21,280,931

\$3,874,552

Adjusted

Funding for Question 5[†]

^{*}The "Reported funding" totals reflect the funding and projects coded to this Question of the Strategic Plan as reported in the Portfolio Analysis Report corresponding to the year indicated at the top of the column. When reading each column vertically, projects and funding may not add up to the reported funding total. The projects and funding associated with these reclassified objectives are now reflected under the Question in which they appear in the 2011 Strategic Plan.

[†]The "Adjusted funding" total reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan (the most recent version in which objectives were revised) and incorporates funding for projects that may have been coded differently under previous versions of the Plan.



ASPIRATIONAL GOAL: ALL PEOPLE WITH ASD WILL HAVE THE OPPORTUNITY TO LEAD SELF-DETERMINED LIVES IN THE COMMUNITY OF THEIR CHOICE THROUGH SCHOOL, WORK, COMMUNITY PARTICIPATION, MEANINGFUL RELATIONSHIPS, AND ACCESS TO NECESSARY AND INDIVIDUALIZED SERVICES AND SUPPORTS.

RESEARCH FOCUS OF QUESTION 6

With increasing societal awareness of the needs of people on the autism spectrum across the lifespan, Question 6 addresses the question "What does the future hold, particularly for adults?" Question 6 encompasses research to identify and address issues surrounding transition to adulthood, access to services across the lifespan, and quality of life. Some of the research in Question 6 represents projects that assess the long-term outcomes (in terms of measures such as quality of life, health, independence, and employment) for people on the autism spectrum, particularly with respect to interventions and services they might have received. Many projects assigned to Question 6 focus on adolescents transitioning from the education system to employment, as well as vocational/job skills and social skills training for both transitional aged youth and adults.

In an effort to describe the research funded in Question 6 in 2014 and 2015, a word cloud was created using the project titles listed under this question (**Figure 56**). The size of each word within the word cloud indicates

the frequency of its use in project titles. The word cloud visually portrays the main research themes and topics that were funded in Question 6.



Figure 56. Word cloud representing themes in Question 6 project titles.

ANALYSIS OF 2014-2015 QUESTION 6 PORTFOLIO

In 2014, research on lifespan issues associated with ASD (Question 6) accounted for 2% (\$5.5 million) of total ASD research funding and included 35 projects (2% of all projects). In 2015, Question 6 funding totaled \$6.1 million (2% of funding) and maintained 37 projects (3% of all projects). This Question area has the smallest portion of funding and number of projects in both years. In 2014, the agencies and organizations with the largest stakes in this research are the National Institutes of Health, Department of Defense (Army), and Autism Speaks. In 2015, the National Institutes of Health and Department of Defense continued to lead funding in Question 6, but the Department of Education became the third largest funder. Question 6 consists of eight objectives. Figures 57 & 58 provide a detailed overview of each objective's total funding as well as the number of projects assigned to each objective.

In 2014, six objectives received funding, and one objective included an active project with no funding. The largest portion of funding for this question went to projects that did not fit into any of the specific Question 6 research objectives and were assigned as Core/Other (\$2.4 million, 44%). Objective 6.L.A followed in funding (\$1.3 million; 24%), which focuses on developing community-based interventions that improve quality of life for adults with ASD. Also, Question 6 Core/Other and Objective 6.L.A had the largest portions of projects; Core/Other had 14 projects and 6.L.A had 9 projects. The remaining objectives in Question 6 that received funding received significantly smaller portions of funding. Objectives 6.S.D did not receive funding but has been funded in previous years.




Figure 57. Question 6 objectives broken down by their funding and project count in 2014.

In 2015, five objectives received funding and one objective (6.S.B) included an active project with no funding. As in 2014, most projects that were categorized under this question did not fit into any of the specific Question 6 research objectives and were assigned as Core/Other (\$1.8 million, 30%); this continued to be the largest number of projects as well (11 projects). Objective 6.L.A had the next largest

portion in funding (\$1.4 million; 23%); followed closely by Objective 6.S.A (\$1.3 million; 22%), which supports studies assessing quality of life for adults with ASD and service delivery systems. Objectives 6.S.D and 6.L.D did not receive funding but have been funded in previous years. **Table 10** lists all the objectives and their progress to date.




Figure 58. Question 6 objectives broken down by their funding and project count in 2015.

QUESTION 6 SUBCATEGORY ANALYSIS

Because Question 6 had so few assigned projects (35 in 2014; 37 in 2015) and because many projects encompassed more than one topic, it was difficult to formulate and group the research into subcategories in the same fashion as was done for the other questions.

However, this will likely change as the research field concerned with ASD across the lifespan grows and matures, allowing the development of subcategories in the future.

PROGRESS MADE ON QUESTION 6 FROM 2008-2015

Figure 59 shows the trend in Question 6 funding over time using the adjusted funding total in **Table 10**. The adjusted funding reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan that may have been coded differently under previous versions of the plan. Research related to Question 6 received the lowest level of annual funding for every year of the eight-year time period. Although there was a small increase in funding for this question area from

2009-2010 and 2014-2015, the overall trend shows that funding for this question has stayed low and relatively flat over the eight-year period. The adjusted funding for 2008 and 2009 reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan and incorporates funding for projects that may have been coded differently under previous versions of the Plan. Based on the adjusted funding amounts, there was a slight increase in funding from 2008-2010.




Figure 59. Question 6 ASD research funding from 2008-2015. Funding for Question 6 remained low over the eight-year span but recently has experienced a slight increase.

PROGRESS MADE ON QUESTION 6 OBJECTIVES FROM 2008-2015

One Question 6 objective reached its recommended budget and seven objectives have been partially completed since 2008 (**Figure 60**). Since 2013, one objective made enough progress to change its overall status from partial progress to complete. Objective 6.L.B, which focuses on studies that assess the impact of childhood interventions and services on adult health and quality of life, reached its recommended budget. **Table 10** provides snapshot of progress made on all eight of the research objectives within Question 6 over the period from 2008-2015.




Figure 60. Overall status of progress for the eight Question 6 objectives.



Question 6: What Does The Future Hold, Particularly For Adults? IACC Strategic Plan Objectives

Year	2008	2009	2010	2011	2012	2013	2014	2015	Total
of the ser self-dete	rvice delivery sy rmination, relati	stem (e.g., safety,	integrated employ ss to health servic	ment, post-secon	of life for adults on idary educational of y-based services)	opportunities, con	nmunity inclusion,	,	
	6.2 \$60,000 1 project	6.S.A \$20,000 1 project	6.S.A \$283,837 2 projects	6.S.A \$542,193 6 projects	6.S.A \$1,013,156 10 projects	6.S.A \$1,118,557 9 projects	6.S.A \$588,335 6 projects	6.S.A \$1,347,686 8 projects	\$4,973,763
Administr	ration, Rehabilita		ninistration) meet		rams to assist peo sitioning youth and			urity	
	N/A	6.S.B \$0 0 projects	6.S.B \$700,000 2 projects	6.S.B \$700,000 2 projects	6.S.B \$700,000 2 projects	6.S.B \$0 0 projects	6.S.B \$499,621 1 project	6.S.B \$0 1 project	\$2,599,62
better un	derstand preva		outcomes with co		ot be diagnosed, o ical issues (insura				
	N/A	6.S.C \$0 0 projects	6.S.C \$28,000 1 project	6.S.C \$28,000 1 project	6.S.C \$0 1 project	6.S.C \$240,000 1 project	6.S.C \$240,000 1 project	6.S.C \$240,000 1 project	\$776,000
spectrum developm	n with ASD throu nent of ASD-spe		ecialized training ecessary, by 2015.		oorts being deliver ff, parents, and leg				
	N/A	6.S.D \$0 0 projects	6.S.D \$619,163 3 projects	6.S.D \$0 2 projects	6.S.D \$0 1 project	6.S.D \$0 1 project	6.S.D \$0 0 projects	6.S.D \$0 0 projects	\$619,163
ASD by 2	015.	vidualized commu et: \$12,900,000 ove	-	entions that improv	ve quality-of-life o	r health outcomes	for the spectrum	of adults with	
	6.5 \$0 0 projects	6.L.A \$509,965 2 projects	6.L.A \$2,285,071 18 projects	6.L.A \$2,154,170 15 projects	6.L.A \$616,119 11 projects	6.L.A \$290,180 5 projects	6.L.A \$1,312,217 9 projects	6.L.A \$1,395,480 9 projects	\$8,563,202
supports	delivered during	ouilds on carefully g childhood impac et: \$5,000,000 <i>over</i>	t adult health and		nd youth with ASD comes by 2015.	to determine how	interventions, se	rvices, and	
	N/A	6.L.B \$718,290	6.L.B \$1,280,790	6.L.B \$1,348,557	<mark>6.L.B</mark> \$639,346	<mark>6.L.B</mark> \$353,910	<mark>6.L.B</mark> \$179,994	6.L.B \$1,075,704	\$5,596,59

Question 6: Multiyear Funding Table, see Appendix C for a color-coding key and further details.



Question 6: What Does The Future Hold, Particularly For Adults? IACC Strategic Plan Objectives

	2008	2009	2010	2011	2012	2013	2014	2015	Total
	parative effective								
	to improve health y housing for peo		uality of life for a	dults on the ASD	spectrum over ag	ge 21 by 2018. To	pics should includ	le:	
	l life transitions for	•), including from	post-secondary e	ducation to adult	services, employ	ment, sibling rela	ationships,	
, ,	ograms; and ne service and sup	mart needs of als	lar adulta with AC	.D					
_	ended Budget: \$6,0	•		oD.					
	N/A	6.L.C	6.L.C	6.L.C	6.L.C	6.L.C	6.L.C	6.L.C	
	,	\$0	\$774,644	\$0	\$0	\$0	\$234,684	\$255,247	\$1,264,575
		0 projects	2 projects	0 projects	0 projects	0 projects	1 project	2 projects	
Conduct impl	ementation resea	rch to test the re	sults from compa	rative effectivene	ess research in re	al-world settings,	including a cost-	effectiveness	
component to	o improve health o	outcomes and qua	ality of life for adu				J		
ACC Recomm	ended Budget: \$4,0	000,000 over 5 yed	ars						
	N/A	6.L.D	6.L.D	6.L.D	6.L.D	6.L.D	6.L.D	6.L.D	
		\$0 0 projects	\$0 0 projects	\$75,000 2 projects	\$60,000 3 projects	\$60,000 2 projects	\$0 1 project	\$0 0 projects	<mark>\$195,000</mark>
		ODIORECTS	ODIORCIS						
		o projects	- p,	2 projects	3 projects	2 projects	1 project	o projects	
Not Specific t	o any objective	o projects	- F. J. 2000	2 projects	3 projects	2 projects	1 project	o projects	
Not Specific t	• •	, ,	,	, ,	, ,	, ,	. ,	,	
Not Specific t	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	
Not Specific t	6. Core/ Other Activities	6. Core/ Other Activities	6. Core/ Other Activities	6. Core/ Other Activities	6. Core/ Other Activities	6. Core/ Other Activities	6. Core/ Other Activities	6. Core/ Other Activities	\$7,468,399
Not Specific t	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	6. Core/ Other	\$7,468,399
·	6. Core/ Other Activities \$467,683 2 projects	6. Core/ Other Activities \$159,444 2 projects	6. Core/ Other Activities \$671,619	6. Core/ Other Activities \$50,000	6. Core/ Other Activities \$830,556	6. Core/ Other Activities \$1,090,239	6. Core/ Other Activities \$2,401,208	6. Core/ Other Activities \$1,797,650	\$7,468,39
·	6. Core/ Other Activities \$467,683	6. Core/ Other Activities \$159,444 2 projects	6. Core/ Other Activities \$671,619	6. Core/ Other Activities \$50,000	6. Core/ Other Activities \$830,556	6. Core/ Other Activities \$1,090,239	6. Core/ Other Activities \$2,401,208	6. Core/ Other Activities \$1,797,650	\$7,468,39
Total Fund	6. Core/ Other Activities \$467,683 2 projects ding for Ques	6. Core/ Other Activities \$159,444 2 projects stion 6	6. Core/ Other Activities \$671,619 3 projects	6. Core/ Other Activities \$50,000 3 projects	6. Core/ Other Activities \$830,556 4 projects	6. Core/ Other Activities \$1,090,239 7 projects	6. Core/ Other Activities \$2,401,208 14 projects	6. Core/ Other Activities \$1,797,650 11 projects	
·	6. Core/ Other Activities \$467,683 2 projects	6. Core/ Other Activities \$159,444 2 projects	6. Core/ Other Activities \$671,619 3 projects	6. Core/ Other Activities \$50,000 3 projects	6. Core/ Other Activities \$830,556 4 projects	6. Core/ Other Activities \$1,090,239 7 projects	6. Core/ Other Activities \$2,401,208 14 projects	6. Core/ Other Activities \$1,797,650 11 projects	\$7,468,39 \$41,325,12
Total Fund Reported unding for	6. Core/ Other Activities \$467,683 2 projects ding for Ques	6. Core/ Other Activities \$159,444 2 projects stion 6	6. Core/ Other Activities \$671,619 3 projects	6. Core/ Other Activities \$50,000 3 projects	6. Core/ Other Activities \$830,556 4 projects	6. Core/ Other Activities \$1,090,239 7 projects	6. Core/ Other Activities \$2,401,208 14 projects	6. Core/ Other Activities \$1,797,650 11 projects	

Question 6: Multiyear Funding Table, see Appendix C for a color-coding key and further details.

Table 10. Multiyear funding table for Question 6.

^{*}The "Reported funding" totals reflect the funding and projects coded to this Question of the Strategic Plan as reported in the Portfolio Analysis Report corresponding to the year indicated at the top of the column. When reading each column vertically, projects and funding may not add up to the reported funding total. The projects and funding associated with these reclassified objectives are now reflected under the Question in which they appear in the 2011 Strategic Plan.

[†]The "Adjusted funding" total reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan (the most recent version in which objectives were revised) and incorporates funding for projects that may have been coded differently under previous versions of the Plan.



ASPIRATIONAL GOAL: DEVELOP AND SUPPORT INFRASTRUCTURE AND SURVEILLANCE SYSTEMS THAT ADVANCE THE SPEED, EFFICACY, AND DISSEMINATION OF ASD RESEARCH.

RESEARCH FOCUS OF QUESTION 7

Question 7 ("What other infrastructure and surveillance needs must be met?") covers the topics of research infrastructure, data sharing, workforce development, ASD surveillance, and communication/dissemination of research findings and evidence-based practices. With 16 objectives, Question 7 has the greatest number of objectives of all seven questions in the *Strategic Plan*.

A word cloud was made using the project titles listed under this question to describe the research funded in Question 7 in 2014 and 2015 (**Figure 61**). The size of each word within the word cloud indicates the frequency of its use in project titles. The word cloud visually portrays the main research themes and topics that were funded in Question 7.



Figure 61. Word cloud representing themes in Question 7 project titles.

ANALYSIS OF 2014-2015 QUESTION 7 PORTFOLIO

Projects assigned to Question 7 comprised 14% (\$43.6 million) of the total ASD research supported in 2014 and consisted of 145 projects, which was 10% of the total number of projects. In 2015, funding for Question 7 consisted of 16% (\$53.3 million) of the overall ASD funding and totaled 131 projects (10% of all projects). In 2014 and 2015, the National Institutes of Health

and Simons Foundation funded nearly three-quarters of research in Question 7. There are 16 objectives that fall under the Question 7 research area. **Figures 62 & 63** provide a detailed overview of each objective's total funding as well as the number of projects assigned to each objective.




Figure 62. Question 7 objectives broken down by their funding and project count in 2014.

In 2014, ten objectives received funding and six objectives did not have any active projects or funding. The largest portion of funding categorized under Question 7 did not fit into any of the specific research objectives and was assigned as Core/Other (\$15.4 million, 35%). Of the 16 Question 7 objectives, programs enhancing the research workforce and developing interdisciplinary training (7.K) received the largest amount of funding (\$8.6 million, 20%) and greatest portion of projects (45 projects). Objective 7.N followed with \$5.8 million (13%) in funding and 37 projects; this objective funds the expansion of clinical research sites collecting and coordinating standardized and comprehensive diagnostic, biological, and medical data. Although Objective 7.G was not funded in 2014, it was already considered completed due to activity in previous years. Objective 7.E, which did not receive funding in 2014 to support the development of a virtual toolbox for researchers to disseminate findings, has received funding in previous years and is considered complete. Objectives 7.A, 7.B, 7.F, and 7.M also did not receive any funding in 2014. Objective 7.B has received funding in previous years and is considered partially completed. However, objectives 7.A, 7.F, and 7.M have never received funding, which may be due to the wording or specificity of the goal (e.g., the "Promising

Practices" papers program mentioned in objective 7.M was piloted by Centers for Medicare & Medicaid prior to the launch of the *Strategic Plan* in 2009, but the program was not continued).

In 2015, the funding patterns were comparable to previous years. The majority of Question 7 funding went towards Core/Other (\$18.8 million, 35%). The second largest funding amount went towards Objective 7.K, which supports enhancing the research workforce and developing interdisciplinary training (\$11.4 million, 21%); it also had the largest number of projects (37 projects). Objective 7.I followed with \$4.9 million (9%) in funding; this objective supports conducting analyses evaluating prevalence using existing ADDM Network sites. As in 2014, Objective 7.G did not receive funding in 2015, although it was already considered completed due to activity in previous years. Again, Objective 7.B did not receive funding but has received funding in previous years. After seven years of no funding activity, Objective 7.A, which assesses linking databases to track involvement of people with ASD in health, education, and social services, received funding for one project in 2015. However, 7.F, and 7.M continued to have no funding or activity through 2015. Table 11 lists all the objectives and their progress to date.




Figure 63. Question 7 objectives broken down by their funding and project count in 2015.

QUESTION 7 SUBCATEGORY ANALYSIS

The six subcategories in Question 7 reflect the broad array of ASD research infrastructure needs that have been identified by the IACC: **Biobanks**; **Data tools**; **Research infrastructure**; **Research recruitment and clinical care**; **Research workforce development**; and **Surveillance and prevalence studies** (**Figures 64 & 65**).

In Question 7, the subcategories encompass a diverse set of project types, with funding distributed relatively evenly across them. In 2014 and 2015, **Research infrastructure** received the largest portion of funding (32% in 2014; 37% in 2015). **Data tools**, such as National Database for Autism Research (NDAR) and the Autism Genetics Resource Exchange (AGRE), experienced an increase in funding and encompassed 25% (\$11.3 million) of Question 7 funding in 2014; it

continued to have a significant portion of funding in 2015 with 16% (\$8.7 million) of funding. **Research** workforce development, which supports conferences and training for autism researchers, accounted for 21% (\$9 million) of funding in 2014 and 22% (\$11.8 million) of funding in 2015. **Surveillance and prevalence studies**, such as studies under the ADDM Network, had 11% of funding (\$4.7 million) in 2014 and 12% (\$6.5 million) in 2015. **Research recruitment and clinical care**, which helps increase participation in research studies and conduct medical evaluations of participants, received 7% (\$3.0 million) in 2014 and 8% (\$4.2 million) in 2015. **Biobanks** received the smallest portion of funding both years, 4% (\$1.8 million) in 2014 and 5% (\$2.4 million) in 2015.




Figure 64. Question 7 funding by subcategory in 2014.




Figure 65. Question 7 funding by subcategory in 2015.

PROGRESS MADE ON QUESTION 7 FROM 2008-2015

Figure 66 shows the trend in Question 7 funding over the eight-year span of 2008-2015 using the adjusted funding totals from **Table 11**. The adjusted funding reflects funding for projects aligned to objectives in the *2011 IACC Strategic Plan* that may have been coded differently under previous versions of the plan. Research falling within this question area experienced a rapid increase in funding from 2008-2010. However, after 2010 funding levels for

these infrastructure and surveillance projects leveled off to a flat, moderate level from 2010-2014. The year 2015 noticed a slight spike in funding for Question 7 research projects. The adjusted funding reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan and accounts for funding of projects that may have been coded differently under previous versions of the Plan.




Figure 66. Question 7 ASD research funding from 2008-2015. Following an initial increase from 2008-2010, funding for Question 7 remained primarily flat from 2010-2015.

PROGRESS MADE ON QUESTION 7 OBJECTIVES FROM 2008-2015

An assessment of total progress since 2008 indicates that ten Question 7 objectives were considered completed, four objectives saw partial progress toward their overall recommended budgeted goals, and two objectives - Objectives 7.F (replication studies) and 7.M (promising practices papers about successful services delivery strategies) - have experienced no progress as of 2015 (Figure 67). The Committee felt uncertain of whether the objective 7.F was feasible, and of whether or not 7.M had been replaced by other modes of dissemination. Objective 7.A (to support a needs assessment toward linkage of administrative databases) had not experienced any funding or activity in prior years, but the amount of funding it received in 2015 was enough for it to meet its recommended budget. Outside of Objective 7.A., the Question 7 objectives did not experience enough progress in funding to change the overall status of any of the objectives from what was reported in 2013. **Table 11** provides a snapshot of progress made on all 16 of the research objectives within Question 7 over the period from 2008-2015.



Figure 67. Overall status of progress for the 16 Question 7 objectives.



Question 7: What Other Infrastructure And Surveillance Needs Must Be Met? IACC Strategic Plan Objectives

onduct a	needs assessn	nent to determine	how to merge or	link administrative	and/or surveillan	ce databases that	allow for tracking	the	
ıvolvemer	nt of people livi		alth care, education	on, and social serv				,	
	6.4	7.A \$0	7.A \$0	7.A SO	7.A SO	7.A \$0	7.A SO	7.A \$668,316	\$668,316
	0 projects	0 projects	0 projects	0 projects	0 projects	0 projects	0 projects	1 project	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		of the States" ass t: \$300,000 each y		ng State program:	s and supports for	people and famili	es living with ASD	by 2011.	
	5.1 \$311,670 6 projects	7.B \$7,061 1 project	7.B \$197,128 1 project	7.B \$88,154 1 project	7.B \$0 1 project	7.B \$13,495 1 project	7.B \$0 0 projects	7.B \$0 0 projects	\$617,508
ASD rese	earch by 2010.	le to the research	•	ns by which to mer	ge or link databas	es that allow for t	racking the involv	ement of people	
	6.1	7.C	7.C	7.C	7.C	7.C	7.C	7.C	
	\$6,767,808	\$1.665.180	\$2,785,368	\$1,387,146	\$985,158	\$1,177,741	\$1,244,603	\$3,921,510	\$19,934,5
stablish ar biologica / 2011. • This incl • Protocol including	4 projects and maintain an al material, by a ludes support f ols should be pu	or post-processing into place to exposts, promoting place to expost posts, promoting the contract of the contr	nat use standardiz ng of tissue, such a pand the capacitie ng detection of bio	7 projects for the collection of the protocols for place genotyping, RN as genotyping large slogical signatures	henotyping, collect A expression proficescale children's s	ction, and regulate ling, and MRI. studies to collect a	d distribution of li	mited samples al biomaterials,	
stablish ar r biologica y 2011. • This incl • Protocol including • Support quantita for quan	4 projects and maintain an al material, by a ludes support f ols should be pu ag newborn bloo t should also be ative anatomica ntitative morph	international netwacquisition sites the or post-processing it into place to expodspots, promoting provided to deve	work of biobanks fact use standardizing of tissue, such a pand the capacitient detection of bioelop an internation of patients with Apy 2014.	for the collection of ed protocols for p as genotyping, RN es of ongoing large	of brain tissue, fibr henotyping, collect A expression profi e-scale children's s tal brain atlas that	oblasts for pluripo tion, and regulate ling, and MRI. studies to collect a	otent stem cells, and distribution of lind store additionary.	nd other tissue mited samples al biomaterials, images and	
stablish ar r biologica y 2011. • This incl • Protocol including • Support quantita for quan	4 projects and maintain an al material, by a ludes support f ols should be pu ag newborn bloo t should also be ative anatomica ntitative morph	international netwacquisition sites the or post-processing it into place to expodspots, promoting provided to deveal data from tissue ological studies, b	work of biobanks fact use standardizing of tissue, such a pand the capacitient detection of bioelop an internation of patients with Apy 2014.	for the collection of ed protocols for p as genotyping, RN es of ongoing large slogical signatures nal web-based digital ASD and disease of	of brain tissue, fibr henotyping, collect A expression profi e-scale children's s tal brain atlas that	oblasts for pluripo tion, and regulate ling, and MRI. studies to collect a	otent stem cells, and distribution of lind store additionary.	nd other tissue mited samples al biomaterials, images and	
stablish and biologically 2011. This inclusion Protocol including Support quantitation quantita	4 projects and maintain an al material, by a ludes support f ols should be pu ag newborn bloo t should also be ative anatomica ntitative morph nmended Budge	international netwacquisition sites the or post-processing it into place to expodspots, promoting provided to deveal data from tissue ological studies, but: \$82,700,000 over	work of biobanks for the standardization of the capacitient of the capacitient of the standardization of patients with App 2014.	for the collection of ed protocols for p as genotyping, RN es of ongoing large slogical signatures nal web-based digi ASD and disease c	of brain tissue, fibr henotyping, collect A expression profi e-scale children's s tal brain atlas that ontrols across the	oblasts for pluripo ction, and regulate ling, and MRI. studies to collect a would provide hig lifespan, which co	otent stem cells, and distribution of linds and store additional shapes of the store additional shapes of the store as an or of the store as a	nd other tissue mited samples al biomaterials, images and nline resource	\$32,339,2
stablish air biologica y 2011. • This incl • Protocol includin; • Support quantita for quan CC Recom	4 projects and maintain an all material, by a ludes support follows should be pure growth and also be ative anatomical antitative morph an anatomical budge. 2.1 & 2.6 \$55,018,579 1 project & 1 project elopment of a vocople with ASI	international netwacquisition sites the for post-processing the into place to expodspots, promoting provided to deveal data from tissue ological studies, but: \$82,700,000 over 7.D \$436,815 2 projects	work of biobanks in the use standardizing of tissue, such a pand the capacitient of the particular of patients with A particular of patients with A particular of y 2014. To Syears 7.D \$7,814,918 6 projects To assist research of health practition	for the collection of ed protocols for plants genotyping, RN es of ongoing large slogical signatures hall web-based digital SD and disease control of the projects.	of brain tissue, fibr henotyping, collect A expression profice-scale children's state that tal brain atlas that ontrols across the 7.D \$2,950,550 5 projects	roblasts for pluripo ction, and regulate ling, and MRI. studies to collect a would provide hig lifespan, which co 7.D \$3,369,545 8 projects	otent stem cells, and distribution of list and store additional store additional store as an order of the store of	and other tissue mited samples all biomaterials, images and nline resource 7.D \$2,404,633 8 projects	\$32,339,2
stablish air biologica y 2011. • This incl • Protocol includin; • Support quantita for quan CC Recom	4 projects and maintain an all material, by a ludes support follows should be pure growth and also be ative anatomical antitative morph an anatomical budge. 2.1 & 2.6 \$55,018,579 1 project & 1 project elopment of a vocople with ASI	international netwacquisition sites the acquisition site of the acquisition o	work of biobanks in the use standardizing of tissue, such a pand the capacitient of the particular of patients with A particular of patients with A particular of y 2014. To Syears 7.D \$7,814,918 6 projects To assist research of health practition	for the collection of ed protocols for plants genotyping, RN es of ongoing large slogical signatures hall web-based digital SD and disease control of the projects.	of brain tissue, fibr henotyping, collect A expression profice-scale children's state that tal brain atlas that ontrols across the 7.D \$2,950,550 5 projects	roblasts for pluripo ction, and regulate ling, and MRI. studies to collect a would provide hig lifespan, which co 7.D \$3,369,545 8 projects	otent stem cells, and distribution of list and store additional store additional store as an order of the store of	and other tissue mited samples all biomaterials, images and nline resource 7.D \$2,404,633 8 projects	\$32,339,2
stablish and biological y 2011. This including Support quantitation q	4 projects and maintain an all material, by a ludes support following newborn blood to should also be ative anatomical thitative morph an anatomical thitative morph and anatomic	international netwacquisition sites the acquisition sites to expossor, promoting a provided to deveal data from tissue ological studies, but: \$82,700,000 over 7.D \$436,815 2 projects web-based toolbood, their families, and get: \$400,000 over 7.E \$330,663 2 projects	work of biobanks in the use standardizing of tissue, such a condition of the capacities of detection of biological particular in the property of patients with A by 2014. To Syears 7.D \$7,814,918 6 projects A to assist research dealth practition of patients with a by 2014. To Syears 7.E \$390,134 1 project The replication of the standard project The replication of the project of the syears 7.E \$390,134 1 project	for the collection of the protocols for possible set of ongoing large slogical signatures and web-based digital set of the projects. 7.D \$8,531,425 6 projects hers in effectively oners by 2011.	of brain tissue, fibrhenotyping, collect A expression profice-scale children's second to the controls across the control a	roblasts for pluripostion, and regulate ling, and MRI. studies to collect as would provide highlifespan, which collects a projects. 7.D \$3,369,545 8 projects isseminating their so of projects	otent stem cells, and distribution of list and store additions and store additions and store as an order of the collection of the collecti	nd other tissue mited samples all biomaterials, images and nline resource 7.D \$2,404,633 8 projects ommunity, 7.E \$62,500	

Question 7: Multiyear Funding Table, see Appendix C for a color-coding key and further details.



Question 7: What Other Infrastructure And Surveillance Needs Must Be Met? IACC Strategic Plan Objectives

Year	2008	2009	2010	2011	2012	2013	2014	2015	Total
identified IACC Recor	by the ADDM N	Network by 2012. (t: \$200,000 over 2	This objective ca		ce for States base completed - CD				
	N/A	7.G \$0 0 projects	7.G \$0 0 projects	7.G \$0 0 projects	7.G* \$0 0 projects	7.G* \$0 0 projects	7.G* \$0 0 projects	7.G* \$0 0 projects	\$0
Research	(NDAR), and lin	pecifically support lk NDAR with othe t: \$6,800,000 over	r existing data res		of newly initiated p	rojects to the Nat	ional Database foi	r Autism	
	N/A	7.H \$1,932,996 2 projects	7.H \$2,453,253 3 projects	<mark>7.H</mark> \$1,517,596 1 project	7.H \$3,679,808 5 projects	7.H \$1,026,179 3 projects	7.H \$5,448,890 2 projects	7.H \$4,343,675 1 project	\$20,402,397
factors the	at may contribu	OM Network sites the site of the state of the site of	ASD prevalence by		e data to conduct	at least five hypot	hesis-driven analy	yses evaluating	
	N/A	7.1 \$6,715,815 15 projects	7.1 \$6,137,128 13 projects	7.1 \$4,928,453 13 projects	7.1 \$6,028,878 13 projects	7.1 \$5,747,286 13 projects	7.1 \$4,113,033 13 projects	7.1 \$4,903,557 11 projects	\$39,378,447
investigati	ing potential ch		alence of ASD and		and other countri		sistance describir	ng and	
	N/A	7.J \$494,449 11 projects	7.J \$170,490 4 projects	7.J \$545,414 6 projects	7.J \$159,610 4 projects	7.J \$151,545 2 projects	7.J \$123,217 2 projects	<mark>7.J</mark> \$121,537 1 project	\$1,766,262
ly-career s	scientists into t	f funding mechani he ASD field by 20 t: \$5,000,000 over	13.	the research work	force, enhance int	erdisciplinary rese	earch training, and	l recruit ear-	
	N/A	7.K \$2,527,472 7 projects	7.K \$7,358,427 34 projects	7.K \$4,813,286 27 projects	7.K \$10,003,091 25 projects	7.K \$9,560,821 31 projects	7.K \$8,566,735 45 projects	7.K \$11,432,489 37 projects	\$54,262,321
completer	ness of ongoing	DDM sites in order surveillance; and st: \$16,200,000 ove	expand efforts to		dren and adults; co btypes by 2015.	onduct compleme	ntary direct scree	ning to inform	
	N/A	7.L \$699,304 2 projects	7.L \$1,429,602 8 projects	7.L \$705,552 6 projects	7.L \$847,002 6 projects	7.L \$874,638 6 projects	7.L \$506,669 6 projects	7.L \$1,500,000 8 projects	\$9,039,827

Question 7: Multiyear Funding Table, see Appendix C for a color-coding key and further details.



Question 7: What Other Infrastructure And Surveillance Needs Must Be Met? IACC Strategic Plan Objectives

rice recomm	ended Budget: \$75								_
	N/A	7.M \$0 0 projects	7.M \$0 0 projects	7.M \$0 0 projects	7.M \$0 0 projects	7.M \$0 0 projects	7.M \$0 0 projects	7.M \$0 0 projects	\$0
omprehensi for conducti	ve diagnostic, bio	ological (e.g., DNA ffectiveness rese	ering clinical care A, plasma, fibrobla earch and clinical 1 ar	sts, urine), medic	al, and treatment	history data that			
	N/A	N/A	7.N \$6,662,790	7.N \$7,419,887	7.N \$5,270,828	7.N \$7,616,296	7.N \$5,826,353	7.N \$4,641,459	\$37,437,6
			3 projects	22 projects	22 projects	23 projects	37 projects	25 projects	
ethods acro • This including links to inf • This can so including o	oss projects by 20 des common prot ormation on how erve as a bidirect	D13. ocols, instrument to acquire and u ional information ns, screening too	chers (e.g., PhenX ts, designs, and of tilize technology in reference, with an ols, and analytic te	Project) to share ther procedural do n development. utism research dri	e information to fa	ncilitate data shar	ing and standardi	zation of nology and	
• This include links to inf • This can see including i	oss projects by 20 les common prot ormation on how erve as a bidirect new model syster	D13. ocols, instrument to acquire and u ional information ns, screening too	chers (e.g., PhenX ts, designs, and of tilize technology in reference, with an ols, and analytic te	Project) to share ther procedural do n development. utism research dri	e information to fa	ncilitate data shar	ing and standardi	zation of nology and	\$3,335,7
nethods acre This including to inference of the common of	oss projects by 20 des common prot ormation on how erve as a bidirect new model syster nended Budget: \$2, N/A	ocols, instrument to acquire and u ional information ms, screening too 000,000 over 2 years. N/A or facilities that dof current model systems by 2013.	chers (e.g., PhenX ts, designs, and of tilize technology in reference, with a ols, and analytic te ears 7.0 \$605,338 3 projects evelop promising systems, and sup	Project) to share ther procedural do not development. In the search drichniques. 7.0 \$1,070,941 3 projects	e information to factorize information information to factorize information to factorize information i	ncilitate data shar build include upda ment of new reso 7.0 \$728,000 1 project	ing and standardi ates on new technology urces and technology 7.0 \$127,575 2 projects	zation of nology and logies, 7.0 \$75,908 2 projects more easily	\$3,335,76

Question 7: What Other Infrastructure And Surveillance Needs Must Be Met? IACC Strategic Plan Objectives

Year	2008	2009	2010	2011	2012	2013	2014	2015	Total
Not Specific to a	any objective								
	N/A	7. Core/ Other Activities \$1,000,000 2 projects	7. Core/ Other Activities \$13,253,709 26 projects	7. Core/ Other Activities \$12,314,084 18 projects	7. Core/ Other Activities \$16,863,272 23 projects	7. Core/ Other Activities \$13,732,127 23 projects	7. Core/ Other Activities \$15,405,816 25 projects	7. Core/ Other Activities \$18,791,492 25 projects	\$91,217,896
Total Fundi	ng for Quest	ion 7							
Reported Funding for Question 7*	N/A	\$15,809,755 46 projects	\$50,847,065 108 projects	\$43,855,291 111 projects	\$47,516,197 112 projects	\$43,022,248 117 projects	\$43,570,016 146 projects	\$53,301,448 132 projects	\$302,161,197
Adjusted Funding for Question 7 [†]	\$12,098,057 12 projects	\$15,809,755 46 projects	\$50,847,065 108 projects	\$43,855,291 111 projects	\$47,516,197 112 projects	\$43,022,248 117 projects	\$43,570,016 146 projects	\$53,301,448 132 projects	\$314,259,254

Question 7: Multiyear Funding Table, see Appendix C for a color-coding key and further details.

Table 11. Multiyear funding table for Question 7.

^{*}The "Reported funding" totals reflect the funding and projects coded to this Question of the Strategic Plan as reported in the Portfolio Analysis Report corresponding to the year indicated at the top of the column. When reading each column vertically, projects and funding may not add up to the reported funding total. The projects and funding associated with these reclassified objectives are now reflected under the Question in which they appear in the 2011 Strategic Plan.

[†]The "Adjusted funding" total reflects funding for projects aligned to objectives in the 2011 IACC Strategic Plan (the most recent version in which objectives were revised) and incorporates funding for projects that may have been coded differently under previous versions of the Plan.

SUMMARY AND CONCLUSION

The 2014-2015 IACC ASD Research Portfolio Analysis Report represents the eighth year of data collected and the sixth comprehensive report of U.S. ASD research funding across both the Federal and private sectors; it will also be the last analysis to measure research progress against the objectives from the 2011 IACC Strategic Plan. Future portfolio analyses will monitor new objectives created in the 2016-2017 IACC Strategic Plan. For this analysis on the 78 objectives from the 2011 IACC Strategic Plan, data were collected from 18 Federal and private funders. The diverse missions of the different funders are reflected in the ASD research portfolio across the seven questions of the Strategic Plan. In 2015, federal agencies continued to fund four-fifths of ASD research while private organizations contributed nearly 20% of funding. Among the participating funders, National Institutes of Health continued to contribute the largest amount of Federal funding toward autism research, and the Simons Foundation was the largest private funder.

Overall, funding for ASD research among both Federal and private funders totaled \$309.9 million and spanned 1,441 projects in 2014 and reached \$342.6 million covering 1,410 projects in 2015. With eight years of ASD research funding data available, it was possible to continue analyzing funding trends, enabling meaningful observations about the long-term progress of the field of ASD research over the period from 2008-2015. Over the

eight years, autism research showed a general upward trend in funding, increasing by 54% since 2008.

One of the key aims of the Portfolio Analysis Report is to evaluate the progress made in addressing the research priorities as outlined in the Strategic Plan objectives. In 2015, significant progress was made toward completing the objectives in the 2011 Strategic Plan, with 97% (76 objectives) of the 78 objectives either partially or fully completed. Considering the period from 2008-2015, only 3% (2 objectives) of the 2011 Strategic Plan objectives were not active at any point across this eight-year window. This indicates that the vast majority of priority areas identified in the Strategic Plan objectives were deemed by Federal and private research funders to be worthy of investment and were implemented either partially or fully. While broad implementation efforts across most of the Strategic Plan objectives demonstrated commitment of Federal and private funders to pursuing the research areas prioritized by the Committee, many areas of partial funding still left significant gaps that were not filled over this period. Further attention and additional funding may be needed in the future to stimulate and develop more robust research efforts in those areas. The Committee has taken these gaps into consideration in the development of the forthcoming 2016-2017 IACC Strategic Plan.

In addition to analysis of progress made on completing the specific research objectives outlined in the *Strategic Plan*, the subcategory classification system, introduced in the *2010 Portfolio Analysis*, continues to provide an alternative perspective on the content of the autism research portfolio. Even with future changes in *Strategic Plan* objectives, the subcategory analysis will allow tracking of growth and change in general research areas over time, including the emergence of new fields that attract investment from research funders.

As in the 2013 IACC ASD Portfolio Analysis Report, additional analyses on the geographical distribution of autism research funding, investments in long-term (ongoing) research compared to newly funded projects, and the types of research funded by different agencies and organizations were included in the portfolio analysis to provide more detailed information for the Committee and community stakeholders on the autism research landscape.

This annual IACC ASD Research Portfolio Analysis Report assists the Committee with carrying out its charge to monitor autism activities and to inform the process of updating the IACC Strategic Plan for ASD Research. While this is the last portfolio analysis using the Strategic Plan objectives developed in 2011, in the next IACC Strategic Plan (2016-2017), the Committee will put forward objectives and budget recommendations to encourage funders to direct investment toward a new set of research priorities that reflect the most pressing needs of the autism community and incite greater attention to the needed autism research areas. Future portfolio analyses using the 2016-2017 IACC Strategic Plan's new objectives will continue to serve as a resource for the Committee, funders, and the broader ASD community to identify and address knowledge gaps, recognize emerging trends and new opportunities, and guide future research priorities to better meet the needs of families and individuals affected by ASD.

APPENDICES

APPENDIX A

Federal Agency and Private Organization Mission Statements

FEDERAL AGENCIES - DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Administration for Community Living (ACL)

Formed in 2012, ACL serves as the Federal agency responsible for increasing access to community supports, while focusing attention and resources on the unique needs of older Americans and people with disabilities across the lifespan. ACL funds the AutismNOW web resource, which provides information for the ASD community on topics including detection, intervention, education, transition from high school into early adulthood, employment, advocacy, community inclusion, aging issues, and public policy.

Agency for Healthcare Research and Quality (AHRQ)

The mission of AHRQ is to improve the quality, safety, efficiency, and effectiveness of health care for all Americans. Their portfolio includes projects to evaluate the comparative effectiveness of autism interventions and to conduct systematic reviews of the literature on topics such as autism screening and autism interventions, with the goal of evaluating the strength of the evidence supporting practices and identifying gaps in research. AHRQ also funds projects aimed at disseminating information about best practices and other findings from their reviews to researchers, practitioners, the patient community, and other stakeholders.

Centers for Disease Control and Prevention (CDC)

The mission of CDC is to create the expertise, information, and tools that people and communities need to protect their health. This is achieved through health promotion, prevention of disease, injury and

disability, and preparedness for new health threats. CDC's autism research portfolio includes projects to collect data on ASD prevalence and risk factors, and projects to improve awareness, early detection, and intervention.

Health Resources and Services Administration (HRSA)

HRSA is the primary Federal agency for improving access to health care services for people who are uninsured, isolated, or medically vulnerable. The Maternal and Child Health Bureau (MCHB) supports autism-related programs through its Combating Autism Act Initiative (CAAI), including projects to increase awareness, reduce barriers to screening and diagnosis, promote the development of guidelines for evidence-based practices, and train health care professionals to provide screening as well as diagnostic and early, evidence-based intervention. Flagship programs include the Autism Intervention Research Networks (AIR-B and AIR-P), the Developmental Behavioral Pediatrics Research Network (DBPNet), and the Leadership Education in Neurodevelopmental and Related Disabilities (LEND) program.

National Institutes of Health (NIH)

The mission of NIH is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The NIH supports a broad range of research on ASD, including projects on the basic neuroscience of ASD, risk factors, diagnosis, intervention, and services research. One of the flagship autism programs funded

by NIH, the Autism Centers of Excellence (ACE), is a collection of research centers and networks across the country that conduct research on ASD. NIH also funds interdisciplinary data repositories such as the National Database for Autism Research (NDAR) to facilitate the sharing of autism research data among scientists worldwide.

FEDERAL AGENCIES - OTHER

Department of Defense (DoD)

The Department of Defense **(DoD)** is charged with coordinating and supervising all agencies and functions of the government concerned directly with national security and the United States Armed Forces. Within the DoD's Defense Health Research Program, the Congressionally Directed Medical Research Program's Autism Research Program **(ARP)** was established in 2007, with the mission to improve the lives of individuals with ASD by promoting innovative research that advances the understanding of ASD and leads to improved outcomes for those with ASD. The projects that the ARP funds span the scope of the IACC.

The U.S. Air Force (DOD-AF) also funds research on ASD, and is developing a multidisciplinary autism research and services program for military families, part of which involves the creation of a comprehensive registry to provide higher quality data for autism clinical and genetics research.

Department of Education (ED)

The mission of the U.S. Department of Education is to promote student achievement by fostering educational excellence and ensuring equal access. The department funds a portfolio of ASD-related projects relating to development and delivery of educational interventions and services, particularly for children and

transition-aged youth. A large portion of ED's funding goes towards developing practitioner training as well as investment in training researchers.

Environmental Protection Agency (EPA)

The mission of the U.S. EPA is to protect human health and the environment. EPA co-funds the Center for Children's Environmental Health (CCEH) at the University of California at Davis with the National Institute of Environmental Health Sciences (NIEHS)/NIH, which conducts research into how environmental exposure to toxins might interact with a person's genes and immune system to influence the risk and severity of ASD.

National Science Foundation (NSF)

NSF is an independent Federal agency, formed by Congress to promote the progress of science and to advance the national health, prosperity, and welfare. NSF funds basic research in biology, mathematics, computer science, and the social sciences as well as technology development, but it does not focus on health or disease-related research. Although NSF does not have a program focused on ASD, it funds several projects that involve basic science or technologies with the potential to be applied to ASD in the future. NSF is a leading funder of projects involving technological interventions and supports, including robotics and virtual reality technologies that could be used to enhance daily living skills and activities of individuals with disabilities.

PRIVATE ORGANIZATIONS

Autism Research Institute (ARI)

ARI's mission is to meet the needs of the global autism community through research, networking, education, and support for families and people of all ages on the autism spectrum. ARI is dedicated to developing a standard of care for individuals with autism spectrum disorders and their families, and funds a range of work with a particular emphasis on investigation of the biological underpinnings of autism, including immune and metabolic pathways.

Autism Science Foundation (ASF)

ASF's mission is to support autism research by providing funding and other assistance to scientists and organizations conducting, facilitating, publicizing, and disseminating autism research. The organization also provides information about autism to the general public and serves to increase awareness of autism spectrum disorders and the needs of individuals and families affected by autism. ASF funds pre- and postdoctoral trainees to conduct basic and clinical research relevant to ASD, including studies focused on a wide range of topics such as identification of biomarkers, molecular and cellular mechanisms, genetic and environmental risk factors, treatments, and service delivery.

Autism Speaks (AS)

AS is the world's largest autism science and advocacy organization, dedicated to funding research into the causes, prevention, treatments, and a cure for autism; increasing awareness of autism spectrum disorders; and advocating for the needs of individuals with autism and their families. AS funds a broad profile of ASD research ranging from basic neuroscience and the molecular causes of autism to implementation and testing of interventions for those diagnosed with autism. Autism Speaks supports the **Autism Treatment Network**, a collaboration of 14 specialty centers dedicated to providing families with state-of-the-art, multidisciplinary healthcare for children and teens affected by autism.

Brain and Behavior Research Foundation (BBRF)

BBRF funds basic neuroscience research to elucidate the molecular mechanisms underlying brain disorders and conditions. BBRF's autism research portfolio primarily includes studies on the genetics and molecular mechanisms underlying autism.

Center for Autism and Related Disorders (CARD)

CARD is one of the world's largest organizations using applied behavior analysis (ABA) in the treatment of ASD, and other related disorders. CARD's research portfolio is centered around developing new behavioral interventions, assessing existing behavioral interventions, and developing and implementing training/intervention programs for individuals on the autism spectrum from birth to age 21.

Organization for Autism Research (OAR)

The mission of OAR is to support research that directly impacts the day-to-day quality of life of those with ASD. This includes research to inform and improve education, communication, self-care, social skills, employment, behavior, and adult and community living. In this context, it extends to issues related to family support, the efficacy of service delivery systems, and demographic analyses of the autism community.

New England Center for Children (NECC)

The New England Center for Children is a private, nonprofit autism research and education center dedicated to transforming the lives of children with autism worldwide through education, research, and technology. NECC strives to be a global leader in the provision of effective, evidence-based educational services for the millions of under-served children with autism and their families.

Patient-Centered Outcomes Research Institute (PCORI)

PCORI helps people make informed healthcare decisions and improves healthcare delivery and outcomes by producing and promoting high-integrity, evidence-based information that comes from research guided by patients, caregivers, and the broader healthcare community.

Simons Foundation (SF)/Simons Foundation Autism Research Initiative (SFARI)

The mission of SF is to advance the frontiers of research in mathematics and the basic sciences. SF's single largest initiative is the Simons Foundation Autism Research Initiative (SFARI), which seeks to improve the diagnosis and treatment of ASD by funding, catalyzing, and driving innovative research of the greatest quality and relevance. The SF ASD portfolio includes research on genetic and cellular factors underlying autism, identification of genetic and environmental risk factors, and development of potential treatments.

APPENDIX B

ASD-Related Research Projects not included in the IACC Portfolio Analysis

This section contains lists of projects that are not specifically focused on autism, but may be helpful in understanding the broader landscape of ongoing research on disabilities and other topics that may be relevant to autism.

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NECC	Chata Dickson Jackie MacDonald Kelly McConnell	Evaluating the performance of typically developing children on the New England Center for Children's Core Skills Assessment	The purpose of this study was to evaluate the performance of typically developing children on the NECC Core Skills Assessment (CSA). These results will provide a normative reference to those looking to teach skills to young children diagnosed with autism.
NECC	Chata Dickson Kim Walter	Effects of task difficulty on behavioral resurgence	In this translational study of effects of task difficulty on resurgence, we evaluated rate of responding following reinforcement and extinction of two different responses. This study will be replicated with individuals with autism serving as participants.
ACL	Thomas Keating, PhD	MyLife: Development of a Cloud- Based Transition ePortfolio for Individuals with Cognitive Disabilities	http://www.naric. com/?q=ProgramDatabase
ACL	Sandra M. Magaña, PhD Tamar Heller, PhD Joe Caldwell, PhD	Rehabilitation Research and Training Center (RRTC) on Family Support	http://www.naric. com/?q=ProgramDatabase
ACL	Daniel K. Davies	Mobile Connect: A Cloud-Based, Universally Designed Text Messaging and Email Program to Facilitate Social Connectedness and Community Inclusion for Individuals with Intellectual Disabilities	http://www.naric. com/?q=ProgramDatabase

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
HRSA	Stephen Sulkes	Leadership Education in Neurodevelopmental and Related Disabilities (LEND)	https://mchdata.hrsa.govdgisreports/ AbstractAbstractDetailsaspx?cbAbstract- Summary=73MC00029 2013 NonRe- search 4&tbKeyword=atism&rbKey- word=Exact&rbTimePeriod=0&tFrom- Date=01/01/2013&tbTDate=12/31/2013&ddl- ResultsBy=ProjectTitle&rbSortedBy=ASC
NIH	Didier Hodzic	Nuclear Dynamics in Retinal Development Homeostasis	https://projectreporter.nih.gov/project info_description.cfm?aid=8826128&ic- de=29944362&ddparam=&ddvalue=&ddsub- =&cr=1&csb=default&cs=ASC
NIH	David Cobrinik	Modeling Optic Nerve Hypoplasia with Patient iPSC- Derived Retinal Ganglion Cells	https://projectreporter.nih.gov/project info_description.cfm?aid=8874012&ic- de=29944424&ddparam=&ddvalue=&ddsub- =&cr=1&csb=default&cs=ASC
NIH	Martina Brueckner	Genetics and Genomics of Congenital Heart Diseases and Associated Neurodevelopmental Abnormalities	https://projectreporter.nih.gov/project_info description.cfm?aid=8952979
NIH	Jane W. Newburger	The Genomic Basis of Congenital Heart Disease and Neurodevelopmental Outcomes	http://projectreporter.nih.gov/project_info_description.cfm?aid=8952616
NIH	Deepak Srivastava	Genetics of Hypoplastic Left Heart Syndrome	http://projectreporter.nih.gov/project_info_description.cfm?aid=8952652
NIH	Martin Tristani- Firouzi	Bridging the Gap Between Genomics and Clinical Outcomes in CHD	http://projectreporter.nih.gov/project info description.cfm?aid=8950472
NIH	Paul Thompson	ENIGMA Center for Worldwide Medicine, Imaging & Genomics - Adminstrative	https://projectreporter.nih.gov/project_info_description.cfm?aid=8935792&icde=0
NIH	Paul Thompson	ENIGMA Center for Worldwide Medicine, Imaging & Genomics - Consortium Activities	http://projectreporter.nih. gov/project info description. cfm?projectnumber=5U54EB020403-02

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NIH	Paul Thompson	ENIGMA Center for Worldwide Medicine, Imaging & Genomics - Data Science research	https://projectreporter.nih.gov/project info_description.cfm?aid=8935792&icde=0
NIH	Paul Thompson	ENIGMA Center for Worldwide Medicine, Imaging & Genomics - Training	https://projectreporter.nih.gov/project info_description.cfm?aid=8935792&icde=0
NIH	Marji Warfield	The impact of parental military deployment on children with disabilities	https://projectreporter.nih.gov/project info_description.cfm?aid=8881255&icde=0
NIH	Michael Guralnick	Intellectual and Developmental Disabilities Research Center	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD083091-02
NIH	Gail Mandel	The Mechanism of Rett Syndrome Rescue by Astrocytes	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R01HD081037-01A1
NIH	Gary J. Latham	Development of a Reliable and Standardized Molecular Assay for Fragile X Protein	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R43HD082900-01A1
NIH	Marsha Ruth Mailick	FMRI1 Premutation Phenotypes in Population-Based & Clinically- Ascertained Samples	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R01HD082110-01A1
NIH	Joseph E. Donnelly	Weight Management for Adolescents with IDD	https://projectreporter.nih. gov/project info description. cfm?projectnumber=1R01HD079642- 01A1%5C
NIH	Hongjie Yuan	NMDAR Mutations & Neurodevelopmental Disorder: From Mechanism to Targeted Therapy	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R01HD082373-01
NIH	Jonathan Oren Lipton	Sleep and Circadian Rhythms in Tuberous Sclerosis Complex	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5K08HD071026-04

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NIH	Jennifer C. Darnell	Cell-specific RNA Targets of the Fragile X Mental Retardation Protein Family	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01HD040647-12
NIH	Paul J Hagerman	Expression of the Fragile X Gene	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01HD040661-13
NIH	Carlos Portera-Cailliau	Imaging Dendritic Spine Abnormalities and Circuit Defects in Fragile X Mice	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01HD054453-07
NIH	Lee-Way Jin	The Role of Astrocytes in Rett Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R01HD064817-05
NIH	Carolyn R Houser	GABA System Alterations and Fragile X Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R01HD067225-04
NIH	Frederick T Chin	Cross-Species Multi-Modal Neuroimaging to Investigate GABA Physiology in Fragile X Syndrome	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01HD084214-02
NIH	Lu Chen	Developmental Pathophysiology of Synapses in a Mouse Model of Fragile X Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R01HD084215-02
NIH	Alan Kenneth Percy	Rett Syndrome; MECP2 Duplications; And Rett-Related Disorders Natural History	http://projectreporter.nih. gov/project info description. cfm?projectnumber=5U54HD061222-12
NIH	Alan Kenneth Percy	MECP2 Duplication Syndrome: Longitudinal Studies; Biomarker and Clinical Outcome Development	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD061222-12
NIH	Alan Kenneth Percy	Rett-Related Disorders: Longitudinal Studies; Biomarker and Clinical Outcome Development	http://projectreporter.nih. gov/project info description. cfm?projectnumber=5U54HD061222-12

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NIH	Alan Kenneth Percy	Development of a Behavioral Outcome Measure for Rett Syndrome (RETTBE) and Metabolic Profiling of Rett Syndrome; MECP2 Duplication Syndrome; and Rett- Related Disorders	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5U54HD061222-12
NIH	Kimberly Huber	Mechanisms of Neocortical and Sensory Hyperexcitability in Fragile X Syndrome	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD082008-02
NIH	Kimberly Huber	Molecular and Synaptic Mechanisms of Auditory Circuit Dysfunction in FXS Mice	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD082008-02
NIH	Kimberly Huber	Auditory Processing Deficits in FMR1 KO Mice	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD082008-02
NIH	Kimberly Huber	Neurophysiological and Acute Pharmacological Studies in FXS Patients	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD082008-02
NIH	Joel D. Richter	Rescuing the Fragile X Syndrome by CPEB Depletion	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD082013-02
NIH	Joel D. Richter	Strategies to Rescue PI3K Dysregulation in Fragile X Syndrome	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD082013-02
NIH	Joel D. Richter	Rescuing Fragile X Syndrome by Targeting P70 S6 Kinase 1	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5U54HD082013-02
NIH	Susan Y Bookheimer	Intellectual and Developmental Disabilities Research Centers	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5P30HD004612-44
NIH	Jeffrey L. Neul	Characterization of Autonomic Dysfunction in Rett Syndrome & Other MECP2 Disorder	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R01HD062553-05

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NIH	Scott S. Hall	Understanding Severe Disruptive Behaviors in Adolescents with Fragile X Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R21HD072282-02
NIH	Lisa D. Marceau	Improving Pediatric Developmental Screening and Communication: A CME	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R44HD063173-03
NIH	Leonard Abbeduto	Expressive Language Sampling as an Outcome Measure	http://projectreporter.nih.gov/project info_details.cfm?aid=8627630
NIH	Mary Oschwald	Pregnancy and Support Services for Women with Developmental Disabilities	http://projectreporter.nih.gov/project info_details.cfm?aid=8700656
NIH	Lin L. Zhu	Using FMRI to Understand Verbal and Nonverbal Human Communication	https://projectreporter.nih. gov/project info description. cfm?projectnumber=1F30DC014911-01A1
NIH	Karen P. Usdin	Gene Silencing in Fragile X Syndrome	http://projectreporter.nih. gov/project info description. cfm?projectnumber=1ZIADK057602-19
NIH	Karen P. Usdin	Mechanism of Repeat Expansion and Chromosome Fragility in Fragile X Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1ZIADK057808-09
NIH	Jane Yu	Prostaglandin Biosynthesis: A Novel Therapeutic Target in TSC Disorders	http://projectreporter.nih. gov/project info description. cfm?projectnumber=7R01DK098331-02
NIH	Carmen Joseph Marsit	Environment; Imprinting; and Neurodevelopment	http://projectreporter.nih. gov/project info description. cfm?projectnumber=3R01ES022223-03S1
NIH	Carmen Joseph Marsit	Environment; Imprinting; and Neurodevelopment	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01ES022223-03
NIH	Paul J. Hagerman	Epigenetic Regulation of the FMR1 Gene	https://projectreporter.nih. gov/project info description. cfm?projectnumber=1R01GM113929-01

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NIH	James F. Gusella	Neurodevelopmental Loci	https://projectreporter.nih.gov/project info_description.cfm?projectnumber=2P- 01GM061354-11A1
NIH	Olga, Troyanskaya	Integration and Visualization of Diverse Biological Data	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=2R01GM071966-10A1
NIH	Cynthia He	Linking Defects in Cortical Network Activity with Altered Sensory Perception in Fragile X Mice	http://projectreporter.nih. gov/project info description. cfm?projectnumber=1F30NS093719-01
NIH	Caitlyn M. Riedmann	Determination of the Epigenetic Regulation of Gene Transcription by MECP2 in Neurons	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1F31NS092418-01A1
NIH	Jimmy L. Holder	Rescuing Motor Deficits in Shank3 Related Disorders	http://projectreporter.nih. gov/project info description. cfm?projectnumber=1K08NS091381-01A1
NIH	Molly-Maureen Huntsman	Cortical Circuit Dysfunction in Fragile X Syndrome	https://projectreporter.nih. gov/project info description. cfm?projectnumber=1R01NS095311-01A1
NIH	Michaela Fagiolini	VIisual circuit Regression and ITS Rescue in RTT Mouse Models	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R01NS095959-01A1
NIH	Benjamin Deneen	The Nature of Astrocyte Heterogeneity in RTT	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R21NS089366-01A1
NIH	Michael Wong	Mechanisms of Brain Dysfunction in Tuberous Sclerosis	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=2R01NS056872-09A1
NIH	Huda Y. Zoghbi	Molecular Pathogenesis Studies of Rett Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R01NS057819-10

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NIH	Scott H. Soderling	Fragile X Phenotypes Modulated by Altered Signaling to the Synaptic Cytoskeleton	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R01NS059957-07
NIH	Zhaolan Zhou	Understanding the Pathogenic Mechanisms of Rett Syndrome	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01NS081054-03
NIH	Vitaly A. Klyachko	The Role of PK Channels in Neuropathology of Fragile X Syndrome	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01NS089449-02
NIH	Marl F. Bear	Validating a Novel Target for correction of Pathophysiology in Fragile X and TSC	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5R21NS087225-02
NIH	Samie R. Jaffrey	Testing the Role of Small RNAs in FMR1 Promotor Silencing in Fragile X Syndrome	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5R21NS087859-02
NIH	Kerstin Maria Ure	Rescue of Gabaergic Function in a Mouse Model of Rett Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1F32NS083137-01A1
NIH	Peter K. Todd	Pathogenic Mechanisms in Fragile X Tremor Ataxia Syndrome	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=5K08NS069809-05
NIH	Onanong Chivatakarn	Analysis of the Tumor Suppressor Gene TSC1 in Motor Neuron Patterning	https://projectreporter.nih. gov/project info description. cfm?projectnumber=5K99NS083758-02
NIH	Peter K. Todd	CGG Repeat Associated Translation in Fragile X-Associated Tremor/Ataxia Syndrome-Diversity Supplement	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=3R01NS086810-01S1
NIH	Robert Macdonald	GABA(A) Receptor Assembly/ Trafficking/Function and Epilepsy Missense Mutations	http://projectreporter.nih. gov/project info description. cfm?projectnumber=5R01NS033300-20
NIH	Michael Greenberg	Neuronal Activity-Dependent Regulation of MeCP2	https://projectreporter.nih.gov/project info_details.cfm?aid=8635394&icde=0

FUNDER	PRINCIPAL INVESTIGATOR(S)	PROJECT TITLE	WEBLINK/ PROJECT DESCRIPTION
NIH	Edward Cooper	KCNQ2 Epileptic Encephalopathy: Overcoming Hurdles to Effective Disease- Modifying Therapy	https://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R13NS095592-01
NIH	William Dobyns	The genetic basis of Dandy- Walker and other mid-hindbrain malformations	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=2R01NS050375-11
NIH	Shigeki Iwase	Neutralizing epigenomes in neurodevelopmental disorders	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=1R01NS089896- 01A1
NIH	Elliott Sherr	ACC: Callosal Agenesis as a Window into Common Neurodevelopmental Disorders	http://projectreporter.nih. gov/project_info_description. cfm?projectnumber=2R01NS058721-07A1
PCORI	C. William Shuttleworth, PhD	Pathways to Partnership: Communication and Collaboration Skills for Creating PCOR Teams	http://www.pcori.org/research- results/2015/pathways-partnership- communication-and-collaboration-skills- creating-pcor
PCORI	Megan O'Boyle, BA	Phelan-McDermid Syndrome Data Network (PMS_DN)	http://www.pcori.org/research- results/2015/phelan-mcdermid- syndrome-data-network-pmsdn
PCORI	Geraldine Bliss, MS	Phelan-McDermid Syndrome Patient-Centered Outcomes Workshop	http://www.pcori.org/research- results/2015/phelan-mcdermid- syndrome-patient-centered-outcomes- workshop
PCORI	Kenneth D. Mandl, MD, MPH	Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS)	http://www.pcori.org/research- results/2015/scalable-collaborative- infrastructure-learning-healthcare- system-scilhs
PCORI	Christopher B. Forrest, MD, PhD	Development of the PROMIS Pediatric Sleep Health Item Banks	http://www.pcori.org/research- results/2014/development-promis- pediatric-sleep-health-item-banks

APPENDIX C

ASD Research Progress on IACC Strategic Plan Objectives: Summary of Years 2008-2015

The tables include data (project numbers and funding) from Federal and private funders of ASD research for years 2008 through 2015, as aligned with the objectives of the 2011 IACC Strategic Plan. Please note the following:

During the updating of the *Strategic Plan from* 2008-2010, the wording and numbering of objectives changed. Data included in each *Portfolio Analysis Report from* 2008-2015 was categorized at the time with respect to the most recent iteration of the *Strategic Plan* where the objectives had changed. For the purpose of this eight-year comparison, data from the Portfolio Analyses conducted in 2008 and 2009 were aligned with the most recent objectives, found in the 2011 *Strategic Plan*. The full wording of the 78 objectives listed in the 2011 *Strategic Plan* is depicted above the objective's abbreviation and annual funding.

The middle eight columns of the table contain the data (project numbers and funding) for each individual year from 2008-2015, with the objective number (as it appeared in the annual *Portfolio Analysis*) listed above it. The format of objective numbers are abbreviations

representing the question number (indicated by a numeral 1-7), whether the objective is a short- or long-term objective (indicated by the letter "S" or "L", respectively), and the objective designation (indicated by a letter). The IACC recommended budget listed below the project data represents the most updated budget listed in the 2011 Strategic Plan. If the recommended budget has been revised since 2008, the year the revision took place is found in parentheses following the budget figure. Therefore, if there is no mention of a revision, the IACC recommended budget has remained constant from 2008-2011. The annual project status for each objective from 2008-2015 is indicated within the table by colored highlighting of the objective number. An objective is considered active if its status is green or yellow, and inactive if its status is red.

• Any objective colored green has funding which is greater than or equal to the recommended funding for that year (determined by annualizing the recommended budget associated with that objective); any objective colored yellow has actively funded projects, but with funding that totals less than the annualized recommended amount; any objective colored red has no active, funded projects.³

Objectives whose overarching aim (e.g., the ultimate goal of the research, irrespective of the number of projects or the budget for the objective) were achieved/partially achieved either in a previous year, with less annual funding than was recommended, or with funding that was not captured in the portfolio analyses,⁴ are colored pale green/pale yellow.

The far right column of the table lists the sum of the total funding aligned with each objective from 2008-2015. Highlighting of each total gives an indication of the overall progress toward completing each objective.

 Green highlighting indicates that funding fully meets the recommend budget. Yellow highlighting denotes

- that funding for a particular objective partially meets the IACC recommended budget, while **red** highlighting indicates that there has been no funding towards the particular objective.
- Objectives whose overarching aim (e.g. the ultimate goal of the research, irrespective of the number of projects or the budget for the objective) was achieved/partially achieved either with a lower funding level than was recommended or with funding that was not captured in the portfolio analyses, are colored pale green/pale yellow.

³Please note that while the green, yellow, and red indicators suggest a funding status for each year and that looking across all years may give some indication of a trend, some agencies and organizations provide all the funding for multiyear grants in a single year, resulting in the appearance of "less funding" in other years; projects completing the objectives may still have been ongoing in the years where the funding appears to be less. Thus, it is important to note the numbers of projects in looking across the chart, and to keep in mind that in a series, where, for example, most of the indicators are green, that the objective is likely to be largely "complete" according to the funding-based measure.

⁴Reasons why funding for certain projects may not have been captured in the portfolio analyses include projects that were supported by funding that was not specific for autism (i.e., projects that benefited autism but were supported by general neuroscience or developmental disorder funding) or projects supported by funders that did not participate in the portfolio analysis in a given year.

APPENDIX D

Subcategory Definitions



Diagnostic and screening tools

This subcategory includes projects that are developing new autism diagnostic and screening tests, as well as those establishing the usefulness of new or revised assessments for autism symptoms. It also encompasses projects aimed at adapting clinical assessments into other languages for use in multi-lingual community settings and non-U.S. countries.

Early signs and biomarkers

Projects which use a variety of methods to search for signs of autism in very young children (generally under age 3) that could be used for diagnosis, such as eye-tracking, physiological measures, and autism-specific behavioral patterns are included in this subcategory. More examples include projects investigating metabolic measures, such as the levels of specific chemicals, hormones, or proteins in the blood that could be used as biomarkers of the disorder.

Intermediate phenotypes/Subgroups

Included in this subcategory are projects aimed at identifying distinct subgroups of people with autism, or those that share common morphological, physiological, or behavioral features. Projects in this subcategory use a variety of methods to identify and distinguish these groups.

Symptomology

These projects seek to define the broad range and severity of autism symptoms, including both biological and behavioral characteristics. Among these studies are some that examine how children and adults with autism vary in their development of social communication and language. Other projects seek to understand the emergence of problem behaviors and how neurocognitive impairments can contribute to symptom development and phenotypic variability in those with an autism diagnosis.



Cognitive studies

These are studies of psychological and mental processes, including memory, producing and understanding language, solving problems, and making decisions.

Projects in this subcategory consist of those that investigate theory of mind, social cognition and empathy, understanding facial expressions of emotion (and how and why this is impaired in ASD), and recall and memory.

Computational science

Computational methods and modeling allow for the synthesis and study of large and complex sets of data. Some projects in this subcategory collect extensive experimental biological and behavioral data and use powerful computing techniques to reveal new insights. Other aspects of computer science are also included, such as developing statistical modeling techniques to better understand the biology of autism.

Co-occurring conditions

Research on conditions that often co-occur with ASD is included here, such as seizures/epilepsy, sleep disorders, gastrointestinal dysfunction, wandering/elopement behavior, attention deficit hyperactivity disorder (ADHD), and familial autoimmune disorders.

Developmental trajectory

Projects in this subcategory often include longitudinal studies following various aspects of biological and behavioral development in the same individuals over time. Examples include brain growth, face processing, change in neural connectivity over time, and development of communication skills and language processing. These studies often compare children with ASD to typically developing children or to their unaffected siblings.

Immune/Metabolic pathways

These projects focus on understanding the biological mechanisms of metabolism and the immune system that may be altered in autism, typically in cells and animal models. This largely includes studies on inflammation and inflammatory molecules (i.e., cytokines), as well as on the role of mitochondria, energy metabolism, and oxidative stress. Also included in this group are projects seeking to identify specific immune and metabolic triggers in early prenatal and post-natal life, such as maternal infection, maternal auto-antibodies, and toxic exposures.

Molecular pathways

This subcategory includes studies on specific molecules and proteins (other than the immune and metabolic systems) that may be involved in the development of ASD and related genetic disorders (e.g., fragile X syndrome and Rett syndrome). Many of these projects use animal and cellular models to explore the biological effects of specific candidate genes and to identify common molecular pathways, including alterations in synaptic functioning and intracellular signaling cascades.

Neural systems

Studies in this subcategory explore the structure and activity of the brain and underlying neural systems involved in autism, including functional connections between brain regions. Many projects seek to identify the precise neural networks underlying communication and language processing, social interactions, and behavioral issues. These studies frequently employ imaging techniques, such as functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI), and other physiological measures of brain activity, such as electroencephalography (EEG).

Neuropathology

These projects typically include post-mortem examination of brain tissue from ASD individuals. Many of the studies in this subcategory explore how the architecture of the brain may be altered in individuals with autism or how gene expression varies in different areas of the brain.

Sensory and motor function

Projects in this subcategory explore the neural underpinnings of motor skills and abilities in children with ASD and assess visual, auditory, and other sensory processes in the brain.

Subgroups/Biosignatures

Because there is so much heterogeneity among individuals with autism, research to understand how certain subgroups of individuals that share certain behavioral or biological characteristics could help understand some of the underlying biology in ASD. This can be done by searching for certain biological factors ("signatures"), such as hormone levels or structural abnormalities in the brain, that define a particular subgroup. Many of these projects try to make the connection between certain genes with a known or suspected link to autism and the observable characteristic, or phenotype, that they cause.



Environmental risk factors

This subcategory includes a number of projects investigating potential environmental risk factors for autism. Example projects include studies of the effects of the microbiome, environmental contaminants and toxins, maternal dietary factors, medications taken during pregnancy or to induce labor, assistive reproductive treatments, child and maternal response to immune challenge, and registries where many of these factors can be tracked simultaneously.

Epigenetics

Epigenetics is the study of heritable changes in gene function that occur without a change in the DNA sequence (such as methylation of DNA). Environmental factors can cause these changes in gene expression, and projects in this subcategory seek to identify some of the environmental influences that may lead to these epigenetic changes.

Gene-Environment

These studies include efforts to identify and understand the contributions of environmental factors, genetic susceptibility, and human physiology (e.g., the immune system, metabolic processes) that may increase the risk for ASD, as well as studies that directly examine gene-environment interactions. (Note: While epigenetic studies are a subset of gene-environment studies, they are tracked as a separate subcategory because there is a substantial number of these projects and the topic of epigenetics is of significant public interest.)

Genetic risk factors

Projects in this subcategory seek to identify new genes that are implicated in increased risk for ASD or to better understand genetic risk factors that were previously identified.



Behavioral

Projects in this subcategory involve a wide array of behavioral research and training methods, including applied behavior analysis (ABA), cognitive-behavioral therapy, discrete trial training, Early Start Denver Model, imitation training, joint attention training, Lovaas method, pivotal response training, sibling-mediated interventions, and social skills training.

Complementary, dietary, and alternative

This subcategory includes research on acupressure; acupuncture; antioxidants; cholesterol supplementation; glutathione metabolism; nutritional supplements, vitamins, and minerals; probiotics; and special diets (e.g., gluten-free, casein-free).

Educational

Nearly all research in classroom settings falls under this subcategory, including curricula, educational best practices, inclusive education programs, math and reading training, positive behavioral supports, special education programs, TEACCH (Treatment and Education of Autistic and Related Communication-Handicapped Children), and the "Social Stories" approach.

Medical/Pharmacologic

This subcategory includes research on drugs (e.g., antidepressants, anticonvulsants, antipsychotics, anxiolytics, melatonin, and stimulants) to treat autism and its co-occurring conditions, as well as medical therapies such as transcranial magnetic stimulation (TMS).

Model systems/Therapeutic targets

Animal models mimicking behaviors of ASD and those that are being used to develop or test new drug treatments, as well as cell lines used to discover new drug targets or to screen potential drug candidates, are included in this subcategory.

Occupational, physical, and sensory-based

Therapies in this subcategory encompass art therapy, motor training (including fine motor skills such as handwriting as well as gross motor training involving balance and posture), music therapy, occupational therapy, pet (animal) therapy, physical activity plans and exercise therapy (bike riding, swimming), physical therapy, sensory integration, therapeutic horseback riding, training in self-care and daily living skills, and vocational rehabilitation.

Technology-based interventions and supports

Augmentative and alternative communication (AAC), computer applications and software, picture exchange communication system (PECS), social robots, teleconferencing, video modeling and virtual reality (including virtual and 3D environments to mimic social situations), and wearable sensors are all examples of the types of technology in the projects in this subcategory.



Community inclusion programs

These programs provide instruction in social, communication, and leisure skills to enable individuals with autism to participate in sports, recreation, and social-integration activities in fully integrated settings and to build successful relationships with others.

Efficacious and cost-effective service delivery

This subcategory includes programs involving web-based curricula and interventions as well as telehealth methodology, all of which could benefit those in underserved areas. Various parent training projects (to deliver a behavioral therapy, for example) using web-based methods such as teleconsultation and video feedback make distributing the training programs cost-effective and accessible across the country. Studies to improve dental care are also in this subcategory for effective service delivery.

Family well-being and safety

Studies in this subcategory evaluate issues of caregiver stress and measures of quality of life for individuals with ASD and their families, as well as assess programs to help parents navigate the service system after their child receives an ASD diagnosis. It also surveys safety issues for those with autism, including wandering and bullying.

Practitioner training

Projects in this subcategory seek to increase skill levels in service providers, including medical providers, direct support workers, parents and legal guardians, education staff, and public service workers.

Services utilization and access

These projects include surveys of service systems available in different States, evaluations of patterns of medical service use among children with autism, a comprehensive online resource for autism services, and specific efforts in several states to coordinate services for people with autism. They also evaluate disparities in diagnosis and service utilization as well as barriers to access for racial and ethnic minorities.



Due to the small number of projects (35 in 2014 and 37 in 2015) and the significant overlap between topics covered in these projects, no subcategories were created for this question in the 2014-2015 Portfolio Analysis Report. As the research field grows, subcategories that encapsulate the scope of projects in this question may be defined in the future.



Biobanks

A biobank is a type of biorepository which stores human biological samples for use in research. Projects in this subcategory support collection of DNA and tissue samples from autism patients.

Data tools

These projects include bioinformatics databases to store genetic, phenotypic, and other medical information from autism patients. They also support infrastructure for several of these major databases to interact.

Research infrastructure

This subcategory includes coordinating centers that support multiple research projects by running tests, analyzing data, and providing statistical analyses.

These projects also support facilities that operate large, shared instruments used by several scientists to test research samples.

Research recruitment and clinical care

Projects in this subcategory help increase participation in research studies and conduct medical evaluations for the participants, often collecting data that can be used for multiple studies.

Research workforce development

Workshops, conferences, and training programs that serve to expand the research workforce, enhance interdisciplinary research training, and recruit early-career scientists into the ASD field are included in this subcategory.

Surveillance and prevalence studies

Research that measures autism prevalence in the U.S. and internationally is contained in this subcategory, including the Autism and Developmental Disabilities Monitoring (ADDM) Network sites maintained by the Centers for Disease Control and Prevention (CDC).

IACC COMMITTEE ROSTER OARC STAFF LIST



Interagency Autism Coordinating Committee Member Roster

CHAIR

Joshua Gordon, M.D., Ph.D.

Director National Institute of Mental Health (NIMH) and Chair, IACC National Institutes of Health Rockville, MD

FEDERAL MEMBERS

James F. Battey, M.D., Ph.D.

Director
National Institute on Deafness and Other
Communication Disorders
National Institutes of Health
Bethesda, Maryland

Linda Birnbaum, Ph.D.

Director

National Institute of Environmental Health Sciences and National Toxicology Program National Institutes of Health Research Triangle Park, North Carolina

Aaron Bishop, M.S.S.W.

Commissioner

Administration on Intellectual and
Developmental Disabilities

Administration for Community Living

Washington, DC

Francis S. Collins, M.D., Ph.D.

Director National Institutes of Health Bethesda, Maryland

Denise Dougherty, Ph.D.

Senior Advisor for Child Health and Quality Improvement Agency for Healthcare Research and Quality Washington, DC

Ruth Etzel, M.D., Ph.D.

Director
Office of Children's Health Protection
Environmental Protection Agency
Washington, DC

Tiffany R. Farchione, M.D.

Medical Officer
Division of Psychiatry Products
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Silver Spring, Maryland

Melissa L. Harris

Acting Deputy Director
Disabled and Elderly Health Programs Group
Center for Medicare and CHIP Services
Centers for Medicare and Medicaid Services
Baltimore, MD

Laura Kavanagh, M.P.P.

Director

Division of Research, Training and Education Maternal and Child Health Health Resources and Service Administration Rockville, Maryland

Walter J. Koroshetz, M.D.

Director

National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda, Maryland

Laura Pincock, PharmD, MPH

Pharmacist Officer Agency for Healthcare Research and Quality Rockville, MD

Marcella Ronyak, Ph.D., LCSW, CDP

Deputy Director Division of Behavioral Health, Indian Health Service (IHS) Headquarters Rockville, MD

Stuart K. Shapira, M.D., Ph.D.

Associate Director
Science and Chief Medical Officer
National Center on Birth Defects
and Developmental Disabilities
Centers for Disease Control and Prevention
Atlanta, GA

Melissa Spencer

Deputy Commissioner
Office of Disability Policy
Social Security Administration

Larry Wexler, Ed.D.

Director
Research to Practice
Office of Special Education Programs
U.S. Department of Education
Washington, DC

Nicole Williams, Ph.D.

Program Manager
Congressionally Directed Medical Research Programs
U.S. Department of Defense
Frederick, MD

PUBLIC MEMBERS

David Amaral, Ph.D.

Distinguished Professor Department of Psychiatry & Behavioral Science University of California, Davis (UC) Research Director, UC Davis MIND Institute Sacramento, CA

James Ball, Ed.D., B.C.B.A.-D.

President and CEO JB Autism Consulting Cranbury, NJ

Samantha Crane, J.D.

Legal Director and Director of Public Policy Autistic Self Advocacy Network Washington, DC

Geraldine Dawson, Ph.D.

Professor

Department of Psychiatry and Behavioral Science Duke University School of Medicine

Director

Duke Center for Autism and Brain Development Durham, NC

Amy Goodman, M.A.

Self-Advocate Charles Town, WV

Shannon Haworth

Public Health Program Manager Association of University Centers on Disabilities Silver Spring, MD

David S. Mandell, Sc.D.

Director

Center for Mental Health Policy and Services Research Associate Professor Psychiatry and Pediatrics Perelman School of Medicine University of Pennsylvania Philadelphia, PA

Brian Parnell, M.S.W, C.S.W.

Administrator

Medicaid Autism Waiver & Community Supports Waiver

Division of Services for People with Disabilities Utah Department of Human Services Draper, UT

Kevin Pelphrey, Ph.D.

Carbonell Family Professor and Director Autism & Neurodevelopmental Disorders Institute George Washington University & Children's National Medical Center Washington, DC

Edlyn Peña, Ph.D.

Associate Professor Educational Leadership and Director of Doctoral Studies California Lutheran University Thousand Oaks, CA

Louis Reichardt, Ph.D.

Director Simons Foundation Autism Research Initiative New York, NY

Robert H. Ring, Ph.D.

Chief Executive Officer Vencerx Therapeutics New York, NY

John Elder Robison

Neurodiversity Scholar in Residence College of William and Mary Amherst, MA

Alison Tepper Singer, M.B.A.

President Autism Science Foundation Scarsdale, NY

Julie Lounds Taylor, Ph.D.

Assistant Professor of Pediatrics and Special Education Vanderbilt University Investigator Vanderbilt Kennedy Center Nashville, TN



Office of Autism Research Coordination (OARC)

6001 Executive Boulevard, Room 6182 A, Bethesda, MD 20892 National Institute of Mental Health National Institutes of Health

Email: IACCPublicInquiries@mail.nih.gov

Website: http://www.iacc.hhs.gov

STAFF

Susan A. Daniels, Ph.D.

Director

Amanda Garton, M.S., M.S.P.P.

Presidential Management Fellow

Oni Celestin, Ph.D.

Science Policy Analyst

Julianna Rava, M.P.H.

Science Policy Analyst

Angelice Mitrakas, B.A.

Management Analyst

Jamie Kleiner

Science Policy Intern

Karen Mowrer, Ph.D.

Science Policy Analyst

Rebecca Martin, M.P.H.

Public Health Analyst

Jeffrey Wiegand, B.S.

Web Development Manager



